The impact of cytokine modulation in acquired and inherited inflammatory disease and AA amyloidosis by Lane, T
The impact of cytokine modulation in
acquired and inherited inflammatory
disease and AA amyloidosis
Thirusha Lane
National Amyloidosis Centre,
Centre for Amyloidosis and Acute Phase Proteins
University College London
Division of Medicine
Rowland Hill Street, London, NW3 2PF
Submitted for the degree of
Doctor of Philosophy
2016
2 | P a g e
Declaration
I, Thirusha Lane, confirm that the work presented in this thesis is my own. Where
information has been derived from other sources, this has been declared within the thesis.
Signature:
(Electronically signed)
Date: 11th May 2016
3 | P a g e
Abstract
Background
Inflammatory disorders (IDs) cause significant morbidity. SAA and CRP are acute phase
proteins used to diagnose and monitor IDs. SAA is also the precursor to AA amyloidosis
(AAA), a serious complication of chronic inflammation, causing renal failure and poor
quality of life (QoL). The aim of treatment is thus to prevent AAA or to halt its
progression to renal failure, protect renal allografts, and restore QoL. Novel biological
therapies have transformed the landscape, but their longer term effects are yet to be
elucidated.
Aims
We set up a nurse-led clinic to explore safety and efficacy of modulation of cytokines IL-
1 and IL-6 in patients with IDs and AAA, and studied the changing epidemiology of
AAA. We also sought to investigate whether CRP was itself pro-inflammatory.
Results
Suppressing SAA using anti-IL-1 and anti-IL-6 agents resulted in stabilisation of amyloid
deposits and in some, amyloid regression and improved renal function. Treatments were
safe and effective in dialysis and renal transplantation, even where the underlying cause
of AAA was uncertain. Improvement was seen in almost all anti-IL-1-treated CAPS
patients. Common adverse events were infections. QoL improved when treatment was
effective. Referral rates of AAA have remained steady whilst other types have increased.
The commonest causes of AAA are changing; unknown aetiology has increased. Injection
of purified CRP into volunteers did not provoke inflammation.
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Conclusions
Suppressing SAA by effectively treating the underlying ID can lead to improved renal
function and regression of amyloid, even when the cause is uncertain. Anti-cytokine
agents offer the possibility of targeted therapies to suppress systemic inflammation. Work
reported here shows safety, even in dialysis and transplantation. AAA is becoming less
common as some IDs have become easier to control. Single cytokine blockade has proved
useful in AAA of unknown aetiology and treatment generally improves symptomatology
and inflammation. CRP is itself not pro-inflammatory.
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1.1 The Innate Immune System
The mammalian immune system is composed of two arms, the acquired or adaptive
immune system and the innate immune system. Innate immunity is a genetically encoded,
hardwired system that provides a rapid response to danger signals (1). The systemic
autoinflammatory syndromes are recognised as disorders of innate immunity, and are
entirely distinct from the classical autoimmune diseases such as systemic lupus
erythematosus or rheumatoid arthritis, diseases rooted primarily in adaptive immunity (2).
There is no doubt, however, that the two immune systems are intertwined, and that the
range of self-reactive immunological disease represents a continuum between the two (3).
Two major classes of receptors involved in innate immunity are the Toll-like receptors
(TLRs) which are membrane-bound, and the nucleotide-binding oligomerisation domain
(NOD)-like receptors (NLRs) which are cytosolic. Both receptor classes recognise
pathogen-associated molecular patterns, PAMPs, and the NLRs in particular appear to
sense endogenous danger signals, the so called damage-associated molecular patterns
(DAMPs). More than 20 NLR-encoding genes have been identified in man. The majority
of proteins appear to have a leucine-rich repeat domain at the C-terminal; this is thought
to be the ligand binding motif, a nucleotide-binding oligomerisation domain that is central
to the formation of multimeric complexes, and an N-terminal effector domain. These
regulate activation of caspases (a group of intracellular cysteine proteases) which, in turn,
activate a variety of cellular responses including apoptosis pathways, transcription of
nuclear factor κB (NFκB) and cytokine activation (4). NLRP3, also known as cryopyrin, 
is the most studied and best understood member of the NLR family, and contains an N-
terminal pyrin domain, a nucleotide binding domain and a leucine-rich repeat domain at
the C- terminal. NLRP3 is the key component of the NLRP3 inflammasome.
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1.2 Autoinflammatory pathogenic mechanisms
1.2.1 The NLRP3 inflammasome
The NLRP3 inflammasome is a multimeric cytosolic complex. Upon activation by
PAMPs or DAMPs, NLRP3 associates with an adaptor protein, ASC (apoptosis-
associated speck-like protein with a caspase activation and recruitment domain) and a
pyrin domain. The NLRP3-ASC complex oligomerises, and this oligomerisation results
in cleavage of procaspase-1 to caspase-1, which in turn cleaves inactive pro-IL-1β to the 
mature, active IL-1β (5, 6). This is summarised in Figure 1.1. 
IL-1β is a key proinflammatory cytokine with pleiotropic effects (7).  Binding of IL-1β to 
its receptor IL-1R1 induces intracellular signaling and transcription of other pro-
inflammatory genes; hence dysregulation of IL-1β production has serious pathological 
consequences. Its transcription, activation and release are tightly regulated, and the
activity of IL-1β after release is further regulated by IL-1Ra, an endogenous antagonist of 
IL-1α and IL-1β.  IL-1β leaves the cell and then binds to the IL-1 receptor (8). The 
binding of IL-1β to its receptor type I, IL1-RI, and to the IL-1 accessory receptor (IL-
1RAcP) stimulates intracellular signalling and transcription of other pro-inflammatory
genes. The primary role of the NLRP3 inflammasome is therefore to tightly regulate
activation of IL-1β. Once released into the extracellular environment the activity of both 
IL-1β and IL-1α is further regulated by IL-1Ra, which antagonises their binding to IL-
1RI (9, 10).
Pivotal to the recent developments in our understanding of the role of IL-1β in 
autoinflammatory diseases has been the success of agents which block IL-1 in these
disorders. Anakinra (a recombinant IL-1 receptor antagonist), rilonacept (an IL-1 trap)
and canakinumab (a fully human anti- IL-1β monoclonal antibody) are the three anti-IL-
CHAPTER ONE
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1 agents that have been widely studied and used in the clinical arena, and there are phase
II clinical trials with another anti- IL-1β antibody, XOMA 052.  
Anti-IL-1 therapies have been successfully used in many inflammatory conditions, even
those not directly associated with mutations in NLRP3, providing evidence of the
pleiotropic effects of IL-1 and the NLRP3 inflammasome; some of these diseases are
discussed in more detail in Section 1.3 below. Whilst direct inhibition of assembly of the
NLRP3 inflammasome by means of blocking IL-1 has been successful in many
conditions, other inflammatory molecules are known to either activate the NLRP3
inflammasome by mechanisms other than that described above, or by activating
completely separate pathogenic inflammatory pathways.
1.2.2 Other players and mechanisms driving inflammation
1.2.2.1 ASC
It has been shown that the recruitment of ASC by NLRP3 is a fundamental step in
inflammasome activation, and that if ASC recruitment fails the NLRP3 inflammasome
complex does not assemble. Formation of the NLRP3-ASC complex is established
between the pyrin domains (PYDs) in each molecule. ASC is composed of two death
domains, the PYD and a caspase activation and recruitment domain (CARD); it therefore
acts as an adaptor molecule not only in inflammation (as discussed above), but also in
apoptosis (11). Furthermore, it has been shown that ASC can, via CARD-CARD
interactions, recruit members of the caspase family (12); it can also oligomerise into
functional complexes like the pyroptosome, a potent caspase-1 activator responsible for
pyroptosis (13); and it can act as a scaffold for other molecular platforms involved in
caspase activation (14).
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Figure 1.1. Activation of the NLRP3 inflammasome leads to the release of IL-1β 
which stimulates widespread inflammatory responses. Pathogen-associated and
danger-associated molecular patterns (PAMPs and DAMPs) enter monocytes and
macrophages and are recognised by pattern recognition receptors such as NLRP3. This
results in activation of NLRP3, leading to its interaction with the other components of
the NLRP3 inflammasome (ASC and procaspase-1) and activation of the NLRP3
inflammasome. The active NLRP3 inflammasome cleaves procaspase-1 to produce the
active form, caspase-1. Caspase-1 in turn cleaves pro-IL-1β to yield the active cytokine, 
IL-1β. IL-1β is released from the cell and stimulates inflammatory responses: The 
production and release of the acute-phase proteins is stimulated by direct action on the
liver or indirectly by stimulation of the production of IL-6 from endothelial and other
cells; IL-1β acts on the hypothalamus to induce fever; IL-1β stimulates bone to induce 
bone resorption and breakdown of cartilage, and production and enhanced activation of
lymphocytes, neutrophils, and platelets. The anti-IL-1 therapies anakinra, rilonacept and
canakinumab act by blocking binding to the IL-1 receptor, trapping the IL-1β molecule 
or by binding to it, respectively.
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1.2.2.2 Pyrin
Pyrin is part of the TRIM family of proteins. It contains a PYD at its N-terminus, bZIP
basic, B-box and coiled coil domains, as well as a B30.2/SPRY domain at its C- terminus.
Direct interaction of pyrin with ASC via the cognate pyrin domain suggests possible
molecular mechanisms for the inflammatory features of familial Mediterranean fever
(FMF). There are data to support both an anti-inflammatory and a pro-inflammatory role
for wild-type (WT) pyrin. Chae and colleagues demonstrated that mice deficient for
MEFV showed increased cytokine production and subsequent endotoxin-induced
lethality (15). Other groups have shown that the B30.2 domain of WT pyrin interacts with
caspase-1, thereby inhibiting the maturation and processing of IL-1β (16, 17). These data 
support the anti-inflammatory role of WT pyrin; mutations in MEFV would therefore
confer a loss of function.
Other groups have shown a pro-inflammatory role of WT pyrin whereby overexpressing
WT pyrin resulted in activation of the inflammasome (18) or silencing WT pyrin resulted
in reduced IL-1β production (19). Experimental conditions in these reports are varied 
and these conflicting results notwithstanding, the role of pyrin in the regulation of IL-1β 
is undeniable, and this has been proven by the successful treatment with anti-IL-1
therapies of some FMF patients with incomplete colchicine response (20, 21) or complete
colchicine resistance (22-24). It remains to be seen whether the conflicting reports actually
point to subtle variations in sensing mechanisms associated with different genotypes,
inheritance patterns and epigenetic conditions.
The physiological role of pyrin has long been sought. Recently, the group of Xu (25)
showed that pyrin acts as a sensor of the modification and inactivation of Rho GTPases
by bacterial toxins. Toxin B of Clostridium difficile (TcdB) plays a key role in the
pathogenesis of Clostridium difficile by glucosylating Rho GTPases in order to modulate the
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host actin cytoskeleton for the purposes of virulence (26). Xu et al demonstrated that the
glucosyltransferase activity of TcdB could induce caspase-1 activation in bone marrow
derived murine and human macrophages and that this activation is absent in Asc null
cells, suggesting a requirement of a PYD-containing sensor. Pyrin knockdown completely
inhibited TcdB-induced inflammasome activation, thereby uncovering the crucial role of
pyrin in immunity.
1.2.2.3 IL-18 and IL-1α 
A member of the IL-1 cytokine superfamily, IL-18 is an important regulator of acquired
and innate immunity, and is expressed in a variety of cells including macrophages. IL-1α 
is a pleiotropic cytokine involved in various inflammatory processes; it is produced by
monocytes and macrophages as a proprotein, which is proteolytically processed and
released in response to cell injury, making it a key player in the regulation of immune
responses. A recent study demonstrated that secretion of both IL-18 and IL-1α is 
upregulated in endotoxin-stimulated monocytes from CAPS patients (27). IL-18 release
is also stimulated by inflammasome-activated caspase-1 so this is not an unexpected
finding. By comparison, IL-1α is bioactive even as a non-activated precursor and exerts 
its pro-inflammatory activity when released by dying cells, thereby behaving as a DAMP
(28). Another study has shown that IL-1α is also actively secreted in response to cell stress 
(29), and others have found that, the inflammasome itself can  mediate IL-1α secretion, 
despite IL-1α having no cleavage site for caspase-1 (30, 31). 
1.2.2.4 Tumor necrosis factor (TNF)-α and the TNF receptor 
TNFα is a pro-inflammatory cytokine secreted mainly by activated macrophages, but also 
by many other cell types. The biological effects of TNFα are mediated primarily through 
the TNF receptor 1 (TNFR1), a 55 kDa protein encoded by the TNFRSF1A gene.
TNFRSF1A is part of the death domain superfamily, and TNFR1 is composed of an
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extracellular domain containing four cysteine-rich motifs, a transmembrane domain and
an extracellular death domain. Binding of TNF to the extracellular domain of TNFR1
leads to trimerisation of the receptor, resulting in inflammation triggered by activation of
nuclear factor kappa-B (NF-κB), or apoptosis as a result of caspase cleavage. Under 
physiological conditions binding of TNF to the extracellular TNFR1 domain results in
termination of TNF signalling and shedding of the extracellular domain of the soluble
TNFR1 into the plasma. The circulating soluble TNFR1 competitively inhibits binding
of free plasma TNFα to membrane-bound TNF receptors, thereby regulating TNF 
signalling. Mutations in TNFRSF1A result in dysregulation of TNF processing via a
variety of proposed pathways although the exact mechanism are not completely
understood (32, 33). The effects of mutations in TNFRSF1A are discussed in further
detail in Chapter 1.3.3.
1.2.2.5 Mevalonate kinase
Mevalonate kinase is an enzyme in the isoprenoid pathway, an essential metabolic
pathway in the biosynthesis of isoprenoids including cholesterol. The enzyme itself is not
involved in inflammation, however, deficiency of mevalonate kinase as a result of
mutations in the MVK gene is the cause of the autoinflammatory disease known as
mevalonate kinase deficiency or hyper-IgD and periodic fever syndrome. The mechanism
by which the deficiency of mevalonate kinase triggers the autoinflammatory pathway
remains incompletely understood. Bisphosphonates have been used in some experimental
models for blockade of the isoprenoid pathway downstream of mevalonate kinase,
leading to inflammation and IL-1β secretion, suggesting one possible mechanism (34-36). 
The clinical syndrome of MKD is described in more detail in Chapter 1.3.4.
1.2.2.6 IL-6
IL-6 is a pleiotropic cytokine with a broad range of biological effects which include pro-
inflammatory and immunoregulatory effects. IL-6 production has been detected in many
different cell types but the main sources of IL-6 are, during an acute inflammatory
episode, macrophages and monocytes at the site of inflammation, and T cells in chronic
inflammation (37). IL-6 acts via two pathways, the classical signalling pathway and the
alternate signalling pathway. In the classical signalling pathway IL-6 binds to the IL-6Rα 
present on the surface of hepatocytes and some immune cells such as neutrophils,
monocytes, and B and T cells. The main purpose of this pathway is the promotion of
growth and differentiation and prevention of apoptosis (38). The alternate (or trans-)
signalling pathway is believed to be responsible for the negative effects of IL-6 in
inflammation; this is based on the finding that blocking the alternate pathway abolishes
maintenance and progression of disease (39). In this pathway, free IL-6 binds to soluble
IL-6Rα (sIL-6Rα), and this complex is capable of signalling any cell that has gp130 on its 
surface, i.e. most cells. Binding of free IL-6 to sIL-6Rα activates and recruits gp130 and 
JAK1 leading to STAT3 activation. The systemic response to infection or inflammation
is fever, leucocytosis and increased synthesis of hepatic acute phase proteins such as
serum amyloid A protein and C-reactive protein; IL-6, together with IL1β and TNFα, is 
responsible for generating this systemic response, and IL-6 is believed to be almost
completely responsible for the fever and the hepatic acute phase response (37). In chronic
inflammatory conditions serum IL-6 levels have been found to be persistently elevated.
1.2.2.7 Cellular stress
The electron transport chain, the final step in aerobic respiration, takes place in the
mitochondrial inner membrane. The end result of the process is the generation of energy
in the form of adenosine triphosphate (ATP), as oxygen acts as an electron acceptor.
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When the electron transport chain breaks down during episodes of cellular stress, toxic
reactive oxygen species (ROS) can accumulate within cells. Studies have demonstrated
that ATP-induced ROS production stimulates inflammasome activation in macrophages
(40).
Furthermore, extracellular ATP can act as a DAMP. Present at a high concentration inside
cells, intracellular ATP is released extracellularly in the event of cell injury. This
extracellular ATP induces inflammation by binding P2X7R on inflammatory cells
resulting in the stimulation of a series of intracellular processes that leads to
inflammasome activation and IL1β secretion (27, 41, 42). 
1.3 Systemic Autoinflammatory Diseases
The discovery of pathogenic genetic mutations which result in dysregulation of the innate
immune response signalled a major breakthrough in medicine, as the systemic
autoinflammatory diseases (SAIDs) were recognised as a spectrum of rare genetic
disorders characterised by periodic or chronic systemic inflammation, accompanied by
unexplained fever, in the absence of immune cell (T or B cell) activation (43). Also
referred to as the inherited periodic fever syndromes (IPFS), or hereditary periodic fever
syndromes (HPFS), it is now known that in some SAIDs, the pathogenic mutations may
occur de novo. There are now over 30 different syndromes recognised but the four
commonest are familial Mediterranean fever (FMF), cryopyrin-associated periodic
syndrome (CAPS), tumour necrosis factor (TNF) receptor-associated periodic syndrome
(TRAPS) and mevalonate kinase deficiency (MKD).
Although there exists some overlap in clinical features between these disorders – fever
and systemic inflammation involving the skin, joints, eyes and serosa - there are major
differences in the aetiology, pattern of inheritance and length and frequency of attacks,
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between the various syndromes (Table 1.1). Attacks do resolve spontaneously without
immunosuppressive, anti-cytokine or anti-inflammatory drugs, although patients
experience severe discomfort, pain and poor quality of life during the attacks. Between
attacks patients may feel well and return to normal daily activities, although some do
suffer continuous low grade symptoms which may be debilitating.
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Syndrome Gene and
Location
Protein Inheritanc
e
Ethnicity Age at
Onset
Distinctive Clinical Features Attack
duration
Attack frequency Treatment
FMF MEFV
Chromosome
16
Pyrin Autosomal
recessive
Mainly Eastern
Mediterranean
Childhood
<10 years
or early
adulthood
Erysipelas erythema,
monoarthritis (usually of lower
limbs), aseptic meningitis
1 to 3
days
Variable Colchicine
CAPS NLRP3
Chromosome
1
Cryopyrin Autosomal
dominant;
CINCA
may be
sporadic
Mainly Northern
European
Infancy
usually, but
atypically in
adulthood
Spectrum including fever,
arthralgia, urticarial rash,
conjunctivitis and towards the
more severe end, sensorineural
deafness, aseptic meningitis,
mental retardation
<24
hours
Varies between
dependency on
environmental stimuli,
to daily, to continuous
along the severity
spectrum
Anti-IL-1
drugs
TRAPS TRNRSF1A
Chromosome
12
TNF
Receptor
Autosomal
dominant
Mainly Northern
European
Childhood
or early
adulthood
Migratory rash, arthralgia, red
eyes, periorbital oedema,
abdominal pain, serositis
Days to
weeks
Variable, may be
continuous
Anti-TNF
and anti-IL-1
drugs
MKD MVK
Chromosome
12
Meval-
onate
kinase
Autosomal
recessive
North Western
European
Infancy,
usually <1
year
Macular papular rash, red eyes,
arthralgia
3 to 7
days
Once to twice monthly Anti-TNF
and anti-IL-1
drugs
Table 1.1. Summary of features of the systemic autoinflammatory diseases.
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between the various syndromes (Table 1.1). Attacks do resolve spontaneously without
immunosuppressive, anti-cytokine or anti-inflammatory drugs, although patients
experience severe discomfort, pain and poor quality of life during the attacks. Between
attacks patients may feel well and return to normal daily activities, although some do
suffer continuous low grade symptoms which may be debilitating.
1.3.1 Familial Mediterranean Fever
Familial Mediterranean fever (FMF) (MIM 249100) is the commonest inherited
monogenic autoinflammatory disorder, characterised by recurrent self-limiting episodes
of fever and systemic inflammation usually manifest as serositis, peritonitis, arthritis,
myalgia and sometimes pleurisy and pericarditis (44). Attacks may last between 12 and 72
hours, and common precipitants are physical or emotional stress and menstrual periods.
Peritonitis is often intense and misdiagnosed as acute abdomen with about 40% of
patients undergoing a negative laparoscopy before FMF has been diagnosed. First
presentation usually occurs in childhood or early adulthood. FMF is most prevalent in
the eastern Mediterranean coastal populations – Armenians, Sephardic Jews, Arabs and
Turks – but is known to affect other groups found along the Mediterranean basin,
including Italians, Greeks and Spaniards (45-47).
FMF is the result of mutations in MEFV, the gene encoding the 781-amino-acid protein
pyrin (previously known as marenostrin), located on chromosome 16p13.3, and the
mutation is inherited in an autosomal recessive fashion. MEFV is 10 exons long and
mutations most commonly occur on exon 10, the longest exon on the gene. Over 300
sequence variants have been identified to date (48); although some are more frequently
seen than others and pathogenicity is variable. For example, M694V, most commonly
seen among Sephardic Jews, is associated with a more severe phenotype, whilst E148Q
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(common amongst Europeans and Turks) and V726A are associated with reduced
penetrance and milder phenotype; however, some who are compound homozygous for
the V726A/E148Q alleles are also known to have a more severe form of the disease (49).
Consequently, genetic testing holds only a 70% to 80% positive predictive value, and the
diagnosis of FMF remains clinical. The Tel Hashomer revised criteria for diagnosis are
listed in Table 1.2.
Pyrin is a member of the death domain superfamily, the members of which are known to
play important roles in the assembly and activation of apoptotic and inflammatory
complexes. Pyrin is expressed in granulocytes and cytokine-activated mononuclear cells
and expression is up-regulated in the presence of activators of inflammation such as
TNFα and interferon (IFN) γ (50, 51). The range of genotypic and phenotypic variation 
in FMF suggests multiple pathogenic mechanisms, and the field appears to be divided
broadly between the theories of a pro-inflammatory role and an anti-inflammatory role
for pyrin as discussed above. Colchicine is the treatment of choice for FMF and its long
term safety and efficacy is well known and well-documented (52). Those who are
unresponsive (22-24), or incompletely responsive (20),(21) to colchicine may be
successfully treated with anti-IL-1 therapies.
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Major Criteria Minor Criteria
Recurrent febrile episodes with serositis Recurrent febrile episodes without signs
of serositis
AA amyloidosis Erysipelas-like erythema
Good response to colchicine FMF in a first-degree relative
Table 1.2. Revised Tel Hashomer Criteria for the diagnosis of FMF. The diagnosis
is definitive in the presence of 1 major and 2 minor criteria, or 2 major criteria. The
diagnosis is probable if only 1 major criterion and 1 minor criterion are present.
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1.3.2 Cryopyrin-Associated Periodic Syndrome
Previously described as three separate syndromes, cryopyrin-associated periodic
syndrome (CAPS) is now known to comprise a spectrum of disorders. At the milder end
of the spectrum is familial cold autoinflammatory syndrome (FCAS) (MIM 120100)
which shows some phenotypic overlap with Muckle-Wells syndrome (MWS) (MIM
191900) towards the middle of the disease spectrum. At the more severe end of the
spectrum is Chronic Infantile Neurological Cutaneous Articular (CINCA) (MIM 60711)
Syndrome also known as neonatal onset multisystem inflammatory disease (NOMID).
CAPS is characterised by recurrent episodes of fever accompanied by urticarial rash,
arthritis, myalgia, iritis and fatigue. These attacks may last up to 12 hours and may be
triggered by physical or emotional stress, infection or cold temperatures. The more
severely affected may suffer profound fatigue, sensorineural deafness, joint deformation
or central nervous system (CNS) symptoms manifest as headaches and raised intracranial
pressure on lumbar puncture. The worst affected are those with CINCA/NOMID who
have severe joint deformities often preventing mobility, and severe CNS manifestations
including chronic aseptic meningitis, cerebral atrophy, visual loss due to optic nerve
atrophy, seizures and mental retardation.
CAPS results from mutations in the gene encoding cryopyrin, NLRP3, resulting in
dysregulation of the activity of the pro-inflammatory cytokine, interleukin-1β (IL-1β). 
NLRP3 is located on chromosome 1q44, and there are now more than 140 known
pathogenic sequence variants, most of which are single nucleotide substitutions (48).
FCAS and MWS display an autosomal dominant inheritance pattern in about 75% of
cases; CINCA syndrome on the other hand is often the result of de novo mutation, and
in approximately 40% of affected individuals, conventional genetic sequencing methods
reveal no identifiable mutation (53). CAPS most commonly affects Northern Europeans
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and North Americans (54), but has been identified in other ethnic groups such as South
Asians and North Africans.
Cryopyrin is expressed in peripheral blood leucocytes and chondrocytes and is the most
studied and best understood member of the NLR family. It is the key component of the
NLRP3 inflammasome, as previously discussed. Treatment of CAPS involves inhibiting
the activity of IL-1, by blocking binding to its receptor or by means of anti-IL-1 antibodies
(55).
1.3.3 Tumor Necrosis Factor Receptor-Associated Periodic Syndrome
Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) (MIM
142680) is characterised by self-terminating episodes of fever accompanied by localised
and systemic inflammation presenting as abdominal pain, pleurisy, myalgia and a
geographical rash. TRAPS may first present in childhood or early adulthood, and flares
may persist for several weeks. As with FMF the abdominal pain may be intense,
mimicking acute abdomen, and often results in unnecessary laparotomy before the
diagnosis of TRAPS has been made. Although first described in, and predominantly
affecting Northern Europeans, TRAPS does also affect other ethnic populations such as
Japanese, Southern Europeans and African Americans (56-58).
TRAPS is associated with mutations in the TNF receptor superfamily 1A (TNFRSF1A)
gene located on chromosome 12p13, and the pattern of inheritance is autosomal
dominant. More than 100 pathogenic variants have been identified to date, and all bar six
are single nucleotide substitution mutations (48). Phenotype-genotype studies reveal that
some variants, particularly those involving the highly conserved cysteine residues, are
associated with a severe phenotype, whilst others, such as the R92Q polymorphism are
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associated with a milder phenotype (or a ‘carrier’ phenotype) and incomplete penetrance
(56).
There are several proposed pathways by which mutations cause systemic inflammation,
although the precise mechanisms remain unclear. One proposal is that TNFR1 mutations
may lead to impaired cleavage of the extracellular domain (receptor shedding), which is
the commonest method of TNFR1 inactivation; another is by impaired trafficking to the
cell surface and of retention of mutant receptors within the endoplasmic reticulum. Both
proposed mechanisms may give rise to enhanced or prolonged signalling (59). Other
studies have shown that impaired intracellular trafficking and retention of mutant TNFR1
within the endoplasmic, and/or cytoplasmic aggregation of the mutant protein triggers
the unfolded protein response (UPR) and release of pro-inflammatory cytokines including
IL-1β (32, 33). For patients with a relapsing-remitting disease course, corticosteroid
treatment during flares can be effective. For patients with a more chronic phenotype, long
term treatment is either by blockade of the TNF receptor, although this has not been
successful in many patients or, more successfully, by blocking IL-1 (60-63).
1.3.4 Mevalonate Kinase Deficiency
Previously known as the hyperimmunoglobulin D and periodic fever syndrome (HIDS),
MKD (MIM 260920) presents as recurrent episodes of fever, associated with
lymphadenopathy, malaise, rash, arthralgia and gastrointestinal symptoms of abdominal
pain, diarrhoea and vomiting. MKD is a rare autosomal recessively inherited
autoinflammatory disease resulting from mutations in the gene encoding mevalonate
kinase, MVK. Located on chromosome 12q24, more than 200 mutations have been
identified in MVK, more than half of which are thought to be pathogenic (48). The
precise pathogenic mechanisms by which mevalonate kinase deficiency results in the
autoinflammatory phenotype remain unclear. Mevalonate kinase is known to be involved
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in the cholesterol, farnasyl and isoprenoid biosynthesis pathway; it has been demonstrated
that a downstream consequence of isoprenoid deficiency is activation of pro-
inflammatory cytokines (64). Magnitude of deficiency of MKD can vary between patients
and complete deficiency is associated with the rather severe phenotype of mevalonate
aciduria, which is associated with mental retardation, myopathy, cerebellar ataxia, failure
to thrive, and often fatality in early life (65). Current treatment of MKD is by IL-1
blockade, although there are reports of the successful use of anti-IL-6 therapy (66).
The systemic autoinflammatory diseases are generally compatible with normal life
expectancy, however a proportion of these patients develop AA amyloidosis as a serious
and often life-threatening complication.
1.4 Amyloidosis
Amyloidosis is a disorder of protein folding whereby endogenous proteins become
misfolded and auto-aggregate in an abnormal but highly stable fibrillar conformation in
the extracellular space, progressively disrupting organ structure and function (67).
Amyloid deposition may be localised and incidental, having little or no sequelae, or, at the
opposite end of the spectrum, may be more widespread causing multi-organ damage and
failure, and death. Over 20 endogenous proteins are known to be amyloidogenic, and the
type of amyloid is classified according to the precursor protein. Accurate diagnosis and
typing is of the utmost importance, as management and treatments vary greatly between
different amyloid types.
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1.4.1 Precursor proteins and fibrillogenesis
Under the correct in vitro conditions almost any polypeptide can be driven towards
misfolding and aggregation (68), but not many are amyloidogenic in vivo (Table 1.3).
There are three circumstances under which amyloidogenesis will take place in vivo:
Firstly, when there is a prolonged period of excess or overproduction of a normal
endogenous protein, e.g. sustained periods of elevated levels of serum amyloid A protein
(SAA) as a result of a prolonged acute phase response, is the cause of AA amyloidosis;
Secondly, when there are normal levels of an inherently amyloidogenic endogenous
protein, present over a prolonged period of time, such as in wild-type transthyretin
(ATTRwt) amyloidosis; and lastly, when there are highly amyloidogenic mutant proteins,
such as variant transthyretin in hereditary transthyretin (ATTRv) amyloidosis, or variant
fibrinogen in fibrinogen (AFib) amyloidosis.
Amyloid fibrils in vivo are usually composed of fragmented precursor proteins which are
partially or completely dissociated into their monomers, or which have undergone partial
cleavage (69, 70). However, there are some circumstances in which amyloid fibrils may
be composed of fully intact precursor proteins as in lysozyme amyloid (71) and certain
forms of TTR amyloid (72). Despite being structurally and functionally diverse in their
native states, during amyloidogenesis the precursor proteins all assume the remarkably
similar but extremely abnormal configuration of a common core structure made up of
anti-parallel β-strands forming sheets lying with their long axes perpendicular to the long 
axis of the fibril (73). And whilst the precise mechanisms of fibrillogenesis remain unclear,
the mechanism proposed by David Booth and colleagues (74) for in vitro lysozyme
amyloid fibril formation is widely believed to be similar for all amyloid types.
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Amyloid
Type
Precursor Protein Clinical Syndrome
AL Monoclonal immunoglobulin free light chains Systemic amyloidosis associated with monoclonal plasma cell dyscrasias
AH Monoclonal immunoglobulin heavy chains Systemic amyloidosis associated with monoclonal plasma cell dyscrasias
AA Serum amyloid A protein Systemic amyloidosis, primarily affecting the kidneys, associated with chronic inflammation
ATTRwt Wild type plasma transthyretin Wild type transthyretin amyloidosis with cardiac-dominant disease
ATTRv Genetically variant transthyretin Familial amyloid polyneuropathy and/or cardiomyopathy (autosomal dominant)
AFib Genetically variant fibrinogen A alpha chain Non-neuropathic with renal-dominant disease (autosomal dominant)
AGel Genetically variant gelsolin Predominant cranial nerve involvement with lattice corneal dystrophy (autosomal dominant)
ALys Genetically variant lysozyme Non-neuropathic with prominent visceral involvement (autosomal dominant)
AApoAI Genetically variant apolipoprotein AI Predominantly non-neuropathic with prominent visceral involvement (autosomal dominant)
AApoAII Genetically variant apolipoprotein AII Non-neuropathic with prominent renal involvement (autosomal dominant)
A2M 2-microglobulin Periarticular and/or systemic amyloidosis associated with long-term dialysis
A -protein precursor (and rare genetic variants) Cerebrovascular and intracerebral plaque amyloid in Alzheimer’s disease
ALect2 Normal plasma leukocyte chemotactic factor 2 Sporadic systemic amyloidosis; lowly progressive proteinuric renal failure
ACys Genetically variant cystatin C Cerebral haemorrhage with cerebral and systemic amyloidosis
Table 1.3. Classification of amyloidosis by precursor protein.
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1.4.2 Non-fibrillar components
Amyloid deposits in vivo also contain various non-fibrillar constituents.
Glycosaminoglycans and proteoglycans such as heparan sulphate and chondroitin
sulphate are found universally in amyloid deposits. Although their function remains
uncertain, their presence in all amyloid deposits implies a significant role, perhaps in
stabilisation of the deposits (75), or in fibrillogenesis (76). The normal plasma
glycoprotein, serum amyloid P component (SAP), acts as the precursor to another
universal non-fibrillar component of amyloid deposits, tissue amyloid P (TAP) (77). TAP
binds to amyloid fibrils in a reversible calcium-dependent manner (78). Whilst the
physiological role of SAP is not fully understood, in vitro studies have demonstrated that
SAP binding has a stabilising effect on the amyloid fibril, protecting it from degradation
by proteases and phagocytic cells (79). The universal presence of TAP in all amyloid
deposits has formed the basis of the specialised in vivo nuclear medicine imaging
technique, SAP scintigraphy, in which the localisation of 123I-labelled SAP to amyloid
deposits in the organs is used to diagnose visceral amyloid (80). It is also the basis of the
anti-SAP approach to therapeutic clearance of visceral amyloid (81).
1.5 Systemic AA amyloidosis
Previously known as secondary or reactive amyloidosis, AA amyloidosis is a rare
complication of chronic infections or inflammatory diseases. The AA amyloid fibrils are
derived from the plasma acute phase reactant serum amyloid A protein (SAA), which is
synthesised by hepatocytes under the transcriptional regulation of pro-inflammatory
cytokines, (82). The median plasma concentration of SAA in health is < 3mg/L, with >
90% of the population having levels < 10 mg/L, however, during a severe acute phase
response, levels can increase more than 1000-fold (83). Prolonged elevation of SAA is a
prerequisite to development of AA amyloidosis.
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The human SAA gene family is made up of four discrete loci on chromosome 11,
containing SAA1 and SAA2, two highly homologous genes, and SAA3 and SAA4,
which are more distantly related. SAA1 and SAA2 are the predominant proteins in the
acute phase response (82), however, AA amyloid fibrils are almost always derived from
SAA1, due perhaps to differences in the processing or catabolism of the two proteins, or
possibly due to specific amino acid sequences in SAA1 which promote amyloidogenicity.
Polymorphisms in the gene encoding the SAA1 isotype may confer increased
susceptibility to the development of AA amyloidosis (84). In humans there are three main
SAA1 alleles, SAA1.1, SAA1.3 and SAA1.5. Associations have been found between
particular alleles and the risk of developing AA amyloidosis. One study linked
homozygosity for the SAA1.3 allele with increased risk of developing AA amyloidosis, a
shorter latency to development of AA amyloidosis and a more severe phenotype (85, 86).
Other studies have linked SAA1.1 homozygosity with a predisposition to AA amyloidosis
in patients with FMF (87, 88) and juvenile idiopathic arthritis (JIA) (89).
The lifetime incidence of AA amyloidosis in those with chronic inflammatory disorders
is 1 to 5% (90), and in the developed world the commonest predisposing conditions are
the inflammatory arthritides, followed by chronic sepsis, inflammatory bowel disease and
the SAIDs. Developments in anti-cytokine therapies have significantly impacted on the
prevalence of AA amyloidosis secondary to SAIDs. Renal dysfunction and its sequelae
dominate the disease course in AA amyloidosis with 80% of sufferers presenting with
nephrotic range proteinuria and > 50% of patients in renal failure at presentation (UK
National Amyloidosis Centre unpublished data).
Treatment of AA amyloidosis is aimed at controlling the underlying inflammatory
condition, thereby suppressing the acute phase response and reducing the supply of the
amyloidogenic precursor protein. Outcomes in AA amyloidosis are favourable when SAA
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concentrations are maintained below 10 mg/L (91) and complete suppression of
inflammation with SAA concentration maintained at < 5 mg/L is associated with
preservation of, or improvement in, renal function, and regression of amyloid (92, 93).
1.6 Hepatic Acute Phase Proteins
C-reactive protein (CRP) and SAA are acute phase proteins synthesised by hepatocytes
under the transcriptional regulation of pro-inflammatory cytokines, in particular IL-1, IL-
6 and tumor necrosis factor (TNF) α (82). An explosion of interest in measurement of 
CRP and SAA in relation to cardiovascular disease occurred following the original
observations in patients with known cardiovascular disease (94, 95)and subsequent
findings in the general population, that baseline values of CRP and SAA are statistically
significantly associated with risk of future coronary events. Although their physiological
roles remain uncertain, they are of enormous value due to their clinical relevance in the
acute phase. The rapid increase in serum concentrations, in proportion to the degree of
inflammation, infection or tissue damage, and dynamic range in the acute phase response
make CRP and SAA ideal biomarkers for objective monitoring of disease activity and
response to treatment.
CHAPTER ONE
39 | P a g e
1.6.1 C-Reactive Protein
CRP is an acute phase protein of the pentraxin family, the synthesis and circulating
concentration of which increases dramatically in response to most forms of tissue injury,
infection and inflammation (96). Normal CRP concentration in healthy individuals is very
low at a median 0.8 mg/L, with 90% of individuals having less than 3 mg/L and 99% less
than 10 mg/L (97). During the acute phase response the CRP concentration can exceed
500 mg/L, and values around 20-30 mg/L are common during minor illnesses such as
upper respiratory tract infection or minor trauma. Ambulant patients in the community
with chronic inflammatory diseases, such as rheumatoid arthritis (RA) or Crohn’s disease
may have circulating CRP values up to 100 mg/L or more for months or even years, and
there is no evidence that such increased circulating CRP concentrations have any acute
adverse effects. CRP is catabolised by hepatocytes, and has a half-life of 19 hours in the
plasma. Human CRP is not glycosylated and is encoded by a single gene with no coding
polymorphism. The physiological role of CRP remains unknown. This is because there
are no known cases of CRP deficiency or structural polymorphism (96); nor are there any
known in vivo depleters or inhibitors of CRP, and so the consequences of absence,
dysfunction or inhibition of human CRP cannot be ascertained (98). The non-specific
nature of the CRP acute phase response means that CRP values can only be interpreted
at the bedside in light of clinical information including medical history, physical
examination and results of all available investigations. With this in mind, CRP is used
worldwide as the main measure of both inflammation and success of anti-inflammatory
therapy.
1.6.2 Serum Amyloid A Protein
SAA, an apolipoprotein constituent of high density lipoprotein (HDL), is a more sensitive
marker of inflammation, having a temporally more rapid elevation in the serum during
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the acute phase response, and a greater dynamic range than CRP. SAA concentrations
may be elevated up to 1000-fold in response to various inflammatory stimuli, including
infection, injury, inflammation and neoplasia (82). Whilst the liver is the main site of SAA
production SAA expression has also been described in the normal (non-diseased) tissue
epithelium (99), in diseased tissues such as atherosclerotic lesions (100) and various
carcinomas, and in adipose tissue (101). Whilst the physiological role of SAA remains
incompletely understood it is proposed to be involved in cholesterol metabolism, and is
known to have an established pathogenic role as the precursor protein in AA amyloidosis
(described in Section 1.5 above). As a high-density lipoprotein–associated apolipoprotein,
SAA is considered as a modulator of inflammatory processes, playing a part in leukocyte
and mast cell tissue infiltration, migration and adhesion (102) and in stimulating
production of inflammatory cytokines including IL-1β and IL-6 (103, 104). 
1.7 Diagnosing AA amyloidosis
Frequently, the diagnosis of amyloidosis is made at an unfortunately late stage, long after
the onset of symptoms, and after prolonged investigation, as often the non-specific and
varied presentations give rise to many differential diagnoses. Not infrequently, patients
have no inflammatory symptoms at all, and already have renal amyloidosis at presentation.
1.7.1 Histology and immunohistochemistry
To date histological confirmation of amyloid remains the diagnostic gold standard; this is
achieved by Congo red staining of amyloidotic tissue with the presence of the
pathognomonic red-green birefringence when visualised under cross-polarised light
(105). Common biopsy sites include the gastrointestinal tract, kidneys and bone marrow.
Abdominal fat pad biopsy is an increasingly popular means of obtaining tissue as this may
be performed in the outpatients’ clinic relatively quickly, and safely. A disadvantage,
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however, is that the yield is frequently insufficient for staining and typing. A positive
Congo red stain should trigger further investigations to determine the amyloid fibril type
and extent of organ involvement.
Immunohistochemistry is used to ascertain fibril type and should be performed on any
tissue in which amyloid has been detected. However, despite recent advances in
immunohistochemical techniques, the result is still frequently inconclusive (106), and a
diagnosis of exclusion must follow. For example, hereditary forms of amyloidosis may be
excluded by genetic screening for mutations in genes encoding known amyloidogenic
fibril precursor proteins (107). Treatment of the different types of amyloidosis varies
greatly, and so precise identification of the amyloid fibril type is absolutely critical.
1.7.2 SAP scintigraphy
This nuclear medicine imaging technique utilises radiolabelled iodine as a tracer which
localises to visceral amyloid deposits in vivo (108). SAP scintigraphy can be used to
monitor regression or progression of visceral amyloid and response to therapy (109). SAP
scintigraphy also provides information on the distribution of visceral amyloid deposits
which may be a useful typing adjunct (110).
1.7.3 Other investigations
Measuring the circulating concentration of amyloidogenic precursor proteins, such as
SAA in AA amyloidosis, is important diagnostically, but longer term monitoring is also
crucial in order to determine the success of treatment. Echocardiography and
electrocardiographs (ECGs), and more recently, cardiac magnetic resonance imaging
(CMR) are used to diagnose cardiac amyloidosis and monitor change in cardiac amyloid
deposits.
CHAPTER ONE
42 | P a g e
1.8 Diagnosing systemic autoinflammatory syndromes
SAIDs are diagnosed by a combination of clinical assessment, biochemical measurement
of SAA and CRP, and genetic sequencing. Clinical assessment involves taking a detailed
symptom history and family history, and physical examination to identify the clinical signs
of the syndrome as described in Tables 1.1 and 1.2. Biochemical and genetic analysis are
discussed in Chapter 2: Methods.
1.9 Measuring quality of life (QoL)
Until fairly recently the so called ‘hard’ clinical endpoints such a hospitalisation or death
were the focus of most clinical trials or disease management programs. When patient-
reported outcomes (PRO) were used, they tended to be in relation to disease specific
indicators, such as joint pain in rheumatoid arthritis. Whilst such outcome measures are
extremely important in disease management, they do not give a sense of the overall health-
related QoL. As people are living longer, healthcare must focus as much on quality as
length of life. Medicine regulatory bodies such as the United States (US) Food and Drug
Administration (FDA) and the United Kingdom (UK) Medicines and Healthcare
Products Regulatory Agency (MHRA) have become increasingly interested in patient-
reported health-related quality of life, and the pharmaceutical industry, as well as academic
and clinical researchers, are now expected to include validated QoL measures as
endpoints in clinical studies (111).
The QualityMetric SF-36v2® and other SF QoL questionnaires are widely recognised as
leading PRO measures, their validity and reliability having been validated in patients with
many different acute and chronic conditions. Although the main intended use of the
survey was initially in population studies, the SF-36v2 has become invaluable to
healthcare professional as a means of evaluating and monitoring disease and success of
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therapy (112, 113). Unlike the standard clinical assessments of health status such as vital
signs, laboratory tests and physician examination, the SF-36v2 provides a broad overview
of a patient’s health status and the effect of the disease/health status on his or her
physical, social emotional and mental functioning – i.e. disease burden (114). In addition
to the utility of the survey in measuring disease burden, the SF-36v2 may be administered
to a single patient at multiple time-points, offering a baseline comparator for long term
monitoring in chronic conditions. Thus, a pre-treatment administration, or administration
during an episode of disease flare may serve as a baseline measure of health-related QoL,
which can then be compared to results of surveys completed during treatment, thereby
providing an objective means of documenting the success of therapy. It is easy to
administer, taking on average less than 10 minutes to complete, and so may easily be
incorporation into clinical practice (115).
The SF-36v2® is composed of 36 questions covering eight health domains or scales:
Physical Functioning (PF): The PF domain is composed of 10 items covering distinct
aspects of physical functioning over a range of severe and minor physical limitations, such
as lifting and carrying groceries, climbing stairs, bending, kneeling, and walking moderate
distances. There is also one item dedicated to describing limitations in self-care activities.
The PF items are designed to capture the presence as well as the extent of physical
limitations with low scores indicating significant limitations in performing physical
activities, whilst high scores reflect little or no limitations in performing physical activities.
Role-Physical (RP): This domain is composed of four items covering a range of physical
role limitations, including limitations in carrying out work or other usual activities and
reduction in the amount of time spent on work or other usual activities. Low scores
indicate interference of physical problems with work or other usual activities.
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Bodily Pain (BP): This domain comprises two items: one designed to measure the
intensity of bodily pain and one measuring the extent of interference with normal work
activities as a result of bodily pain. Low scores indicate high levels of pain which
significantly affect normal activities, whilst high scores indicate no pain or impact on
normal activities.
General Health (GH): The GH scale comprises five items, including a rating of health
from poor to excellent, as well as four items addressing the patient’s opinion and
expectations of his/ her health. Low scores indicate a perception of poor general health,
which is expected to deteriorate. High scores indicate a perception of good general health.
Vitality (VT): This scale is composed of a four-item measure of vitality (i.e. energy level
and fatigue). Low scores indicate feeling tired and worn out a lot of the time, whilst high
scores indicate feeling energetic all or most of the time.
Social Functioning (SF). This two-item domain is designed to assess health-related
physical or emotional problems on the quantity and quality of usual social activities.
Low scores indicate extreme or frequent interference of health-related physical or
emotional problems with normal social activities.
Role-Emotional (RE). This three-item scale assesses the impact of mental health-
related problems on role limitations in terms of time spent on work or other usual
activities, the amount of work or usual activities completed, and the care with which work
or other usual activities were performed. Low scores here are indicative of problems with
work or other usual activities as a result of emotional problems and high scores reflect no
such limitations due to emotional problems.
Mental Health (MH). The five-item MH scale includes items from each of four major
mental health dimensions - anxiety, depression, loss of behavioural and/or emotional
control, and psychological wellbeing. Low scores point to frequent feelings of
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nervousness and depression all or most of the time, whilst high scores indicate feelings
of peace, happiness, and calm (115).
Each domain or scale is scored individually, and the result expressed in comparison to
American norms. Higher scores represent a better QoL and a change of 10 points or
more in a domain between administrations is considered clinically significant.
1.10 The UK National Amyloidosis Centre
The UK National Amyloidosis Centre (NAC) is the UK’s only referral centre specialising
in diagnosis and treatment advice for the national caseload of patients with amyloidosis.
Patients with amyloidosis (diagnosed or suspected) are referred by their local medical
teams for diagnosis (or confirmation of suspected diagnosis) and management advice.
Patients return every six to 12 months for monitoring of the disease burden, and undergo
an extensive battery of tests at every visit. Treatments outside of clinical trials, including
chemotherapy, renal replacement therapy and solid organ or stem cell transplantation take
place at the patients’ local hospitals.
Contained within the UK NAC is the Fever Clinic which specialises in the diagnosis and
treatment of rare and ultra-rare autoinflammatory diseases. Following the discovery of
the causative role of excessive IL-1 production in causing the symptoms of CAPS, the
first CAPS patients were treated with anakinra here, in 2002. Since then several dozens
of patients with CAPS and other SAIDs have been prescribed anakinra. Following
successful clinical trials with canakinumab, the National CAPS Treatment Service was
established at the NAC. This service comprises a medical clinic where patients are
reviewed annually, alongside a specialist nurse clinic which patients attend approximately
every eight weeks to receive their canakinumab injections and to undergo safety and
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efficacy monitoring. Patients undergo annual ophthalmology, audiometry and neurology
assessments and brain MRI, where indicated, and quality of life assessments.
Aims
This thesis is composed of clinical studies of inflammatory disorders and AA amyloidosis,
involving patients and healthy volunteers.
AA amyloidosis is one of the most serious complications of chronic inflammation. It
causes renal dysfunction which if left untreated, inexorably progresses to renal failure.
Renal replacement therapy comprising chronic dialysis and kidney transplantation is
costly to the National Health Service (NHS), is fraught with complications and unwanted
side effects, and has a negative effect on quality and length of life. An obvious target of
therapy is thus prevention of the development of AA amyloidosis, or once it has
developed, halting its progression to end stage renal failure, or protecting renal allografts.
The diseases studied within this thesis are characterised by sustained inflammation
associated with a substantial acute phase response. The main focus of this body of work
is the safe and effective treatment of inflammatory disorders – SAIDs such as CAPS,
acquired inflammatory disorders such as rheumatoid arthritis, and inflammatory disorders
of unknown aetiology. SAIDs are rare diseases characterised by seemingly unprovoked
episodes of inflammation which manifest as a catalogue of symptoms including fever,
rigors, rash, arthralgia, myalgia, serositis and pleurisy, amongst others. Although between
attacks some patients may be relatively well, periods of flare are debilitating and may
impact severely on normal physical and social development, schooling, relationships and
employment. Other inflammatory diseases such as rheumatoid arthritis, juvenile
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idiopathic arthritis and Castleman’s disease can have the same sequelae, as can prolonged
inflammation of uncertain aetiology. Early diagnosis and treatment of these diseases is
essential for these reasons, but also in order to prevent or halt amyloid deposition.
In recent years huge leaps have been made in the understanding of disease pathways,
pathogenic mechanisms and molecular origins in the fields of autoinflammation and
autoimmunity. These developments have resulted in the identification of therapeutic
targets, and for the very first time, successful pharmacological ‘switching off’ of disease
activity for hundreds of sufferers.
Disease activity and success of therapy are monitored by serial measurements of the
hepatic acute phase proteins CRP and SAA. Production of both CRP and SAA are part
of the nonspecific acute-phase response to injury, infection and inflammation.
Serial measurements of serum CRP concentration interpreted in light of other clinical and
pathological information, contribute powerfully to diagnosis and clinical management of
a huge range of infectious and inflammatory disorders. Some published studies however,
suggest that CRP may itself be pro-inflammatory. The conflation of epidemiological
association with causality, has led to claims that a higher baseline CRP concentration is
not only a risk marker for cardiovascular disease but also a risk factor contributing to the
pathogenesis of atherosclerosis and atherothrombosis. This might therefore be of
particular concern for patients with inflammatory conditions in whom the CRP
concentration is very substantially elevated for many years or even decades. We sought
to investigate this phenomenon.
SAA is an even more sensitive and dynamic marker of the acute phase response but it is
also the precursor of AA amyloidosis, which means that monitoring of its serum
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concentration is absolutely crucial to the management of patients with AA amyloidosis,
and those who are deemed to be at risk of developing it.
The main aim of this thesis is to study the safety and efficacy of modulation of cytokines
IL-1 and IL-6 in inflammatory disorders and AA amyloidosis. In doing so I have also
sought to give a more complete picture of this very specialist disease area by characterising
the UK population of patients in whom AA amyloidosis complicated systemic
autoinflammatory disease, as well as an exploration of the role of CRP, and the evolving
epidemiology of AA amyloidosis.
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Chapter Two:
Methods
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2.1 Methods performed by the author
2.1.1 Patient selection and ethical approval
All the patients included in this thesis were under the care of the NAC. In the 5 year
period between 2009 and 2014, more than 5000 patients have been referred to the Centre;
approximately 60% of those have been found to have amyloidosis and 15% of referrals
are to the Fever Clinic. A clinical database has been maintained with demographic and
clinical details (including results of all investigations) of all patients since approximately
1990, and this database, together with the routine medical and research records have
formed the source data for this research. Other nurses, doctors and technicians within
the Centre have also contributed to collection of the data within this database together
with the author, however, every chapter contained herein has been written by the author.
Ethical approval for all studies herein were obtained by the author. All patients included
in this work have given written informed consent. The healthy volunteers in the CRP
Study (Chapter Eight) were not patients of the Centre but were recruited via
advertisements. They too gave written informed consent.
2.1.2 CAPS/Inflammation nurse-led clinic protocol
In 2010 I set up the specialist nurse CAPS/inflammation clinical and research service at
the NAC. All patients receiving anti-IL-1 and anti-IL-6 therapies at the NAC are managed
jointly between this clinic and the medical consultant clinic. Within this specialist nurse
clinic I have administered anti-IL-1 and anti-IL-6 therapies, and have conducted regular
long term follow up - consultation, assessment and dosing approximately every eight
weeks for CAPS patients treated with canakinumab, monthly for patients on intravenous
tocilizumab, three- to six-monthly for patients on anakinra - and monitoring of these
patients in terms of safety and efficacy of treatments, and general holistic care including
QoL surveillance. Further detail on the clinic protocol may be found in Chapter Three.
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Within this clinic I also administered purified human CRP to healthy volunteers, as
described in detail in Chapter Eight.
2.1.3 Definition of response to therapy in SAIDs
We defined a complete response or complete remission (CR) as normalisation of serum
acute phase reactants (SAA < 10 mg/L and CRP < 5 mg/L) and resolution of chronic
disease symptoms and flares/exacerbations. Mild recurrent symptoms such as oral ulcers,
or occasional mild headaches or rash or joint aches, which result in symptom scores of 1
or 2, and which were not bothersome to patients, were not considered to be in conflict
with the classification of complete response. A partial response or remission (PR) was
defined as reduction in, but not normalisation of, SAA and CRP measurements and/or
an improvement in disease symptoms, but not complete resolution as defined above.
Non-responders (NR) or inadequate responders were patients who had no significant
improvement in either or both domains.
2.1.4 Assessment of CAPS disease activity
Assessment of CAPS disease activity at each clinic visit was performed by means of a
scoring tool adapted from one used in clinical trials of canakinumab. The tool scores
patient-reported (and clinician observed) symptoms experienced since the last clinic visit,
out of a maximum score of 20. Mild or moderate symptoms are each allocated one point
and severe symptoms are each allocated two points. Examples of pre- and on-treatment
clinical assessment worksheets may be found in the Supplemental Information section.
2.1.5 Venepuncture and injection of radio-iodinated SAP
Venepuncture and blood sampling for routine clinical tests including serum SAA and
CRP assays was performed by the author and other clinic nurses. Intravenous injection
of 123I-SAP in preparation for SAP scintigraphy was performed by the author and other
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clinic nurses. SAP scintigraphy is discussed in detail below. Approximately 70 μg SAP, 
labelled with approximately 180 megabecquerels 123I is injected intravenously into each
patient. This equates to an effective radiation dose of approximately 4 millisieverts, which
is comparable to exposure to the average UK natural background radiation for 1 year, or
to that from an intravenous pyelogram. Thyroid uptake is inhibited by oral administration
of six doses of potassium iodide solution at a concentration of 10 mg/mL – the first dose
is given just before radio-isotope injection, the second on the same night, and then twice
daily for the next two days
2.1.6 Quality of life assessments
The QualityMetric SF36v2® Health Survey is designed to measure functional health and
well-being from the patient’s perspective. There are eight health domains (physical
functioning, role physical, bodily pain, general health, social function, role emotional,
mental health and vitality) which are scored individually out of 100 points, and the result
expressed in comparison to American norms. Higher scores (closer to 100) represent a
better QoL and a change of 10 points or more in a domain between administrations is
considered clinically significant. Patients were asked to complete the surveys at various
time-points before during and after treatment, and some patients took the survey at
multiple time-points, enabling comparison over the follow-up period. Surveys were
administered by the author and the CAPS/Fever clinic specialist nurse. Data analysis was
performed solely by the author using QualityMetric software.
2.1.7 Statistical analysis
Statistical tests were performed using Graphpad Prism® version 5.04.
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2.2 Methods performed or contributed by others
2.2.1 Criteria for diagnosis of amyloidosis and definition of organ response
Organ involvement and organ response were defined according to International
Consensus Criteria (116) in combination with SAP scintigraphy – an abbreviated version
may be found in Table 2.1. Renal function was measured by means of creatinine levels,
albumin levels and estimated glomerular filtration rate (eGFR) from serum, and
proteinuria from 24-hour urine collections.
Organ Definition of Organ Involvement Definition of Organ Response
Heart Echocardiogram: Mean IVSd > 12 mm (in
absence of other cardiac cause)
OR
Late gadolinium enhancement on Cardiac
MRI
Mean IVSd decreased by 2 mm, 20%
improvement in EF, improvement by 2
NYHA classes without an increase in
diuretic use and no increase in wall
thickness
Kidneys 24 hour non-Bence Jones Proteinuria >
0.5g, or uptake on SAP scintigraphy
50% reduction in proteinuria (at least 0.5
g/day) creatinine and creatinine clearance
has not worsened by > 25% over baseline
Liver SAP scintigraphy 50% decrease in abnormal ALP or
reduced organ uptake on SAP scintigraphy
Spleen SAP scintigraphy Reduced organ uptake on SAP
scintigraphy
Adrenal
glands
SAP scintigraphy Reduced organ uptake on SAP
scintigraphy
Table 2.1. Definition of organ involvement and response. IVSd = intraventricular
septal thickness during diastole; EF = ejection fraction; MRI = magnetic resonance
imaging; NYHA = New York Heart Association; ALP = alkaline phosphatase.
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2.2.2 Histology and immunohistochemistry
The presence of amyloid in biopsy tissue sections was confirmed by a modified version
of the alkaline-alcoholic Congo red staining method described by Puchtler et al. (105).
Formalin-fixed deparaffinised tissue sections, 6-8 µm thick, were stained with Congo red
and viewed in brightfield and under cross-polarised light. Positive controls were obtained
from a known Congo red positive composite block (confirmed by laser microdissection
and mass-spectrometry based proteomic analysis) and were always processed in parallel.
Immunohistochemical staining of formalin fixed de-paraffinised 2 m sections of
amyloidotic tissue followed Congo red staining in order to determine the amyloid fibril
type (117). Sections were washed with water. Endogenous peroxidise activity was
quenched by 30 minute incubation in aqueous (0.3%) hydrogen peroxide (H2O2). Sections
were rinsed again in phosphate-buffered saline (PBS) containing 0.05% Tween
(Calbiochem). Non-specific tissue binding was abrogated by incubation for a further 30
minutes in normal non-immune serum from the species providing the secondary antibody
(Vector part of the ImmPRESS Kit) prior to the application of antisera. Thereafter
sections were incubated overnight with primary antisera at 4oC. Following incubation they
were rinsed with PBS containing 0.05% Tween (Calbiochem) and labelled with secondary
antibodies. Sections were washed in PBS and bound enzyme-antibody bound complexes
were viewed using a metal-enhanced DAB (Fisher Scientific solution).
Immunohistochemical stains were performed using commercial monoclonal antibodies
against SAA protein (Euro-Diagnostica, Huntingdon, UK) and AL kappa and lambda
(Dako Ltd, Denmark House, Ely, UK). Positive and negative controls were used in each
run.
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2.2.3 Serum and plasma assays
2.2.3.1 C-reactive protein (CRP)
Serum CRP was measured using a high sensitivity automated microparticle enhanced latex
turbidimetric immunoassay (COBAS MIRA) (Roche). The lower limit of detection was
0.2 mg/L with an inter-assay coefficient of variance (CV) of 4.2% at 4 mg/L and 6.3% at
1 mg/L. Standardisation of the assay was based on the WHO International Reference
Standard, 1987.
2.2.3.2 Serum amyloid A protein (SAA)
SAA was measured in serum by latex nephelometry (BNII autoanalyser; Dade Behring,
Marburg, Germany). The lower limit of detection was 0.7 mg/L, with an inter-assay CV
of 2.6% at 15 mg/L and 3.7% at 80 mg/L. Standardisation of the assay was based on the
respective WHO International Reference Standards, 1987.
2.2.3.3 Cytokine assays
Procedures for assay of cytokines IL-1β, IL-6, TNFα and IL-10 have been previously 
described (118, 119). Assays were performed on plasma taken at baseline, 4, 8 and
24 hours, in Chapter Four. The assays were all calibrated with the respective WHO
International Standard preparations for each cytokine and spike-recovery assays with
control plasma samples were very close to 100% for all cytokines.
2.2.3.4 Routine haematology, biochemistry, coagulation and anti-nuclear
antibody panels
Haematology, biochemistry, coagulation and anti-nuclear antibody (ANA) panels were
carried out by the Royal Free Hospital Pathology Department according to standardised
protocols.
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2.2.4 Genetic analysis
Genomic DNA was isolated from patients’ peripheral blood using the rapid technique
previously described by Talmud et al. (120). Whole blood was obtained from patients in
a 2 ml BD Vacutainer EDTA® draw tube Sequence variants were identified by
amplification using polymerase chain reaction (PCR) and direct sequencing of the
appropriate exons of the gene in question. The following genes and exons were amplified
using appropriate primers and commercially available amplification kits:
 MEFV exons 1 to 10
 NLRP3 exon 3
 TNFRSF1A exons 2 to 7 including introns 2, 4 and 6
 MVK exons 2 to 11.
Analysis was extended to other exons where required, e.g. where no mutation was
detected in the exons indicated above. PCR was validated by gel electrophoresis.
2.2.5 Purification of human CRP
Authentic natural human CRP administered to healthy volunteers in Chapter Four was
isolated and purified from 38 kg of B+1 paste derived from pooled plasma of US donors
undergoing plasmapheresis. The preparation and characterization of this batch of
pharmaceutical current Good Manufacturing Practice (cGMP) grade CRP have been
previously reported in comprehensive detail, including its purity, full structural and
functional integrity and lack of detectable endotoxin in solutions at 3 mg/mL of CRP,
which is less than 0.1 EU/mg of CRP (118). In summary, the CRP has been prepared in
the BioProducts Laboratory (BPL) under strict cGMP conditions, and has been isolated
from the pooled plasma of donors from the US under precisely the same conditions as
for all commercial pharmaceutical plasma protein products provided by the BPL. The
CRP was isolated from a by- product of the process used to prepare a batch of a licensed
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therapeutic immunoglobulin G (IgG) product. The source plasma from each individual
donor was tested and was negative for all relevant viral pathogens by immunoassay; small
pools of donations were also tested, and were negative, for the major viral pathogens
using sensitive molecular genetics methods. The processed protein preparation was
subjected to a validated solvent detergent virus inactivation procedure and then provided
to the study team as an active pharmaceutical ingredient. It was then virus filtered using
a membrane with a maximum pore size of 50 nm, sterile filtered and dispensed for
pharmaceutical use in the Royal Free Hospital manufacturing pharmacy. In addition to
sterility checking, the product has been independently assayed for endotoxin by Limulus
amoebocyte lysate (LAL) testing by the Scottish Blood Transfusion Service, showing an
endotoxin content of < 0.10 EU/mg which is well within the European Pharmacopeia
standard for administration to humans. The GMP CRP has also been tested in human
peripheral blood monocyte activation assays (121, 122) by the National Institute for
Biological Standard and Control to ensure absence of LAL negative contaminants, as well
as any other unsuspected cellular or pro-inflammatory effects specific exclusively to
human cells. The results of all purity tests were entirely negative.
2.2.6 SAP scintigraphy
This is a sensitive and specific nuclear medicine technique used to image and quantify
amyloid deposits in vivo (123). Highly purified human SAP is radio-labelled with the
gamma emitting isotope 123I, and injected intravenously (described above). In patients
without visceral amyloid deposits no localisation or retention of radiolabelled SAP occurs
and the tracer is rapidly catabolised and excreted. In patients with visceral amyloid
however, radiolabelled SAP localises rapidly and specifically to amyloid deposits in
proportion to the amount of amyloid present (108). In patients with AA amyloidosis the
technique has 100% diagnostic sensitivity, and in patients with AL amyloidosis,
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approximately 90%. SAP scintigraphy is the only method available for serial monitoring
of the progression or regression of visceral amyloid deposits (124).
Anterior and posterior whole body images are obtained from each patient approximately
six or 24 hours after injection of 123I-SAP by means of either a GE Infinia Hawkeye (4
slice) SPECT-CT or a GE Discovery 670 (16 slice) SPECT-CT gamma camera (GE
Healthcare, UK).
The whole body amyloid load was classified as follows: ‘None’ when there was no
abnormal localisation of tracer; ‘Small’ when visceral uptake was visible but the intensity
of the blood-pool background signal remained normal; ‘Moderate’ when abnormal
uptake was sufficiently intense such that the blood-pool background signal was partially
lost when the grey-scale was normalised to encompass the signal in the target-organ; and
as ‘Large’ when the blood-pool background was lost with adjustment of the grey scale to
encompass the target-organ signal. Serial SAP scintigraphy was performed at six-monthly
or annual intervals to monitor change in amyloid load. On serial scans amyloid load was
considered stable if tracer localisation or uptake remained unchanged. Regression of
amyloid was defined as a reduction in tracer uptake in affected organs or an increase in
the blood-pool background signal, or both. Progression (or accumulation) of amyloid was
defined as an increase in tracer uptake in affected organs, new abnormal tracer uptake in
a previously unaffected organ, or a decrease in the blood-pool background signal.
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Chapter Three:
Establishment of Nurse-led Clinical and
Research Services
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3.1 Background
Nurse-led clinics, run by experienced specialist nurses, have emerged increasingly in the
last decade in response to a need to provide additional care to that available within medical
or physician clinics. Nurse clinics have developed to provide education, health
promotion, psychological care and support, to help patients develop coping and self-care
strategies, as well as to perform nursing interventions, administer pharmacological
treatments and to monitor the patient’s condition, disease activity and efficacy of
treatments. A literature search reveals countless publications from around the world,
testifying to the positive impact that nurse clinics have had, not only on service delivery
and clinical outcomes but also on quality of life of the patients who use these services
(for example (125-129).
Nurse-led research clinics extend this already successful model of clinical care to patients
participating in clinical studies, and to those receiving off-license or experimental
treatments outside of a clinical trial. These clinics may be run jointly by specialist and
research nurses, or by specialist nurses with an interest in research, and provide the
infrastructure for nurse-led, multi-disciplinary, academic and clinical research.
In 2010 Novartis was granted the marketing authorisation for the use of canakinumab as
the treatment for CAPS in the UK and Europe. In the UK, treatment with this newly
licensed, ultra-high cost drug would be funded by the NHS on condition that the drug
was administered only by the expert clinical team at the NAC. This meant that all patients
who wished to be treated with canakinumab would need to travel to the NAC every eight
weeks for review, monitoring and dosing. It was expected that the availability of the drug
outside of restrictive clinical trials would open the door to many more CAPS patients,
beyond the few who had participated in the phase III clinical trial. As the medically-led
periodic fever syndrome clinic was already full and often over-booked, a new service
CHAPTER THREE
61 | P a g e
delivery model was required. This need sparked the birth of the nurse-led inflammation
clinical and research service, which encompassed the NHS-funded National CAPS
Treatment Service within the NAC.
3.2 Aims
The primary aim was to establish a protocolised, nurse-led clinical service, in order to
safely reconstitute and administer canakinumab to patients with CAPS, and to provide
long term monitoring of these patients, as well as holistic care. The secondary aims were
to create the infrastructure to closely study the natural history of CAPS and other
inflammatory conditions and AA amyloidosis, to safely administer biological therapies
on- and off-license, and to investigate the safety and efficacy of these therapeutic agents.
3.3 Patients and methods
3.3.1 Patients, volunteers and diagnosis
Patients were reviewed and diagnosed in the medical clinic and then referred to the nurse
clinic for pre-treatment screening and counselling, initiation of therapy and long term
follow up. Funding approval had to be obtained before treatments could be initiated.
Healthy volunteers (CRP study) were recruited via adverts within the university, and were
seen within the research clinic.
3.3.2 Administration of therapies
Canakinumab was administered approximately every eight weeks, at doses of 150 mg, 300
mg or 450 mg to patients weighing > 40 kg. Each 150 mg vial containing canakinumab
powder was reconstituted with 1 ml of sterile water for injection. Once completely
dissolved, the drug was injected subcutaneously in one of the usual sites for subcutaneous
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injection. Tocilizumab was administered at four-weekly intervals, at a dose of 8 mg/kg
intravenously for patients weighing > 30 kg. The vials containing tocilizumab solution at
a concentration of 20 mg/ml were diluted to a final volume of 100 ml with sterile sodium
chloride 0.9% solution for injection and infused over one hour. Patients prescribed
anakinra and subcutaneous tocilizumab were taught to self-inject using pre-filled syringes.
Purified human CRP was administered according to the protocol described in detail in
Chapter Eight.
3.3.3 Other methods
Other methods are described in Chapter Two: Methods.
3.4 Results
3.4.1 CAPS nurse clinic protocol
Once diagnosed, and having discussed treatment options with the medical staff, patients
would be introduced and handed over to the specialist nurse. A full verbal handover
would be given. Patients would then have the opportunity to further discuss treatment
options, side effects, pros and cons and procedure for administration of treatment and
monitoring with the specialist nurse.Before treatment was initiated, the following
assessments are carried out within the nurse clinic:
 Routine biochemistry, including SAA and CRP and haematology (blood tests)
 Screening for TB, HIV and Hepatitis B and C (blood tests)
 Vital signs (resting blood pressure, heart rate, temperature) and weight
 Baseline QoL assessment by means of SF-36v2 health survey
 Baseline CAPS symptom score (see Supplementary Information Section).
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Once canakinumab therapy has commenced patients attend every eight weeks for
assessment and further dosing (unless contra-indicated); patients on anakinra attended
every one to three months initially, and then every six to twelve months once stable and
established on treatment. Vital signs, weight and routine blood tests and CAPS symptom
score are performed at every visit. Patients are examined for signs of CAPS activity and
questioned regarding CAPS symptoms and any other health issues. A clinical summary
letter is sent out to the patient, and his/her local doctors after each clinic visit (see
Supplementary Information for examples), and includes any requests for intervention or
review at the local hospital or GP surgery, where indicated. In between visits patients
would be monitored remotely by telephone or email, and patients were required to post
in serum samples for weekly or fortnightly monitoring of serum inflammatory markers in
the initial phase of treatment, until stabilised.
The quality of life survey is repeated after commencing treatment and annually thereafter.
New patients have brain MRI, audiometry, ophthalmology and neurology assessments at
the start of treatment and then repeated annually (apart from brain MRI, which is
performed annually only in patients in whom this is indicated). Blood tests for anti-
nuclear antibodies are performed annually. Patients are reviewed in the medical clinical
annually, unless referred back sooner for any complications. A monthly multi-disciplinary
team meeting is held monthly, during which patients are reviewed and any changes to
treatment are discussed. Figure 3.1 depicts the patient pathway for canakinumab therapy
diagrammatically.
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Figure 3.1. The patient pathway for canakinumab therapy. *Patients also reviewed
in monthly multi-disciplinary team meetings and annually in medical clinic.
Patient is medically diagnosed with
CAPS and is suitable for canakinumab
therapy
Patient has complex
phenotype or significant co-
morbidities/complications
Patient has no complications
precluding monitoring in the
nurse clinic
Patient remains within medical
clinic for monitoring until
suitable for transfer to nurse
clinic
Patient attends nurse clinic for
discussion, education and pre-
treatment assessments
Pre-treatment tests results reviewed
by multi-disciplinary team – green
light to commence canakinumab
Pre-treatment tests results reviewed
by multi-disciplinary team – red
light to commence canakinumab
Patient attends for dosing and education as
to monitoring protocol, side effects, and any
other holistic care
Remote monitoring according to treatment
stage: weekly bloods initially, then fortnightly,
then monthly until stable on treatment; weekly
or fortnightly email or telephone call until
stable on treatment
Patient attends nurse clinic every eight weeks
for assessment and further dosing*
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3.4.2 Protocols for other therapies
Protocols for administration of other drugs are described in detail in each relevant
chapter.
3.5 Discussion
A great number of publications document the many benefits of nurse-led clinics. In the
context of this body of work, the nurse-led clinic has made possible the provision of very
specialist, perhaps even niche, care to patients with complex inflammatory conditions
requiring treatment with biologic therapies, and careful and close monitoring. Medical
clinics are under great time and capacity pressure, and so the creation of a clinical service
where education, intervention/medication, assessment, monitoring and holistic care can
all be provided by experienced healthcare professionals was an essential step in addressing
the unmet need.
Nurse-led clinics also provide the opportunity for nurses to extend their skills and
knowledge, whilst providing specialist and holistic care. They provide an effective
environment for nurses to feel more valued in their roles and to have ownership over
their work. The recognition of nurses as experts within the multidisciplinary team boosts
the professional profile of nursing, encouraging other nurses to extend their roles and
enhancing recruitment of bright and motivated individuals to the profession.
Finally, in the context of this thesis, the nurse-led clinic has enabled this body of work to
be conducted. Combining research with clinical work, especially in such rare diseases
where patient numbers are small, is the gold standard. In order to make this happen, the
right combination of conditions must exist – adequate funding, infrastructure and human
resources - and resourceful humans. The result when these conditions are met is benefit
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to the patients, the multidisciplinary team of healthcare professionals and to the NHS as
a whole.
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Chapter Four:
Characterisation of AA Amyloidosis
Complicating Systemic
Autoinflammatory Diseases
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4.1 Background
The SAIDs are described in detail in Chapter One: Introduction. The syndromes are
characterised by a marked acute phase response, with some patients experiencing 100-
fold or more increase in circulating concentration of the acute phase protein SAA. When
adequately suppressed, these diseases are associated with normal life expectancy, but a
proportion of patients develop the life-threatening complication AA amyloidosis, with
SAA the amyloidogenic precursor protein. The period of latency between the onset of
inflammation and clinical presentation with amyloidosis is variable and may be prolonged,
but amyloid progression can be rapid. Renal dysfunction is the predominant presenting
feature, and poor outcomes are associated with inadequate suppression of the underlying
inflammation (92).
4.2 Aims
We sought to study the presentation, phenotype and outcome of patients who developed
AA amyloidosis as a complication of SAIDs in a single national referral centre.
4.3 Patients and Methods
4.3.1 Patients and diagnosis
From our database of 854 patients with a sequence variant in a gene associated with a
SAID and 545 patients with confirmed or probable AA amyloidosis, we identified a
cohort of 46 patients with AA amyloidosis complicating a SAID. This comprises all
patients referred to our centre in the 21 years up to September 2011 in whom a SAID
was diagnosed by a combination of clinical presentation, medical history, genetic
sequencing and additional investigation, and in whom AA amyloidosis had been
confirmed by immunohistochemical analysis, or by whole body 123I-SAP scintigraphy and
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additional investigation. Routine investigation and assessment at each visit included
clinical evaluation, electrocardiography and echocardiography, and measurements of
hepatic and renal function, including 24-hour urinary protein excretion. Patients
underwent comprehensive clinical investigation at baseline and were followed up every 3
to 6 months. Ethical approval was obtained for this retrospective study (REC reference
number 06/Q0501/42).
4.3.2 Other methods
Other methods are described in Chapter Two: Methods.
4.4 Results
4.4.1 Whole cohort characteristics
The mutations, ethnic origins and age at presentation of all patients in the cohort are
shown in Table 4.1. The median age at diagnosis of AA amyloidosis was 38 years with an
inter-quartile range (IQR) of 27 to 47 years. In 37 patients there was a clinical history
compatible with a SAID; median age at symptom onset was five years (IQR 2-13), and
median latency between symptom onset and presentation with AA amyloidosis was 23
years (IQR 17-34). Eight patients gave no history of overt inflammatory symptoms and
complete clinical data was unavailable for one patient. In 23 patients (50%) the diagnosis
of a SAID was made at our centre following presentation with AA amyloidosis. Renal
presentation dominated; however, three patients also had liver amyloid diagnosed
scintigraphically, and one had cardiac amyloid, diagnosed post-mortem.
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Patient Ethnicity Sex Sequence
variants/Mutations
Attack symptoms Age at SAID
onset
Age amyloidosis
diagnosed
Latency
period
FMF – MEFV mutations
1 Northern European F M694del/E148Q F, A, P 10 59 49
2 Northern European F K695R homo Asymptomatic Asymptomatic 61 NA
3 Northern European M M694del F, A, P 10 45 35
4 Northern European M M694V het Asymptomatic Asymptomatic 78 NA
5 Northern European M M694V/E148Q Asymptomatic Asymptomatic 63 NA
6 Turkish F M694V homo F, A, J 3 27 24
7 Turkish M M694V het Asymptomatic Asymptomatic 45 NA
8 Turkish F M694V homo F, A, J 15 24 9
9 Turkish M M694V/E148Q F, A, J, R, Ft 7 27 20
10 Turkish M M694V homo F, A, P 17 26 19
11 Arabic F V726A/M694I F, A 7 36 29
12 Arabic M M694V homo A, J 13 19 6
13 Arabic F V726A/ M694V F, A, J 30 62 32
14 Arabic M M694I/ E148Q F, A 41 58 17
15 Arabic F M694V/M680I F, H 10 35 25
16 Greek M M694V het F, A, P 24 38 14
17 Greek M V726A/F479L F, A, J 3 19 16
18 Greek M V726A/E167D/F479L Asymptomatic Asymptomatic 67 NA
19 Egyptian M M694V/V726A A, J 21 42 21
20 Egyptian M M680I homo F, A, P, N, V 25 41 16
21 Armenian F M680I/V726A F, A, P 43 58 15
22 Armenian F V726A/ M694V F, A, P, H, N 3 7 4
23 Jewish-Sephardi F M694V homo F, A, P, J, G 6 32 26
24 South Asian F S154P het Asymptomatic Asymptomatic 37 NA
Table 4.1. Mutations, ethnic origins, sex and clinical characteristics of 46 patients with AA amyloidosis complicating SAIDs - FMF.
F=fever, A=abdominal pain, P=pleuritic chest pain, J=joint pain/arthralgia/swelling, R=rash, Ft=fatigue/malaise, H=headache, N=nausea,
V=vomiting, G=Gastrointestinal disturbance, M=myalgia, L=lymphadenopathy, E=red/swollen eyes, S=sweats, Ri=rigors, St=sore throat,
O=oral ulcers.
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Patient Ethnicity Sex Sequence
variants/Mutations
Attack symptoms Age at IPFS
onset
Age amyloidosis
diagnosed
Latency
period
TRAPS – TNFRSF1A mutations
25 Northern European F D42del F, A, P, R, J 5 20 15
26 Northern European F H22Q F, A, P, R, J, M, L, E Unknown 30 Unknown
27 Northern European M T50M F, A, R, J, E <1 31 30
28 Northern European M T37I A, M, F, R, Ft 2 28 26
29 Northern European F C33Y A, M, E, R 2 24 22
30 Northern European M D42del F, A, M, J, R 6 44 38
31 Northern European F R92P F, A, S 18 46 28
32 Northern European F C33Y F, A, M, R, S, Ft, Ri 3 42 39
33 Northern European M T50M A, S, M, Ri 3 39 36
34 Northern European F D42del F, A, P, R, J, G, Ri 4 46 42
35 Northern European M C33Y F, A, P, R, J, E 1 46 45
36 Northern European F Y38S F, R, J, M, E 4 75 71
CAPS – NLRP3 mutations
37 Northern European M A439V Asymptomatic Asymptomatic 52 NA
38 Northern European M T348M R, F, M, J 1 29 28
39 Northern European M T348M R, E, F, <1 15 14
40 Northern European M R260W R, M <1 23 22
41 South Asian M R260W R, E, F, J 10 29 19
42 South Asian F R260W R, E, F, J 7 45 38
MKD – MVK mutations
43 Northern European M L234P/V337I F, L, V, G, A, H <1 23 22
44 Northern European M I268T/V377I F, L, V, G, N, O, J, Ft 1 15 14
45 Northern European F I268T/V377I F, L, G, R, J, St <1 26 25
46 South Asian M S52N/D386N Asymptomatic Asymptomatic 47 NA
Table 4.1 continued. Mutations, ethnic origins, sex and clinical characteristics of 46 patients with AA amyloidosis complicating SAIDs –
TRAPS, CAPS and MKD. F=fever, A=abdominal pain, P=pleuritic chest pain, J=joint pain/arthralgia/swelling, R=rash, Ft=fatigue/malaise,
H=headache, N=nausea, V=vomiting, G=Gastrointestinal disturbance, M=myalgia, L=lymphadenopathy, E=red/swollen eyes, S=sweats, Ri=rigors,
St=sore throat, O=oral ulcers.
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4.4.2 FMF patients
79% of the 24 FMF patients were born outside Europe, the majority in the eastern
Mediterranean region. The median age at diagnosis with AA amyloidosis was 41 years
(IQR 28-58). Six patients had a family history of FMF and only one had a family history
of AA amyloidosis. Two patients were untreated: one was asymptomatic with normal
inflammatory markers, and one died of metastatic cholangiocarcinoma almost
immediately after the diagnosis of amyloidosis and genetic testing. The remaining 22 were
given a trial of colchicine: 19 patients achieved complete remission (CR) and one achieved
partial remission (PR). Two were intolerant - one continued to take low daily doses (<
1mg) despite severe gastrointestinal side-effects until she died of progressive cardiac
amyloidosis five years later; the other remains untreated, on long term dialysis. Follow-
up data was available for 18 patients for a median follow-up period of 11 years. Two
patients were on dialysis at presentation and remained so at last follow-up. Of the rest,
seven patients experienced improvement of proteinuria; however, only three had
stabilisation of CKD. Eight patients showed amyloid regression on SAP scan, and the
remainder showed a stable load over time. Two patients underwent renal transplantation.
4.4.3 TRAPS patients
Ten of the 12 patients had a family history of TRAPS, and nine (from four known
kindreds) had relatives with AA amyloidosis. The median age at diagnosis of amyloidosis
was 41 years (IQR 29-47). Six patients were treated with the anti-TNF agent etanercept:
one was intolerant; one achieved a PR; four had only a transient response and were
subsequently successfully switched to anakinra. A further four were successfully treated
with anakinra up-front. Four patients have died: two had never received definitive
treatment for TRAPS - one died of progressive amyloidosis aged 49, and the other died
of sepsis following a second renal transplant; one patient died on dialysis of disseminated
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TB after receiving long term immunosuppression with anti-cytokine agents; the fourth
patient died of cervical cancer aged 43 on a background of a longstanding renal transplant.
Follow-up data is available for the eight patients who received anti-IL-1 agents. Median
treatment duration was 23 months; two had renal transplants having reached ESRF
before switching to anakinra. Of the others, three patients experienced improvement in
proteinuria and stable or improved CKD and three had worsening of CKD over a median
follow-up period of 65 months, although only one progressed to dialysis.
4.4.4 CAPS patients
Four of the six patients were Northern European from separate kindreds and two were
South Asian cousins. Half the patients had a family history of CAPS, and only the South
Asian cousins had amyloidosis in the family. The median age at diagnosis with AAA was
31 years (IQR 25- 42). Four patients have been treated with anti-IL-1 agents and
responded dramatically both biochemically and symptomatically. The two other patients
died before the role of IL-1 was recognised in CAPS; one was treated with colchicine and
steroids without benefit and the other was untreated, the diagnosis of CAPS having been
made posthumously. Of the four patients treated with anti-IL-1 agents one had a renal
transplant prior to initiation of this treatment. Of the remaining three patients, all have
had resolution of proteinuria over the follow-up period. Three of the four patients have
had stable CKD and one went from CKD stage 1 to 2 over the 11 year follow-up period,
although his SAP scan showed amyloid regression.
4.4.5 MKD patients
Only one of the four patients had a family history with a sibling subsequently diagnosed
and none had a family history of AA amyloidosis. The median age at diagnosis of
amyloidosis was 25 years (IQR 22-32). Of note, in all four patients the diagnosis of MKD
was made at our centre after presentation with AA amyloidosis and none had had
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previous treatment. Three had suggestive symptoms with onset in early childhood but the
diagnosis of SAID had never been considered; the fourth patient complained of non-
specific malaise only. Three cases presented with incipient ESRF and the fourth had severe
nephrotic syndrome and developed dialysis-dependent renal failure within months of
being diagnosed with AA amyloidosis. Prior to diagnosis one patient underwent cadaveric
renal transplant and two others subsequently received renal grafts from their mothers.
Three patients were treated with various anti- cytokine agents over the follow-up period,
and one received renal transplant associated immunosuppression only, with modest
benefit.
Of the patients who received anti-cytokine treatment one appears to have a sustained
seven-year PR to etanercept; one achieved PR with IL-1 blockade but developed an
anaphylactic reaction - he failed to respond to etanercept but a therapeutic trial of the
synthetic anti-IL-6 monoclonal antibody tocilizumab has been successful. The third
patient failed to respond to anakinra, but had a sustained 14-month CR to tocilizumab,
and showed regression of amyloid on SAP scan (Figure 4.1). One patient died aged 45
having lost her transplant from chronic allograft nephropathy after seven years. Another
patient lost their graft after six years due to recurrent amyloid.
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Figure 4.1. Serial 123I-SAP scans demonstrating amyloid regression following
successful treatment of mevalonate kinase deficiency with the anti-IL-6 agent
tocilizumab.
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4.4.6 Whole cohort renal function
Twenty one patients reached ESRF. Eleven (23%) were in ESRF at presentation, and of
these three had been transplanted prior to referral to our centre. A further 13 progressed
to ESRF over the follow-up period, with 10 undergoing transplantation. The median time
to progression to ESRF from onset of AA amyloidosis was 3.3 years (IQR 2-8), with a
median time to transplant of four years (IQR 4-6). Table 4.2 summarises the
characteristics of the kidney-transplanted patients. Of the entire cohort, 11 patients (23%)
experienced improvement in proteinuria, as defined by consensus criteria (116), with a
median decrease in urine protein of 4.8g/24hr (IQR 2.9-5.7) over the follow-up period.
Five of these patients showed regression of amyloid on SAP scintigraphy, and six showed
a stable amyloid load. Nine experienced CR to treatment of the SAID, and two were
untreated.
4.4.7 Whole cohort survival
Eleven patients (24%) died (one CAPS, four TRAPS, one MKD and five FMF). Median
survival by Kaplan-Meier analysis of the entire cohort was 19 years from diagnosis of AA
amyloidosis (IQR 4.8-12.4); the median age at death was 67 years with no deaths occurring
before 43.
4.5 Discussion
The risk of developing AA amyloidosis in these SAIDs is difficult to characterise based
on this cohort for several reasons. Firstly, much of this data is historical, dating back to
when many of the effective treatments in current use were unavailable. Secondly,
increasing age is a known risk factor for AA amyloidosis; presentation in childhood is
exceedingly rare and so including paediatric patients will result in a prevalence
underestimation. Furthermore, as the SAIDs are generally newly described entities, many
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adults were never diagnosed in earlier decades and are now lost to follow-up so current
cohorts are heavily biased towards children.
In this case series of adults (aged over 18), the 24 FMF patients represented 6%, the 12
TRAPS patients, 18%, the 6 CAPS patients, 10%, and the 4 MKD patients represented
18%, of all adult FMF, TRAPS, CAPS and MKD patients under our care. Whilst there is
the possibility of selection bias associated with a national referral centre, the proportions
of CAPS, TRAPS and MKD patients who develop AA amyloidosis are not dissimilar
from those published by other groups, including international consortia (130-132),
although there appears to be much variability in reported proportions of FMF patients
developing AA amyloidosis (132-134).
Early diagnosis and initiation of treatment of the SAID is important in preventing the
development of AA amyloidosis. Early diagnosis can be problematic, as these diseases
are rare and a high index of suspicion is required. Furthermore, clinical features of the
SAID overlap with other more common diseases. Broad and inconstant phenotypes
combined with variable penetrance add further diagnostic challenges. Finally, recognition
of asymptomatic patients with subclinical inflammation before they develop devastating
complications is difficult as it relies on serendipitous detection of abnormal inflammatory
markers and recognition of its importance. In this cohort eight patients (17%) were
asymptomatic despite biochemical inflammation at the time of diagnosis with AA
amyloidosis. These included patients who had been previously described as ‘phenotype
II FMF’ in which there are no overt symptoms but a response to colchicine (135), as well
as some in whom no pathogenic variants were found on Sanger sequencing of known
autoinflammation-associated genes, i.e. patients with AA amyloidosis of uncertain
aetiology.
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Patient IPFS Treatment Treatment
response
ESRF at
presentation
Time to
ESRF from
onset of
IPFS (y)
Time to
ESRF from
amyloid
diagnosis
(y)
Time to
transplant
from amyloid
diagnosis (y)
Graft
survival
(y)
Reason for
graft failure
Cause of patient death
7 FMF Colchicine Complete No 26 2.62 6.78 8.13 NA NA
12 FMF Colchicine Complete No 41 11.87 15.03 0.04 Patient death CMV sepsis post-transplant
17 FMF Colchicine Partial No 17 4 6.00 4.96 NA NA
24 FMF Colchicine Complete Yes 22 -3.59# -2.31# 3.61 NA NA
27 TRAPS Untreated NA Rtx prior 15 2 4.00 20.9 Patient death Cervical cancer
28 TRAPS Untreated NA Yes Unknown 0 2.00 17 Patient death Renal failure secondary to
recurrent amyloid in graft
30 TRAPS Anti-TNF Complete Rtx prior 26 0 4.00 16.25 NA NA
31 TRAPS Anti-IL-1 Complete No 29 5.68 5.92 6.38 NA NA
37 TRAPS Anti-TNF Intolerant No 47 1.66 2.83 8.13 Patient death Sepsis post second renal
transplant
41 CAPS Anti-IL-1 Complete Rtx prior 18.25 0 3.38 4.73 NA NA
45 MKD Anti-TNF Complete Yes 24.71 1.87 3.87 5.54 NA NA
46 MKD Anti-IL-1 Partial No 16.12 0 2.05 6.08 Recurrent
amyloid
NA
47 MKD Untreated NA Yes 28 2 7.00 7 Patient death Unknown
Table 4.2. Characteristics and outcome of 13 patients who underwent renal transplantation. # Patient progressed to ESRF and transplant prior
to diagnosis of AA amyloidosis; Rtx=renal transplant; NA=not applicable.
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Further difficulties are the expense and time associated with sequencing multiple genes
and exons. Where this facility is unavailable, attempts to narrow the differential diagnosis
clinically can be worthwhile. We routinely monitor disease activity by a combination of
patient diaries and serial serum inflammatory markers. In those with suggestive symptoms
accompanied by elevated CRP and SAA a trial of therapy can be very revealing. Responses
to colchicine, corticosteroids or biologics can help to establish a definitive diagnosis. In
addition a successful therapeutic trial can allow effective management of both symptoms
and complications in cases where the disease aetiology remains unknown even after
extensive genetic investigation.
This series demonstrates that even in patients with established AA amyloidosis effective
treatment of the underlying SAID can lead to improved renal function and regression of
amyloid as long as the renal impairment is not too advanced at diagnosis. Outcome of
renal transplantation in these patients is good, and so for those who reach ESRF, this
should certainly be considered as an option. However, the aim of treatment has to be the
complete prevention of this devastating complication, which has negative impacts on
quality and length of life.
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Chapter Five:
Safety and Efficacy of Inhibition of
Interleukin-6 in Chronic Inflammatory
Diseases and Autoinflammation
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5.1 Background
AA amyloidosis is the most serious potential complication of disorders associated with
chronic inflammation and results in progressive renal insufficiency, poor quality of life
(QoL) and substantial mortality (92, 136). The most important aim of treatment is to
suppress inflammation thereby inhibiting production of the acute phase reactant, SAA,
which is the precursor of AA amyloid fibrils. Sustained suppression of SAA not only
prevents the risk of developing AA amyloidosis, but it is also known to be associated with
regression of AA amyloid deposits, improvement in amyloidotic organ function and
prolonged survival (91).
Treatment of the inflammatory arthritides, inflammatory bowel disease and SAIDs has
been revolutionised by the availability of biological agents that block specific cytokines.
TNF blockade is now very widely used as an effective treatment for rheumatoid arthritis
(RA) and some SAIDs; IL-1 blockade has dramatically improved management of several
previously nigh on untreatable SAIDs, notably cryopyrin -associated periodic syndrome
(CAPS), tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS),
colchicine-refractory familial Mediterranean fever (crFMF) and many cases of mevalonate
kinase deficiency (MKD), also known as hyper-immunoglobulin D and periodic fever
syndrome (HIDS) (137, 138). IL-1 inhibition by means of anakinra or canakinumab has
also been effective in patients with AA amyloidosis complicating CAPS and TRAPS and,
as a result, can reduce proteinuria and salvage renal function (136, 139). Blockade of IL-
6 is frequently effective in RA and systemic onset juvenile idiopathic arthritis (SJIA), the
anti-IL-6 receptor monoclonal antibody tocilizumab (TCZ) (RoActemra®) is now
licensed treatment for both conditions. There are very few published data on the use of
TCZ in AA amyloidosis or the SAIDs or chronic inflammatory.
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The short- and long-term efficacy of TCZ has been established by means of several
clinical trials in RA (140-154) as well as in a real life cohort (155), and in SJIA clinical trials
(156-159). TCZ has also been successfully used within clinical trials in other diseases such
as multicentric Castleman’s disease (MCD) (160) and Crohn’s disease (161).
Current knowledge of the safety profile of TCZ in adults with RA is derived from clinical
trials involving 3577 patients who received treatment for at least six months, 3296 who
were treated for at least one year, 2806 who received treatment for at least two years and
1222 treated for three years. The commonest reported adverse drug reactions (ADRs),
i.e. those occurring in ≥ 5% of patients treated with TCZ monotherapy or in combination 
with sDMARDs were upper respiratory tract infections, nasopharyngitis, headache,
hypertension and increased serum alanine aminotransferase. Preliminary safety data on
TCZ in children with SJIA has been reported from an international phase 3 trial
(TENDER) in 112 children, clinical trials in Japan involving 149 patients, and the
Japanese post-marketing monitoring program which includes 366 cases. The authors
concluded that TCZ was not associated with an increased risk of macrophage activation
syndrome (MAS) (162). In TENDER 57% of patients had at least one episode of
neutropenia. This was associated with an increased risk of infection compared to periods
when the children were not neutropenic. MXT use and younger age were associated with
increased risk for more severe neutropenia, but TCZ exposure was not (163).
The safety and efficacy of TCZ in renal impairment has been supported by a number of
publications; three case reports document the safe and effective use of TCZ in patients
with end stage renal failure and underlying RA (164) and MCD (165, 166). A Japanese
registry study has reported on 102 patients with RA and renal insufficiency showing that
the safety and efficacy profile is comparable with the group with independent renal
function (n=279) (167). In a case series of five patients with AA amyloidosis secondary
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to RA, improvement in renal function was seen at one year (168) with no safety issues.
To our knowledge there are no reports on the use of TCZ after renal transplantation.
5.2 Aims
We assessed clinical and serological responses and adverse reactions to TCZ in 20 adult
patients with a variety of inflammatory disorders refractory to other treatments, 70% of
whom had developed AA amyloidosis, including four patients who underwent renal
transplantation.
5.3 Methods
5.3.1 Patients
Three patients (13, 14 and 15) were commenced on 4 weekly infusions of TCZ within
the specialist nurse fever clinic, and were also monitored and followed up here. Between
2010 and 2014, in a further 17 patients, treatment with TCZ was recommended by the
NAC, but treatment was given locally to minimise unnecessary cost and inconvenience
of travel. These patients were monitored locally but also attended the NAC for further
follow up. All patients were asked to keep symptom diaries, and to send in blood samples
every two to four weeks for monitoring of acute phase reactants until treatment was
established; thereafter SAA and CRP would be monitored at routine clinic visits locally,
and results were sent from the local team to the NAC. Fourteen of the 20 patients had
AA amyloidosis. Disease activity and treatment response were monitored by patient-
reported symptoms and serial SAA and CRP measurements. Amyloid load was evaluated
by whole body 123I-SAP scintigraphy. Renal function was measured by means of serum
and urine chemistry. QoL was measured in 12 patients using the SF36v2® questionnaire.
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Patients gave written informed consent for retrospective analysis and publication of their
clinical data (REC reference number 06/Q0501/42).
5.3.2 Other methods
Other methods are described in Chapter Two: Methods.
5.4 Results
5.4.1 Whole cohort characteristics
Table 5.1 summarises the patient characteristics. Twelve (60%) were male. Six patients
had unclassified inflammatory disorders, two had MKD, seven had RA, four SJIA and
one unicentric Castleman’s disease. All patients in the cohort had received at least one
previous line of treatment with an anti-cytokine therapy or disease-modifying anti-
rheumatic drug (DMARD), which had proved ineffective (including anakinra in two
patients with MKD and one SJIA patient) or had intolerable side effects. Many patients
were extensively pre-treated, one having tried more than ten different therapies over her
disease course. Fourteen patients (70%) had developed AA amyloidosis. The total median
follow-up time for the whole cohort was 56 months, with an interquartile range (IQR) of
18 to 86 months. Median follow-up of patients on TCZ was 23 months. All results are
shown as median (IQR) unless otherwise stated. Details of TCZ therapy are summarised
in Table 5.2.
5.4.2 Serial monitoring of the acute phase response
The whole cohort median pre-treatment SAA (the median of all available SAA
measurements in the year prior to commencement of TCZ) was 70 mg/L (38 – 158). The
first post-treatment SAA measurements were undertaken at 10 days (7 – 13) after the first
dose of TCZ, and were significantly improved to a median of 4 mg/L (3 – 7); this
excellent serological response has been maintained at median 5 mg/L (3 – 8) over an on-
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treatment follow-up period of 23 months (13 – 35) (Mann Whitney p <0.0001) (Figure
5.1).
5.4.3 Change in renal function in AA amyloid cases
Of 14 patients with AA amyloidosis, 12 had renal impairment. Four of the 12 had renal
transplants and a further two were dialysis-dependent. The six patients with measurable
native renal function showed a mean reduction in proteinuria of 3.4g/24 hours over the
on-treatment period when compared with the pre-treatment 24 hour urine collection.
5.4.4 Monitoring of amyloid deposits
Thirteen of 14 patients with AA amyloidosis have had pre- and on-treatment serial SAP
scans. Four patients showed stable amyloid deposits whilst nine showed regression of
amyloid; none showed worsening amyloid deposition whilst on TCZ. The interval
between commencement of TCZ therapy and the first improved SAP scan was 10
months (7 – 13).
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Patient
ID
Sex Ethnicity Inflammatory
disorder
Age at
onset (y)
Previous unsuccessful therapy Renal
impairment
Renal
transplant
AA amy-
loidosis
Follow
-
up (y)
1 M N. European RA 36 MTX, SSZ, ETC, RTX, G, LEF 1 1 1 7
2 F N. European RA 28 MTX, SSZ, ETC, RTX 1 0 1 4
3 F N. European RA 49 MTX, SSZ, ETC 1 0 1 2
4 M N. European RA 19 MTX, ETC, CMB 1 0 1 7
5 M N. European RA 22 MTX, ETC, RTX 1 Dialysis 1 2
6 F N. European RA 40 MTX, RTX, ADA, ETC 1 0 1 8
7 F N. European RA 35 MTX, RTX 0 0 1 6
8 M N. European SJIA 12 CMB, ETC, INF, ADA, RTX 1 1 1 22
9 F N. European SJIA 14 CSP, RTX, LEF, MMF, TAC, ANA, ABT, CMB, CSP, AZA,
MTX
1 1 1 6
10 F N. European SJIA 6 MTX, ETC 0 0 1 3
11 F N. European SJIA 19 MTX, ETC, ADA 1 0 1 5
12 M N. European Castleman's 38 MTX 1 0 1 4
13 M N. European MKD <0.5 ANA, ETC 1 1 1 11
14 M N. European MKD <0.5 ANA 0 0 0 2
15 M S. Asian Unclassified 41 CSP, AZA, MTX, CAM, RTX, INF, ANA 1 Dialysis 1 8
16 M S. European Unclassified 10 ADA, ETC, ANA, MMF 0 0 0 8
17 M S. Asian Unclassified 15 MTX, SSZ, PCM, CSP, COL, INF 0 0 0 18
18 F N. European Unclassified 16 MTX, ANA 0 0 0 4
19 M N. European Unclassified 55 AZA, ANA, ETC 0 0 0 1
20 M N. European Unclassified 19 ANA 0 0 0 2
Table 5.1. Characteristics of patients treated with TCZ. Patients are described in terms of demographics, underlying disease, previous therapies and total
follow-up period. ANA=anakinra, ADA=adalimumab, ETC=etanercept, MMF=mycophenolate mofetil, MTX=methotrexate, SSZ=sulphasalazine,
PCM=penicillamine, CSP=cyclosporine, COL=colchicine, INF=infliximab, RTX=rituximab, G=gold, LEF=leflunamide, CMB=chlorambucil,
CAM=CAMPATH, TAC=tacrolimus, ABT=abatacept.
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Figure 5.2 shows serial SAP scans of patient 4 who had regression of amyloid.
5.3.5 QoL before and after treatment
QoL was measured in 10 patients whilst treatment with TCZ was ongoing, and in three
of these QoL was also measured prior to commencing therapy. Results are shown in
Figure 5.3. A comparison of the mean scores in each domain before and after treatment
were statistically significant (Mann Whitney p=0.0354) whilst clinically significant changes
were seen in all domains apart from mental health, in which the change was 9 points. The
bodily pain domain showed the greatest improvement of 24 points, followed closely by
the vitality and social functioning domains at 22 points each, and the physical functioning
and role physical domains which showed a post-treatment improvement of 20 points
each.
5.3.6 Adverse events
Adverse events (AEs) were reported in eight patients. Patient six developed two urinary
tract infections (UTIs) and a respiratory tract infection within the first year of TCZ
therapy; however, this patient had a long history of recurrent UTIs and was on a long
term rotational antibiotic regimen of cephalexin and nitrofurantoin. Patient nine
developed gallstone pancreatitis which resolved following endoscopic retrograde
cholangiopancreatography. Neither of these patients had their TCZ therapy interrupted
or stopped as a consequence of the AE.
Patient 20 has had an infusion delayed due to a transient drop in his white cell count.
Patient one developed a subclinical Klebsiella ozaenae UTI, discovered coincidentally at
a routine clinical review. Treatment was not stopped at that time; however, TCZ was
temporarily discontinued just prior to renal transplantation.
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Patient
ID
Age at
Therapy
Onset (y)
TCZ dose
(mg/kg),
frequency, route
Serological
response to
TCZ
Clinical
response to
TCZ
Duration
of therapy
(m)
Monotherapy/ with other agent Continuing Reason, if
not
continuing
1 56 162 mg q2w sc Complete Partial 3 Pred 15 mg daily Yes
2 65 8 mg/kg q4w iv Complete Partial 20 Pred 10 mg daily Yes
3 54 8 mg/kg q4w iv Complete Partial 12 Monotherapy Yes
4 56 8 mg/kg q6w iv Complete Partial 23 Monotherapy Yes
5 57 8 mg/kg q4w iv Complete Complete 14 Pred 10 mg Yes
6 53 8 mg/kg q4w iv Complete Partial 34 Pred 5 mg daily Yes
7 64 8 mg/kg q4w iv Complete Partial 30 Monotherapy Yes
8 35 8 mg/kg q6w iv Complete Partial 28 Pred 5 mg Yes
9 39 8 mg/kg q4w iv Complete Partial 44 Monotherapy Yes
10 6 8 mg/kg q3w iv Complete Partial 9 ETC 25 mg bi-weekly; MTX 20 mg weekly; Pred 4 mg daily Yes
11 26 8 mg/kg q4w iv Complete Partial 24 Pred, LEF Yes
12 51 8 mg/kg q4w iv Complete Complete 38 Monotherapy Yes
13 28 8 mg/kg q4w iv Complete Complete 24 Pred 0.5 mg daily Yes
14 24 8 mg/kg q4w iv Complete Complete 13 Monotherapy Yes
15 52 8 mg/kg q4w iv Complete Partial 39 Monotherapy No Deceased
16 15 8 mg/kg q4w iv Complete Complete 18 COL 1.5 mg daily Yes
17 50 8 mg/kg q4w iv Complete Complete 22 Monotherapy Yes
18 25 8 mg/kg q4w iv Complete Partial 19 Pred 5 mg daily; ANA 50 mg weekly Yes
19 59 8 mg/kg q4w iv Complete Partial 6 Pred 15 mg daily Yes
20 49 8 mg/kg q4w iv Partial Partial 4 COL 1.5 mg daily Yes
Table 5.2. Details of tocilizumab treatment. Complete response is defined as complete resolution of symptoms or complete normalisation of serological
inflammatory markers SAA and CRP (<10 mg/L); Partial response is defined as good but incomplete resolution of symptoms or reduction by > 50% but not
complete normalisation of serological inflammatory markers SAA and CRP. Pred=prednisolone.
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Figure 5.1. Sustained suppression of serum SAA after IL-6 blockade by
tocilizumab. Pre-treatment values are shown as the median of all pre-treatment SAA
measurement up to 1 year prior to commencement of tocilizumab therapy. On-treatment
values are shown as the median of all on-treatment SAA measurements to date. Mann-
Whitney test revealed a statistically significant difference between the pre- and post-
treatment measurements (p<0.0001). The on-treatment follow-up period (duration of
treatment) was 23 months (13 - 35).
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In view of ongoing inflammatory activity post-transplant TCZ was recommenced with
excellent and dramatic anti-inflammatory effect, but was unfortunately complicated by a
subcutaneous abscess around a peritoneal dialysis catheter cuff. TCZ treatment was
temporarily halted whilst he was being treated for the infection, and has now
recommenced. Patient eight had a four month break in treatment due to elevated LFTs;
these have now normalised and he has resumed therapy at the same dose.
Patient 19 developed shingles two months after starting treatment, and bacterial
pneumonia four months later; both episodes resulted in hospitalisation. Patient 13
developed EBV septicaemia after his renal transplant, detected on routine monitoring.
His dose of TCZ was halved for six months until this resolved. Patient 10 was hospitalised
for MAS; treatment with TCZ was temporarily halted during the acute period. Despite
these complications, all three patients elected to continue with TCZ therapy.
Patient 14 has elected to have a ‘treatment holiday’; however having had severe disease
flares in the four months off TCZ he has restarted treatment. Patient 15 had a sudden
cardiac death after over three years of successful treatment with TCZ; he had been on
dialysis for six years at the time of his death
5.4 Discussion
The IL-6 gene is located on chromosome 7 (169). IL-6 is a 26-kDa glycopeptide produced
by a variety of cell types including fibroblasts, osteoblasts, endothelial cells, monocytes,
keratinocytes, T cells and B cells. IL-6 acts via two known signalling pathways; classic
signalling through the membrane-bound IL-6 receptor (mIL-6R) via activation of
glycoprotein gp130, or trans-signalling via soluble receptors (sIL-6R) (170).
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Figure 5.2. Serial SAP scans showing regression of amyloid from the liver of patient
4 with corresponding serum SAA measurements over the time period. Previous
treatment with MTX, ETC and CMB had little effect on the underlying inflammatory
disease resulting in further accumulation of amyloid in the liver shown on the anterior SAP
scan in 2012 (panel B) compared with the baseline scan in 2011 (panel A). Subsequent
successful treatment with tocilizumab for two years resulted in regression of amyloid as
shown in the 2014 SAP scan (panel C).
2011 2012 2014
Time-point
Se
ru
m
SA
A
co
nc
en
tr
at
io
n
(m
g/
L)
CHAPTER FIVE
92 | P a g e
There is increasing evidence that classic signalling plays a role in tissue regeneration and
trans-signalling is responsible for the majority of pro-inflammatory responses. Novel
agents that specifically target soluble IL-6R are currently under investigation and may be
advantageous in human disease (171). TCZ is a humanised anti-human IL-6R monoclonal
antibody which binds both sIL-6R and mIL-6R, thereby inhibiting both signalling
pathways (172). The recommended dosing for adults with RA is 8 mg/kg infused once
every four weeks. Dose adjustments are recommended in cases of liver enzyme
abnormalities, low absolute neutrophil count and low platelet count. Successful dose
reduction in patients with low disease activity is possible, with dose escalation to treat
occasional flare (173).
This small series shows that in patients with treatment-refractory chronic inflammatory
conditions which have either already resulted in AA amyloidosis or which are a high risk
of being complicated by it, TCZ can be effective in suppressing the hepatic acute phase
response. In patients with AA amyloidosis suppression of SAA levels is the major goal of
treatment as this is known to dramatically improve outcome. We had been optimistic that
TCZ would reduce SAA levels as IL-6 is the most important cytokine driving the hepatic
acute phase response. This property raises the theoretical possibility that IL-6 blockade
could work at the level of hepatocytes to dissociate on-going symptomatic inflammatory
disease from a measurable hepatic acute phase response.
In AA amyloidosis such an outcome could effectively prevent progressive amyloid
deposition without providing any relief from inflammatory symptoms, particularly in
those patients with chronic joint damage from inflammatory arthritides. Somewhat to our
surprise whilst not all patients reported complete symptom resolution, all patients
reported feeling at least somewhat better. Furthermore, two patients with MKD showed
complete clinical and serological response to TCZ; this has previously been described
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Figure 5.3. Quality of life before and during treatment with tocilizumab. Patients
were surveyed before and whilst on treatment. A comparison of the mean scores in each
domain before and on-treatment were statistically significant (Mann Whitney p=0.0354)
whilst clinically significant changes were seen in all domains apart from mental health, in
which the change was 9 points (a change of 10 points or more is considered clinically
significant). PF=physical function, RP=role physical, BP=bodily pain, GH=general
health, VT=vitality, SF=social function, RE=role emotional, MH=mental health.
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only in one other patient (174). The response has been sustained to date in all patients
who remain on TCZ (17, 85%); none have discontinued treatment due to loss of efficacy,
however, longer follow-up is required. Treatment-related AEs were largely infections.
Despite three patients requiring hospitalisation for AEs, all elected to continue treatment
feeling that their clinical improvement justified the risks. Six patients temporarily stopped
treatment due to AEs, and none yet have permanently discontinued TCZ therapy due to
AEs.
At present IL-1 inhibition remains the first-line therapeutic option in patients with
confirmed or suspected systemic autoinflammatory disorders as they have a proven safety
and efficacy profile (175, 176) and are generally well tolerated. However, this small series
with an on-treatment follow-up of 23 months (13 – 35) demonstrates that TCZ appears
both relatively safe and effective even in the situations of renal failure, solid organ
transplantation and extensively pre-treated diseases, and has resulted in stabilisation or
reduction of amyloid deposits in all patients with AA amyloidosis. A therapeutic trial of
TCZ is therefore reasonable in patients who fail to respond to other treatments, even in
those in whom a firm diagnosis has not yet been made.
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Chapter Six:
Safety and Efficacy of Inhibition of
Interleukin-1 in Inflammatory Disorders
and AA Amyloidosis
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In 1962 the first report of the familial syndrome of urticaria, deafness and ‘aguey bouts’,
with and without amyloidosis, was published by TJ Muckle and M Wells (177). Thereafter
followed several similar reports and 40 years later, mutations in the gene NLRP3
(previously known as NALP3, CIAS1 and PYPAF1) were identified by Hal Hoffman as
the cause of Muckle-Wells syndrome (MWS) and familial cold autoinflammatory
syndrome (FCAS) (178), as well as chronic, infantile, neurologic, cutaneous and articular
(CINCA) syndrome described by Anne-Marie Prieur (179), also known as the neonatal-
onset multisystem inflammatory disease concurrently described by Ivona Aksentijevich
(180). Another year or two hence and the team of Jurg Tschopp described how the
interaction of the pyrin domain of NLRP3 with ASC, stimulated NF-κB signalling and 
increased interleukin (IL)-1β secretion (14); increased IL-1β secretion had previously been 
seen in the unstimulated PBMCs of a child with CINCA syndrome/NOMID (180).
The identification of IL-1 as the key pro-inflammatory cytokine in these diseases heralded
a breakthrough, and in 2003 Philip Hawkins and Helen Lachmann successfully
administered the first anti-IL-1 therapeutic agent (the recombinant IL-1 receptor
antagonist, anakinra) to two patients with MWS and AA amyloidosis here at the UK NAC
(181). In the decade-or-so since, there have been advances such that there are now two
additional therapeutic agents, canakinumab and rilonacept, licensed for the treatment of
cryopyrin-associated periodic syndrome (CAPS), the all-encompassing term now used to
describe the continuum of FCAS, MWS and CINCA/NOMID. The success of these
therapies in modulating disease activity in CAPS has stimulated the empirical use of some
of these drugs in other inflammatory conditions.
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Chapter 6 is composed of two parts. Part one describes the use of anti-IL-1 therapies in
CAPS. Part two describes the empirical use of anakinra in AA amyloidosis of unknown
aetiology.
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Chapter Six Part I:
Interleukin-1 Inhibition in Cryopyrin-
Associated Periodic Syndrome – A 13-
Year, Single-Centre Experience of
Safety and Efficacy
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6.1.1 Background
To our knowledge the first case of CAPS to present at our Centre was a 36 year old
Australian man of Jewish descent in 1993. He presented with renal failure secondary to
AA amyloidosis. MWS was suspected due to the history of urticarial rash since birth,
progressive deafness and AA amyloidosis. Sadly he died of calciphylaxis in the year 2000,
before the identification of the genetic mutation which causes the disease. Since discovery
of the gene in 2001, about 150 cases of mutations in NLRP3 have been identified by our
genetic screening service, and since then, 116 patients have been reviewed in the clinic,
with 113 treated with the anti-IL-1 drugs anakinra or canakinumab. Anakinra had been
used off-license for CAPS and other autoinflammatory diseases for well over a decade
until authorisation for the CAPS indication was obtained in 2013/4 by means of
retrospective safety and efficacy data. Canakinumab went through the usual phases of
clinical trials and achieved license for CAPS in the UK in 2009; this sparked the initiation
of the NHS National CAPS Treatment Service at the UK National Amyloidosis Centre
(NAC) in London.
The NHS National CAPS Treatment Service was set up as a canakinumab treatment and
monitoring service; a few patients are now being treated with anakinra within the service.
Funded directly by NHS England, the aim of the service was to safely reconstitute and
administer this high cost drug to patients in a controlled environment, as well as to closely
monitor drug efficacy and any adverse effects. It is composed of a nurse-led and medical
consultant-led clinic running in parallel. Patients undergo initial assessment and diagnosis
in the consultant clinic, and are assessed, monitored and treated with canakinumab every
eight to 12 weeks in the nurse clinic. They are reviewed by a consultant annually, unless
there are complex issues requiring more frequent medical review or intervention. Patients
treated with anakinra are reviewed every three to six months.
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6.1.2. Aims
We sought to describe a single-centre experience of over a decade of IL-1 inhibition using
anakinra and canakinumab in patients with CAPS.
6.1.3 Patients and Methods
6.1.3.1 Patients and assessments
One hundred and seventeen patients with a clinical and/or genetic diagnosis of CAPS
were seen at our Centre between 1993 and 2015, and these patients make up the ‘whole’
cohort. Seventy three patients treated with an anti-IL-1 agent and who attended regular
follow-up at the NAC were included in the ‘analysis’ cohort. Patients attended clinic
approximately every eight weeks if they were taking canakinumab and every three to
twelve months if they were on anakinra. Some patients were untreated and attended
annually for review. Patients underwent the following assessments at each visit:
 Vital signs measurements (blood pressure, heart rate and weight)
 Blood sampling for biochemistry including renal and liver function and full blood
count; and anti-nuclear antibodies annually
 Urinalysis
 Physical examination where indicated
 Quality of life assessment (annually)
And additional tests for patients treated with canakinumab only:
 CAPS disease activity assessment (symptom score)
 Ophthalmology, audiometry, neurological assessment and brain MRI (where
indicated) annually.
More detail about the clinic protocol may be found in Chapter Two: Methods.
Patients gave written informed consent for retrospective analysis and publication of their
clinical data (REC reference number 06/Q0501/42).
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6.1.3.2 Other methods
Further methods are described in Chapter Two: Methods.
6.1.4 Results
6.1.4.1 Whole cohort characteristics
Of the 117 patients, half were female. Twenty two were children who were followed-up
at a partner paediatric hospital, although their anti-IL-1 therapies were prescribed as part
of the UK NAC National CAPS Treatment Service. A variety of genetic mutations were
found among the cohort (Figure 6.1.1), and in 13 no variant was detected on Sanger
sequencing, although patients exhibited clinical features of the disease. Age at diagnosis
ranged from 10 months to 79 years. Three patients went untreated; two died before
identification of the pathogenic role of IL-1, and one had very mild disease. Five patients
developed AA amyloidosis as a complication.
Figure 6.1.1. Distribution (%) of variants within the whole cohort. *Conventional
Sanger sequencing revealed no variant in 11% of patients.
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6.1.4.2 General characteristics of the analysis cohort
Characteristics of individual patients in the analysis cohort are shown in Table 6.1.1.
Seventy three patients were included. Forty (55%) were female. Patients were
predominantly Caucasian (89%). Median age of the cohort at the first clinic visit (this was
the diagnostic visit in the overwhelming majority of patients) was 32 years (IQR 23 to
48). Ten were children under 16 years of age and four were between 16 and 18 years old.
The youngest child to commence therapy was 8 years old and was treated with
canakinumab (patient 36 in Table 6.1.1). The oldest patient at diagnosis was 78 and was
treated with anakinra (patient 72).
A variety of mutations are represented: 24 A439V (33%), 15 R260W (21%), 10 T348M
(14%), 5 V198M (7%), 4 patients with somatic mosaic mutations (5%) and 15 patients
with a variety of other mutations (21%). Onset of symptoms occurred predominantly in
the neonatal period, infancy or childhood (86% of patients), but 5 patients had onset in
the teenage years (patients 15, 27, 32, 54, and 56), and 5 had adult onset (patient 51 with
V198M and the 4 somatic mosaics, patients 70 to 73). Family history of disease was
present in 42 patients (58%). Twelve kindreds are represented within this cohort.
Sixteen patients (22%) are currently being treated with anakinra and 57 (78%) with
canakinumab. Six patients currently on anakinra have switched from canakinumab due to
inadequate response. Twenty one patients currently on canakinumab have switched from
anakinra, in preference of the eight-weekly (rather than daily) injection regimen; many
also cited painful injections as secondary reason for switching from anakinra. Two female
patients swapped from canakinumab to anakinra during pregnancy and resumed
canakinumab therapy in the post-partum period. The median duration of anti-IL-1
therapy within the analysis cohort was 5 years (IQR 2.5 to 7.8).
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Patient No. Sex Ethnicity Age at
V1 (y)
Variant Clinical
manifestations
Disease
pattern
Family
history
Current therapy Response Previous
therapy
Duration of IL-
1 blockade (y)
1 α F Caucasian 25.3 A439V S, F, MS, E CE Yes Anakinra Complete 8.09
2 α F Caucasian 26.52 A439V S, F, C, MS, E, O CE Yes Anakinra Complete 7.62
3 α F Caucasian 61.34 A439V S, F, C, MS, N, E, O CE Yes Canakinumab Complete Anakinra 7.76
4 α F Caucasian 58.02 A439V S, C, MS, N, E, O CE Yes Canakinumab Complete Anakinra 7.02
5 β M Caucasian 68.44 A439V S, F, C, MS, E R Yes Canakinumab Partial 2.30
6 β M Caucasian 29.10 A439V S, F, C, MS, O R Yes Canakinumab Complete 6.91
7 β F Caucasian 54.63 A439V S, F, C, E, O CE Yes Anakinra Complete 7.14
8 γ F Caucasian 28.67 A439V S, F, C, MS, N, E, O CE Yes Canakinumab Complete Anakinra (p) 3.33
9 γ F Caucasian 27.29 A439V S, C, MS, E, O CE Yes Canakinumab Complete 3.94
10 γ F Caucasian 53.22 A439V S, F, C, MS, E*, O CE Yes Canakinumab Complete 3.94
11 γ F Caucasian 50.33 A439V S, C, MS, E, O CE Yes Canakinumab Complete 3.94
12 € M Caucasian 47.07 A439V S, F, C, MS, E, O CE Yes Anakinra Partial (I) Canakinumab 3.76
13 € F Caucasian 14.25 A439V S, F, C, MS, N, E, O CE Yes Canakinumab Complete 3.76
14 ∞ M Caucasian 20.01 A439V S, F, C, MS, E R Yes Canakinumab Complete Anakinra 7.77
15 ∞ M Caucasian 48.27 A439V S, F, C, MS, E CE Yes Canakinumab Complete Anakinra 7.77
16 ∞ F Caucasian 51.22 A439V S, C, MS, N,E, O C Yes Canakinumab Complete Anakinra 8.33
17 £ F Caucasian 60.56 A439V S, MS, E C Yes Canakinumab Complete 1.63
18 £ F Caucasian 27.00 A439V S, F, C, MS CE Yes Canakinumab Complete 1.63
19 ¥ M Caucasian 46.43 A439V S, F, C, MS, N, E CE Yes Canakinumab Partial 1.73
20 ¥ M Caucasian 50.60 A439V S, F, C, MS, E C Yes Canakinumab Complete 1.00
21 ¥ M Caucasian 23.72 A439V S, F, C, MS, N, E, O C Yes Canakinumab Complete 0.53
22 ¥ F Caucasian 49.61 A439V S, F, C, MS, N, E CE Yes Canakinumab Partial 2.53
23 M Caucasian 28.36 A439V S, F, C, MS, E R Yes Canakinumab Complete. 0.21
24 F Caucasian 21.04 A439V S, F, C, MS, N, E, O CE No Anakinra Complete 2.78
Table 6.1.1. Characteristics of individual patients in the analysis cohort. Symbols next to patient numbers indicate membership of the same
kindred. * indicates severe clinical manifestations. V1 = first clinic visit; S = skin, F = fever, C= other constitutional symptoms, MS = musculoskeletal,
N = neurological, E = eye symptoms, H = hearing loss, O = other. Anakinra (p) indicates use of anakinra only during pregnancy. (I) indicates inadequate
responder to one or both anti-IL-1 therapies.
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Patient
No.
Sex Ethnicity Age at
V1 (y)
Variant Clinical manifestations Disease
pattern
Family
history
Current
therapy
Response Previous
therapy
Duration of IL-
1 blockade (y)
25 × F Asian 12.91 R260W S, MS, E CE Yes Canakinumab Complete 1.08
26 × F Asian 10.10 R260W S, C, MS, O CE Yes Canakinumab Complete 5.26
27 × M Asian 45.58 R260W S, F, C, MS, O C No Canakinumab Complete 5.26
28 × M Asian 8.56 R260W S, F, MS, O R Yes Canakinumab Complete 4.14
29 µ M Caucasian 39.17 R260W S, MS, E CE Yes Anakinra Complete 10.95
30 µ M Caucasian 11.50 R260W S, C, MS, N, E CE Yes Canakinumab Complete Anakinra 10.66
31 µ M Caucasian 5.12 R260W S, MS, E CE Yes Canakinumab Complete 6.25
32 µ F Caucasian 48.94 R260W S, F, C, MS, E CE Yes Canakinumab Complete 9.40
33 π F Caucasian 32.25 R260W S, C, MS, E C Yes Canakinumab Complete 5.42
34 π F Caucasian 57.50 R260W S, C, N, E CE Yes Anakinra Complete 6.97
35 M Caucasian 42.81 R260W S, F, C, MS*, N*, E, O CE No Canakinumab Partial Anakinra 3.92
36 F Caucasian 40.44 R260W S, F, MS, E CE No Canakinumab Complete 7.43
37 M Caucasian 51.00 R260W S, F, C, MS, E, H CE No Canakinumab Complete 4.89
38 F Caucasian 43.29 R260W S, F, C, MS, N, E, H, O R No Anakinra Partial (I) Canakinumab 2.24
39 M Mixed 23.43 R260W S, F, C, MS, E, H, O CE No Canakinumab Complete Anakinra 13.12
40 Ω M Caucasian 14.40 T348M S, MS, N*, E*, H C Yes Canakinumab Complete Anakinra 8.03
41 Ω M Caucasian 11.12 T348M S, N, E, H C Yes Canakinumab Complete 5.08
42 Ω F Caucasian 42.64 T348M S, F, MS, N, E, H CE No Canakinumab Partial Anakinra 8.03
43 ∑ M Caucasian 30.29 T348M S, C, MS, N*, E, H CE Yes Canakinumab Complete 10.70
44 ∑ F Caucasian 33.27 T348M S, F, C, MS, N, E, H CE Yes Canakinumab Complete Anakinra 11.04
45 F Caucasian 18.72 T348M S, C, MS, N, E, H, O CE No Canakinumab Complete Anakinra (p) 8.57
46 M Caucasian 41.53 T348M S, F, C, MS, N*, E, H, O C No Anakinra Partial (I) Canakinumab 3.11
47 M Caucasian 23.47 T348M S, F, C, MS, N*, E, H, O C No Canakinumab Partial (I) 7.48
48 M Caucasian 34.57 T348M S, F, MS, N, E, H CE No Canakinumab Complete Anakinra 10.26
49 M Caucasian 35.23 T348M S, F, C, MS, N*, E, H, O C No Canakinumab Complete 10.50
Table 6.1.1 cont. Characteristics of individual patients in the analysis cohort. Symbols next to patient numbers indicate membership of the same
kindred. * indicates severe clinical manifestations. V1 = first clinic visit; S = skin, F = fever, C= other constitutional symptoms, MS = musculoskeletal,
N = neurological, E = eye symptoms, H = hearing loss, O = other. Anakinra (p) indicates use of anakinra only during pregnancy. (I) indicates inadequate
responder to one or both anti-IL-1 therapies.
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Patient
No.
Sex Ethnicit
y
Age at
V1 (y)
Variant Clinical manifestations Disease
pattern
Family
history
Current
therapy
Response Previous
therapy
Duration of IL-
1 blockade (y)
50 Δ F Caucasian 56.63 V198M S, F, C, MS, N, E, O R Yes Canakinumab Complete 2.03
51 Δ F Caucasian 26.32 V198M S, F, C, MS, E, O CE Yes Canakinumab Complete 2.49
52 F Caucasian 14.70 V198M S, MS R No Canakinumab Complete 5.27
53 F Caucasian 29.49 V198M S, F, CMS, E R No Anakinra Complete 1.67
54 F Caucasian 33.40 V198M S, F, C, MS, O R Yes Anakinra Partial 2.20
55 Ψ M African 35.08 Y859C S, F, C, MS, N*, E, H, O CE Yes Canakinumab Complete 2.93
56 Ψ F African 59.98 Y859C S, MS, H, E, H, O CE Yes Canakinumab Partial 0.67
57 F Caucasian 14.61 Y570F S, F, MS, N*, E, H, O CE No Canakinumab Partial (I) Anakinra 10.54
58 F Caucasian 43.11 A352P S, E R Yes Canakinumab Complete 1.34
59 F Caucasian 24.55 A352T S, C, MS, N*, E, H, O C No Canakinumab Partial (I) Anakinra 2.86
60 M Caucasian 40.43 T346I S, F, C, MS, N, E C No Anakinra Complete (I) Canakinumab 4.81
61 M Caucasian 25.81 D303N S, C, MS, N, E, H, O C No Canakinumab Complete 5.71
62 M Caucasian 26.69 F523C S, F, C, MS, N, E, H, O CE No Canakinumab Partial 6.08
63 F Caucasian 32.15 G569R S, C, MS, E*, H, O CE No Anakinra Complete 8.13
64 M Caucasian 16.71 G755R S, MS, N, E C No Canakinumab Partial Anakinra 8.45
65 F Caucasian 23.10 L353P S, MS CE No Canakinumab Complete 3.36
66 F Caucasian 18.10 L632F S, F, C, MS, N, E, H, O CE No Canakinumab Complete Anakinra 10.62
67 M Mixed 16.34 S547C S, F, C, MS, N CE No None Partial (I) Both 0.44
68 F Caucasian 22.59 V351M S, F, C, N, E*, H C No Canakinumab Complete Anakinra 6.45
69 M Caucasian 22.68 DelT438-A439 F, MS, N, E*, H C No Canakinumab Partial 1.95
70 F Caucasian 66.45 Y563C mosaic F, C, N, E, H C No Anakinra Partial (I) Canakinumab 5.09
71 M Caucasian 47.39 E567K mosaic S, F, C, N*, H, O C No Anakinra Partial (I) Canakinumab 5.60
72 M Caucasian 78.86 G569V mosaic S, C, MS, E CE No Anakinra Complete 0.96
73 F Caucasian 61.43 Y563C mosaic S, F, C, MS, H CE No Canakinumab Partial Anakinra 1.17
Table 6.1.1 cont. Characteristics of individual patients in the analysis cohort. Symbols next to patient numbers indicate membership of the same
kindred. * indicates severe clinical manifestations. V1 = first clinic visit; S = skin, F = fever, C= other constitutional symptoms, MS = musculoskeletal,
N = neurological, E = eye symptoms, H = hearing loss, O = other. Anakinra (p) indicates use of anakinra only during pregnancy. (I) indicates inadequate
responder to one or both anti-IL-1 therapies.
CHAPTER SIX PART ONE
106 | P a g e
6.1.4.3 Clinical characteristics of the analysis cohort
Nineteen patients (26%) exhibited a chronic disease pattern with symptoms every day or
most days prior to treatment. Forty three (59%) reported having a chronic pattern with
intermittent exacerbations prior to commencing therapy. Eleven patients (15%) had a
recurrent pattern with asymptomatic periods between flares. Disease manifestations are
summarised for each patient in Table 6.1.1 above and described in more detail for the
entire analysis cohort in Table 6.1.2 below. Description and categorisation of
manifestations are based on those reported/developed by PRINTO and Eurofever (182).
n %
Fever 47 64
Other constitutional symptoms+ 15 21
No fever or other constitutional symptoms 11 15
Skin manifestations 71 97
Urticarial rash 68 93
Maculopapular rash 3 4
No rash 2 3
Musculoskeletal manifestations 66 90
Myalgia 22 30
Arthralgia 57 78
Arthritis 25 34
Severe musculoskeletal manifestations* 4 5
Neurological involvement 39 53
Headache 39 53
Papilloedema 9 12
Meningitis 8 11
Severe neurological manifestations$ 10 14
Eye involvement 62 85
Conjunctivitis 61 84
Uveitis/Iritis 14 19
Severe eye manifestations# 5 7
Hearing impairment 25 34
Other 38 52
Oral ulcers 29 40
Gastrointestinal manifestations 3 4
Pleurisy 2 3
Pericarditis 1 1
Growth stunting 2 3
AA amyloidosis 1 1
Table 6.1.2. Clinical characteristics and disease manifestations in the analysis
cohort. +Other constitutional symptoms defined as fatigue, malaise or mood
disturbances. *Severe musculoskeletal symptoms were joint contractures, bone
deformities or patellar overgrowth. $Severe neurological symptoms were evidence of
raised intracranial pressure or cerebral atrophy. #Severe eye manifestations were optic
nerve atrophy, glaucoma or impaired vision.
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6.1.4.4 Efficacy of anti-IL-1 therapy
Table 6.1.1 identifies individuals who were complete and partial responders. Fifty nine
patients (81) were considered complete responders to anti-IL-1 therapy. We defined a
complete response as normalisation of serum acute phase reactants (SAA < 10 mg/L and
CRP < 5 mg/L) and resolution of chronic disease symptoms and flares/exacerbations.
Mild recurrent symptoms such as oral ulcers, or occasional mild headaches or rash or
joint aches, which result in symptom scores of 1 or 2, and which were not bothersome to
patients, were not considered to be in conflict with the classification of complete
response. A partial response was defined as reduction in, but not normalisation of, SAA
and CRP measurements and/or an improvement in disease symptoms, but not complete
resolution as defined above. Non-responders or inadequate responders were patients who
had no significant improvement in either or both domains.
Figure 6.1.2 shows typical CAPS urticaria-like rash covering the back of patient 61 prior
to initiation of canakinumab therapy, and with the back rash resolved after the first dose
of canakinumab. Figure 6.1.3 shows the pre-treatment and post-treatment SAA
concentrations within the analysis cohort. Pre-treatment plots are a single SAA
measurement taken before initiation of treatment, as it was often the case that only a
single measurement was available prior to starting treatment. A few patients showed pre-
treatment SAA concentrations within the normal range on the single pre-treatment assay.
Untreated, CAPS has a relapsing-remitting disease course and there is therefore a natural
variability in SAA concentrations. On treatment plots are the medians of all available SAA
measurements in the past year. Figure 6.1.4 show the pre- and on-treatment symptom
scores.
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Figure 6.1.2. Patient 61 before and after first dose of canakinumab. Panel A shows
typical CAPS urticaria-like rash covering the back of patient 61 prior to initiation of
canakinumab therapy. Panel B shows the back rash resolved after the first dose of
canakinumab.
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Figure 6.1.3. Pre- and on- treatment SAA concentration for individuals in the
analysis cohort. Pre-treatment plots are single SAA measurement taken before initiation
of treatment. On treatment plots are the medians of all available SAA measurements in
the past year. Solid lines indicate medians which were significantly different (p < 0.0001).
Broken line indicates upper limit of normal range (10 mg/L).
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Figure 6.1.4. Pre- and on- treatment symptom scores for individual patients in the
analysis cohort. Pre-treatment plots are single symptom scores taken before initiation of
treatment. On treatment plots are the medians of all available symptom scores in the past
year. Solid lines indicate medians which were significantly different (p < 0.0001).
p < 0.0001
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6.1.4.5 Non-responders or inadequate responders
Amongst the cohort we identified 10 patients who had a sub-optimal response to
canakinumab or anakinra, or to both anti-IL-1 therapies.
Patients 38 and 60
Patient 38, with a MWS phenotype, and patient 60, with a CINCA phenotype experienced
only modest and very transient reductions in both serum inflammatory markers and
symptoms when treated with canakinumab. Both patients developed marked
inflammation with morphea-like (Figure 6.1.5) rash bilaterally on their lower limbs shortly
afterwards. Skin biopsy showed only morphea. Patient 60 also developed a diffuse, tender,
erythematous rash over his torso laterally on the left (Figure 6.1.6). Skin biopsy and chest
CT scan were both inconclusive. Both patients were switched to anakinra therapy with
excellent effect, and rash resolved within a few weeks. Figure 6.1.7 shows the treatment
course of patient 60.
Figure 6.1.5. Morphea-like rash on the lower limb of patient 60.
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Figure 6.1.6. Left lateral torso rash of patient 60.
Patients 13, 57, 67 and 70
Patient 13, with a FCAS phenotype, weighed 130 kg. He had a partial response to 300 mg
canakinumab q8w (a dose concentration of < 3mg/kg). He was switched to anakinra, and
remains well on a partial response to 200 mg anakinra daily. Patients 57 and 67 with
CINCA phenotypes, and patient 70 with the Y547C mosaic genotype and atypical
presentation had severe disease. Patient 57, experienced partial response to canakinumab
and anakinra, although subjectively feels better on 300 mg canakinumab (10 mg/kg) q8w.
Patient 67 has had no biochemical or symptomatic response to 300 mg canakinumab (10
mg/kg) q8w, and has elected to come off treatment. He does not wish to have a trial of
anakinra just yet. Patient 70 has been treated with both canakinumab and anakinra over
a 10-year period, at times concurrently. She experienced a severe flare with aseptic
meningitis after attempted conversion to canakinumab.
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She is currently on anakinra 400 mg daily and biochemical inflammation and headaches
have remained consistent.
Patients 46, 47, 59 and 71
These patients had central nervous system (CNS) inflammation symptomatically, and
on lumbar puncture or MRI. Patients 46 and 59 with CINCA had resolution of most
CAPS symptoms and SAA normalised on canakinumab 300 mg q8w, however headaches
and fatigue continued. Both had previous strokes attributed to CNS inflammation. Patient
46 has had some symptomatic improvement on anakinra.
Patient 71 (E567K mosaic with atypical presentation) weighed 102 kg. He had resolution
of most CAPS symptoms and SAA normalised, but headaches, poor balance and fatigue
continued on both treatments. Patient 47 with MWS had normalisation of inflammatory
markers and peripheral symptoms on 300 mg canakinumab q8w. However, headaches
and fatigue remained. Encouragingly, in patients 47 and 71 fatigue and mood have now
begun to improve after 5 years or more of treatment.
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Figure 6.1.7. Disease and treatment course for patient 60, showing drugs and doses administered and corresponding SAA measurement and symptom
score. C150/300/400 with pink arrows= canakinumab 150/300/450 mg doses administered; LR and TR with green arrows indicate timepoint at which leg rash and
torso rash appeared; A100 with purple arrow = anakinra 100 mg administered.
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6.1.4.6. Breakthrough symptoms
Forty two patients (56%) report breakthrough symptoms. These are CAPS symptoms
which recur occasionally and usually mildly despite otherwise effective disease
suppression, and are distinct from disease flares and from the more severe symptoms
experienced by the inadequate responders. These breakthrough symptoms are
responsible for symptom scores of one or two when patients are assessed at clinic visits.
The commonest are:
 Headache, 16 patients (22% of analysis cohort)
 Musculoskeletal symptoms, 15 patients (21%)
 Fatigue, 14 patients (19%)
 Rash, 12 patients (16%)
 Oral ulcers, 10 patients (14%)
 Eye symptoms, 9 patients (12%).
Fig 6.1.8. Severe, large oral ulcers in patient 28. Photos taken on two separate
occasions show two large, severe ulcers on the inside of the lower lip of patient 28.
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6.1.4.7 Quality of life
Two hundred and sixty two SF36v2 QoL surveys were completed by 65 patients between
2010 and 2015. Questionnaires from three patients were excluded from the analysis on
the grounds of inadequate cognitive capacity to complete questionnaires independently.
Eight patients had completed a only single questionnaire at a single time-point and were
also excluded. Pre-treatment questionnaires were not available for 22 patients who had
commenced anti-IL-1 treatment prior to initiation of the CAPS Service (patients who had
been on long term anakinra, or those treated with canakinumab within a clinical trial).
Surveys from complete and partial responders were grouped together for analysis and
inadequate responders were analysed separately. Pre- and post-treatment questionnaires
were completed by 16 complete and partial responders; pre-treatment questionnaires
were available for six inadequate responders.
Domain Mean pre-
treatment score
Mean on-treatment
score
Difference
PF 69 95 26
RP 57 95 38
BP 49 95 46
GH 44 75 31
VT 35 75 40
SF 60 98 38
RE 87 98 12
MH 70 86 16
Table 6.1.3. Change in QoL domain scores in 16 patients who were considered
complete or partial responders to canakinumab after one dose. The survey was
administered before commencing treatment and 2 to 6 months after. PF = physical
function, RP = role physical, BP = bodily pain, GH = general health, VT = vitality, SF
= social function, RE = role emotional and MH = mental health.
CHAPTER SIX PART ONE
117 | P a g e
After initiation of therapy, QoL scores were seen to improve significantly across all
domains in the 16 complete and partial responders, compared to their pre-treatment
scores. Mean scores before canakinumab and the first on-treatment scores ( two months
after first dose) are shown in Table 6.1.3. The biggest improvements were seen in the
bodily pain, vitality, and role, social and physical function. In contrast, patients who were
considered inadequate responders, scores did not improve in some domains, even over
measurement at multiple time-points, and on different treatments (Figure 6.1.9).
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Figure 6.1.9. Change in QoL domain scores in 3 patients who were considered
inadequate responders to anti-IL-1 therapies. Scores are plotted for each time-point in the
on-treatment follow-up period as indicated in the legend of each plot. PF= physical function,
RP=role physical, BP=bodily pain, GH=general health, VT=vitality, SF = social function, RE
= role emotional and MH=mental health. 2m=2 months etc. on treatment.
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One hundred and forty eight surveys taken by complete and partial responders were
available for comparative evaluation ranging from two months to 10 years on treatment
medium- to longer term QoL). Pre-treatment scores of 21 patients are shown in Figure
6.1.10. For comparison over the follow-up period scores in each domain are shown by
box plots at each of the following post-treatment time-points in Figure 6.1.11: two
months, n = 15 patients; six months, n = 14; 12 months, n = 14; 24 months, n = 14; 36
months, n = 14; 48 months, n = 15; 60 months, n = 18; 72 months, n = 14; 84 months,
n = 15; 96 months, n = 8; 108 months, n = 5 and 120 months, n = 2. Mean scores in all
domains are improved on treatment as compared to baseline, and the improvement is
sustained over the longer term follow-up period.
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Figure 6.1.10. Pre-treatment QoL scores by domain. Pre-treatment scores of n = 21
patients (complete and partial responders) are shown as box plot with whiskers
indicating 10th – 90th percentile. PF = physical function, RP = role physical, BP = bodily
pain, GH = general health, VT = vitality, SF = social function, RE = role emotional
and MH = mental health.
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Figure 6.1.11. On-treatment QoL scores by domain. On-treatment scores of patients (complete and partial responders) are shown at various time-
points over the follow-up period (2 m = 2 months on treatment, 6 m = 6 months on treatment etc.). Domain scores are shown as box plots with
whiskers indicating 10th – 90th percentile. PF = physical function, RP = role physical, BP = bodily pain, GH = general health, VT = vitality, SF =
social function, RE = role emotional and MH = mental health.
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Figure 6.1.11 continued. On-treatment QoL scores by domain. On-treatment scores of patients (complete and partial responders) are shown at
various time-points over the follow-up period (60 m = 60 months on treatment, 72 m = 72 months on treatment etc.). Domain scores are shown as
box plots with whiskers indicating 10th – 90th percentile. PF = physical function, RP = role physical, BP = bodily pain, GH = general health, VT =
vitality, SF = social function, RE = role emotional and MH = mental health.
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6.1.4.8 Safety
Both anakinra and canakinumab are associated with increased rates of infections.
In the analysis cohort 289 adverse events (AEs) were reported by 56 patients treated
with canakinumab. Most (n = 231, 80%) were not suspected to be related to
canakinumab. Of the 57 (20%) which were suspected to have a relationship to
canakinumab, 28 (10%) were infections:
 12 episodes of chest infections among 10 patients
 Nine episodes of tonsillitis or throat infections among five patients
 Recurrent urinary tract infections – seven episodes between two patients.
Among patients treated with anakinra, 13 AEs possibly related to anakinra were
reported by five patients. Four (31%) were infections suspected to be related to
anakinra: recurrent urinary tract infections (two to three per year) were reported by one
patient; recurrent tonsillitis in one patient; and two chest infections in another.
6.1.5 Discussion
Wide genotypic and phenotypic ranges are represented within this cohort. Most patients
have first appearance of CAPS symptoms in early life, apart from the patients with
somatic mosaic mutations who have an atypical presentation in adulthood and later life.
Contrary to accepted definitions of SAIDs as hereditary periodic fever syndromes, in this
cohort nearly half had no family history of CAPS, 85% had a chronic disease pattern as
opposed to a periodic or recurrent one, and 15% experienced no fever or other
constitutional symptoms – this points to a broadening of the phenotype and our
understanding of the disease as more patients are diagnosed and follow up time increases.
The majority of patients experienced an excellent and life-changing response to anti-IL-
1 therapies, and this effect has been sustained over a median on-treatment follow-up
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period of five years. A small number of patients, however, did not respond as well as the
majority.
Patients 38 and 60 had an incomplete response to canakinumab but a complete response
to anakinra. Canakinumab is a fully humanised monoclonal antibody against IL-1β. It acts 
by binding free IL-1β, thereby inhibiting binding to the IL1RI and subsequent activation 
of the NLRP3 inflammasome. Measurement of circulating IL-1β levels has proved very 
disappointing with near normal values even in CAPS patients. IL-1β concentration is 
most appropriately assessed by looking at generation of IL-1β, and mathematical 
modelling has allowed this in canakinumab-treated patients (183), demonstrating that IL-
1β is generated at increased but highly variable rates in CAPS, broadly corresponding with 
phenotypic severity. It is therefore possible that in some patients with high levels of IL-
1β production this is not completely neutralised, leaving some free IL-1β to bind to the 
IL-1RI and activate the inflammasome. Anakinra, on the other hand, is a synthetic IL-1
receptor antagonist. It acts by binding to the IL-1RI on the cell surface. Once these are
adequately saturated IL-1β signalling is blocked regardless of the rate of generation of IL-
1β. This provides a possible explanation as to the superior efficacy of anakinra over 
canakinumab in providing IL-1β blockade in some patients. 
The treatment course of patients 13, 57, 67 and 70 suggest incomplete blockade of IL-1
activity with the maximum canakinumab dose available on the NHS (300 mg). Patient 13
is obese and even at the maximum available canakinumab dose was being under-treated
at a dose concentration of < 3 mg/kg; he remains a partial responder on 200 mg anakinra
daily, and does not wish to introduce a third daily injection.
Patients 57 and 67 patients have the CINCA phenotype; patients with CINCA are known
to require higher dose concentrations for efficacy, however both of these patients are
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being treated at the maximum available dose level. Patient 70 is a complex patient with
somatic mosaicism and atypical phenotype. The proportion of somatic cells displaying
the variant genotype in this patient is increasing over time; this may provide an
explanation as to the need for increased doses of canakinumab and anakinra in this patient
over time.
Patients 46, 47, 59 and 71 showed signs and symptoms of severe central nervous system
(CNS) inflammation (headaches, papilloedema, sensorineural hearing loss), with
inflammation and aseptic meningitis confirmed on lumbar puncture and/or brain MRI.
All four had raised intracranial pressure. Patients 46 and 59 both had previous strokes
attributed to CNS inflammation. The cause of headaches in patients with CAPS remains
unclear. Data from our cohort show that some patients do have chronic aseptic
meningitis and/or chronic intracranial hypertension, and/or papilledema eventually
leading to optic atrophy (Parker et al, in press). However, not all patients who suffer
headaches display this severe phenotype. In some patients headaches are not as
debilitating as in others and it is not clear whether mild headaches represent a milder
phenotype or a different pathogenic mechanism (Parker et al, in press). For example, in
a study involving 25 patients suffering migrainous headaches, circulating levels of IL-1β 
were significantly higher during migraine attacks than between attacks (184). Further
investigation is warranted, but the persistent headaches in these patients despite
improvement in some systemic symptoms and/or improvement or normalisation of
serum acute phase proteins suggest that some effects of CNS inflammation may be
irreversible.
Breakthrough symptoms are reported by more than half the patients. This could be due
to inadequate IL-1 blockade on the current dosing regimen, or to activity of other
inflammatory molecules or pathways, and again, further investigation is warranted.
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Health-related quality of life of those patients considered complete or partial responders
is seen to improve in all domains after commencing treatment. The greatest
improvements are seen in the bodily pain, vitality, and role, social and physical function
scales. This is consistent with improvement in, or complete resolution of, the physically
and psychologically debilitating symptoms of fever, rash, arthralgia, myalgia and fatigue,
once successfully treated, and is corroborated by the improvement in clinical symptoms
scores. The improvements in the complete and partial responders are maintained over
the longer term, up to 10 years in two patients. Many have been able to return to education
and employment and have formed relationships and social groups. Patient testimonials
(see Supplementary Information section) provide confirmation of the life-transforming
result of successful therapy. Those considered non-responders or inadequate responders,
as expected, did not enjoy the same level of improvement in health-related QoL, with
some patients actually faring worse on increased doses or after switching to a different
agent. These unfortunate patients require further though with regards to treatments and
other diagnoses.
Both treatments appear to have favourable safety profiles with favourable risk:benefit
ratios within the median five year follow-up period. Longer follow up is required to
confirm these findings.
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Chapter Six Part II:
Safety and Efficacy of Empirical
Interleukin-1 Inhibition in AA
Amyloidosis of Uncertain Aetiology
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6.2.1 Background
AA amyloidosis is a serious complication of persistent inflammation, which, untreated
will progress to renal failure and death (92). Effective suppression of the underlying
inflammatory condition can halt organ damage or even lead to improved organ function
(91), and this is therefore the focus of treatment. However, in approximately 20% of cases
the underlying inflammatory disease is uncertain at the time of diagnosis of amyloidosis,
and in about 7% remains uncharacterised after extensive investigation. This creates a
dilemma as to the choice of empirical treatment.
The use of corticosteroids in these cases is problematic; the presence of AA amyloidosis
points to a chronic, rather than an episodic, inflammatory disorder and chronic
immunosuppression in this already vulnerable patient group is not only unlikely to
address the underlying inflammation, but is likely to contribute significant morbidity due
to side effects. Colchicine works well in in a minority of patients and may provide an
effective and low-cost alternative to steroids. However, a high proportion of patients fail
to benefit from a therapeutic trial and some experience intolerable gastrointestinal side
effects thereby precluding effective long term treatment. The goal of treatment in AA
amyloidosis remains to find a safe, non-toxic long term treatment which rapidly and
effectively suppresses the underlying inflammatory disease.
Interleukin (IL)-1α and IL-1β are potent pro-inflammatory cytokines implicated in a 
variety of chronic inflammatory and autoinflammatory disorders. Both are ligands for the
IL-1 receptor; the activity of both cytokines is inhibited by IL-1Ra, the naturally occurring
IL-1 receptor antagonist. Anakinra (Kineret®) is a recombinant, non-glycosylated
analogue of the interleukin IL-1 receptor antagonist. It is a licensed treatment for
rheumatoid arthritis and Cryopyrin-associated periodic syndromes (185), but is widely
used off-license in several other inflammatory diseases such as TRAPS, MKD, colchicine-
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resistant familial Mediterranean fever (crFMF) and Schnitzler’s syndrome with
encouraging medium term safety and efficacy (52). Anakinra has a short half-life of 4 to
6 hours, meaning that dosing could be paused or stopped with a quick wash-out period
should an adverse event arise.
6.2.2 Aims
We report the result of empirical treatment with anakinra in a cohort of 11 patients with
AA amyloidosis of unknown aetiology who were all referred to a national specialist
referral centre for diagnosis and management advice.
6.2.3 Patients and Methods
6.2.3.1 Patients
We identified 11 patients with AA amyloidosis of unknown aetiology who were under
the care of the UK NAC and who were given a therapeutic trial of anakinra. Table 6.2.1
summarises the patient characteristics, but further clinical information is provided here.
 Patient 1 underwent screening tests after her brother was diagnosed with colonic
cancer. Serum liver function tests revealed mild hepatic dysfunction and liver
biopsy showed hepatic steatosis and mild chronic inflammation. Colonic biopsies
were clear. One year later she developed ankle oedema. Investigation revealed
renal dysfunction and renal biopsy was diagnostic of AA amyloidosis. The biopsy
showed no evidence of vasculitis. Her ANA screen was positive at 1 in 1000 but
repeated autoantibody screens showed no other evidence of autoimmune disease.
Tuberculosis (TB) screen was negative. She had a polyclonal rise in
immunoglobulin (Ig) M with only reactive changes on bone marrow biopsy.
Upper gastrointestinal (GI) tract biopsy was normal. Coeliac screen was normal.
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Echocardiogram was unremarkable, as was PET-CT scan of chest, abdomen and
pelvis.
 Patient 2 had a history of Stage IAE Classical Hodgkin's Lymphoma of the tonsils
with an associated para-vertebral mass. Due to the limited disease, he was treated
with four cycles of ABVD chemotherapy to a complete remission. His remission
was ongoing for three years when the diagnosis of AA amyloidosis was made on
a renal biopsy after he was noted to have elevated creatinine on routine follow-
up blood tests. The biopsy showed no evidence of vasculitis. At this time the
patient was clinically very well, without any constitutional B symptoms or any
other inflammatory symptoms. PET-CT scans repeated at three to six month
intervals did not reveal recurrent disease. Echocardiography was normal. Serial
auto antibody profiles remained negative. Sanger sequencing of known
autoinflammatory genes revealed only the MEFV E148Q polymorphism of
unknown significance.
 Patient 3 was diagnosed with human immunodeficiency virus (HIV) and started
antiretroviral therapy (ART) two years prior to the diagnosis of AA amyloidosis.
A year after the HIV diagnosis she was found to have a disseminated TB which
was treated with two courses of anti-TB therapy. She developed systemic immune
reconstitution inflammatory syndrome after starting ART, and responded well to
steroids. Diagnosis of AA amyloidosis was made on renal biopsy after she was
found to have developed nephrotic range proteinuria during routine follow-up.
The renal biopsy showed no evidence of vasculitis. PET-CT scans have ruled out
Castleman’s tumour and other malignancy. The patient had a normal
echocardiogram and autoantibody screen.
 Patient 4 had a five year history of seronegative polyarthritis, when he presents
with renal dysfunction. Renal biopsy confirmed AA amyloidosis but nil else.
CHAPTER SIX PART TWO
130 | P a g e
Echocardiogram was unremarkable. The patient showed a pattern of marked
variability in his acute phase response raising the possibility of a periodic fever
syndrome, although Sanger sequencing of known autoinflammatory genes was
negative. An eventual tentative clinical diagnosis of urate arthropathy was made,
although this has never been confirmed.
 Patient 5 gave a ten-year history of bowel symptoms but had been diagnosed with
ulcerative colitis two years prior to the diagnosis of AA amyloidosis, and treated
with steroids. Over a nine month period he developed oedema, and on
investigation was found to have proteinuria and elevated serum creatinine. Renal
biopsy confirmed AA amyloidosis. The biopsy showed no evidence of vasculitis.
Repeat gut biopsies (colonic, duodenal and gastric) showed only mild reactive
changes and barium meal follow-through was reported as normal.
Echocardiogram was normal. The patient was obese, but gave no other medical
history of note.
 Patient 6 was well until about four months prior to being diagnosed with AA
amyloidosis when he developed intermittent bone pain in his knees and tibias,
intermittent diffuse abdominal pain, a diffuse scaly skin rash and ankle oedema.
Renal biopsy confirmed AA amyloidosis but nil else. He had a mild left lower
lobe cystic bronchiectasis, little sputum production. There was no medical history
of note apart from a left lower lobectomy for a possible cyst-forming infection in
childhood, and no family history. OGD and sigmoid biopsy revealed only amyloid
and an echocardiogram was normal. High resolution CT scan of his chest,
abdomen and pelvis showed widespread lymphadenopathy but biopsy found only
reactive changes. HIV, hepatitis and HHV6 serology were negative, as was a TB
screen and blood cultures. Bone marrow biopsy was unremarkable.
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 Patient 7 had a complex medical history including mastoidectomy at 18 months
for chronic otitis media and craniopharyngioma at the age of six for which she
underwent surgical excision and radiotherapy. She was also diagnosed with
panhypopituitarism for which she received growth hormone. She had type I
diabetes mellitus. She had chronic diarrhoea but multiple level GI biopsies ruled
out Crohn’s disease or any other specific abnormality. Echocardiogram was
unremarkable. The original renal biopsy showed no evidence of vasculitis.
 Patient 8 had only a five year history of an inflammatory lung mass in the right
middle lobe. CT-guided biopsy and bronchoscopy demonstrated non-specific
inflammation and rigid bronchoscopy yielded no specific diagnosis. A PET scan
showed only low grade uptake suggesting a benign process rather than a malignant
one. Active TB was ruled out. Echocardiogram was normal. The biopsy showed
no evidence of vasculitis. After 2 years treatment with anakinra the lung mass had
entirely resolved on imaging, but the inflammation persists.
 Patient 9 was fit and well until he presented with ankle oedema in acute renal
failure. He had no medical history of note apart from mild asthma and an IgA
monoclonal gammopathy of undetermined significance. Chest x-ray and
bronchoscopy were normal as were CT chest and abdomen. PET-CT and bone
marrow biopsy showed no significant abnormalities. The original renal biopsy
showed no evidence of vasculitis.
 Patient 10 was diagnosed with low grade Non-Hodgkin’s lymphoma (NHL)
twelve years prior to being diagnosed with AA amyloidosis. As he was
asymptomatic he had no therapy and follow-up CT scans showed that the nodes
were decreasing in size over time. He presented with oedema and nephrotic
syndrome and renal biopsy confirmed AA amyloidosis with no evidence of
vasculitis. He then underwent extensive investigation to restage the NHL. CT
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scan showed some small lymph nodes in the para-aortic region but no other
detectable lymphadenopathy. Abdominal ultrasound scan was normal, as was a
bone marrow biopsy. Four years later repeat CT scan of chest, abdomen and
pelvis and bone marrow biopsy with trephine were all again negative. Cardiac
MRI showed hypertensive cardiomyopathy. The patient died of peritoneal
dialysis-related peritonitis and post-mortem examination did not reveal the source
of the underlying inflammation.
 Patient 11 gave a seven year history of pedal oedema and generalised myalgia
before presenting with nephrotic-range proteinuria. CT scan showed a 4 cm
density, which when biopsied was consistent with Ig heavy chain deposition. He
had a reactive Mantoux test after BCG vaccine but this was reviewed by the chest
physicians and repeated chest X-rays ruled out TB infection. Blood-borne virus
screens were negative. Repeat CT scan after four years showed reduction of the
size of the mass. Sanger sequencing of known autoinflammatory disease genes
revealed variants on unknown significance S52N and D386N in MVK. The
original renal biopsy showed no evidence of vasculitis.
All patients had been investigated locally in order to characterise the underlying
inflammatory condition, without success. Sanger genetic sequencing was performed to
exclude known monogenic autoinflammatory diseases. Disease activity and treatment
response were monitored by serial SAA and CP measurements. Amyloid load was
evaluated by whole body 123I-SAP scintigraphy. Renal function was measured by means
of serum and urine chemistry. Patients gave written informed consent for retrospective
analysis and publication of their clinical data (REC reference number 06/Q0501/42).
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6.2.3.2 Other methods
Further methods are described in Chapter Two: Methods.
6.2.4 Results
6.2.4.1 Whole cohort characteristics
Table 6.2.1 summarises the patient characteristics. Eight (73%) were male. Age ranged
from 33 to 67 years. Eight (73%) had been pre-treated with corticosteroids or colchicine
or both, unsuccessfully. All patients were proteinuric at presentation with AA amyloidosis
and three had already progressed to end-stage renal failure (ESRF). The total median
follow-up time for this cohort was 7.7 (3.5 – 8.2) years; the median duration of treatment
with anakinra was 1.6 (0.6 – 7.4) years. Four patients are deceased (patients 7, 9, 10 and
11), with cause of death unrelated to anakinra use; one patient was lost to follow-up
(patient 6) and the rest are alive and under active follow-up.
6.2.4.2 Response to anakinra
Patients 1 to 9 were considered to be either complete responders or partial responders to
anakinra, whilst patients 10 and 11 were considered non-responders (Table 6.2.1).
Response to treatment was characterised as described in Chapter Two: Methods. All
patients tolerated treatment well, with the only adverse events being the transient injection
site reactions known to be associated with anakinra (185).
6.2.4.3 Serial monitoring of SAA
SAA was measured serially before and during treatment with anakinra. The median pre-
treatment SAA (defined as the median of all available SAA measurements prior to
commencing anakinra) for the whole cohort was 116 (39 - 238) mg/L. SAA was measured
at a median of 17 (4 – 28) days after commencing anakinra. For the whole cohort,
including patients 10 and 11 who were considered non-responders, the median on-
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anakinra SAA (defined as the median of all available SAA measurements whilst on
anakinra) was 9 (4 – 62) mg/L. In the patients considered responders to anakinra (c or
partial), the median pre-treatment SAA was 74 (34 – 190) mg/L, and the median on-
treatment SAA was 6 (4 – 16) mg/L. Both comparisons were statistically significant (p =
0.0047). In responders the effect has been maintained for a median on-treatment follow-
up period of 1.8 (1 – 7.6) years. Individual median pre- and on-treatment responses are
shown in Figure 6.2.1.
6.2.4.4 Renal function
Patients 7, 8 and 9 were in ESRF at first presentation at our Centre. At the time of
commencing treatment with anakinra, patients 4, 5, 8, 9 and 11 were in ESRF; patients 1,
3, 6 and 10 had acceptable renal excretory function but were severely nephrotic, all having
> 10g urine protein in 24 hours; and patients 2 and 7 were in CKD stage 3, post renal
transplant. Over the follow-up period, patients 4, 5 and 8 also underwent renal
transplantation. Amyloid recurred in the graft of only one patient (patient 7). Patients 2,
4 and 8 remain stable and well on 100mg daily anakinra post-transplant. Patient 5 stopped
anakinra treatment prior to transplant and has not recommenced as his acute phase
response is reasonably controlled on post-transplant immunosuppressive drugs. Patient
7 continued anakinra therapy until her sudden cardiac death (in the absence of cardiac
amyloidosis). Patients on renal replacement therapy were treated with 100 mg anakinra
three times weekly, after dialysis. Patient 3 had a serum creatinine within the normal range
before commencing anakinra, but she had a heavy protein leak of 10.5 g in 24 hours. Six
months after starting anakinra, the protein leak improved to 7.2 g and one year later had
fallen to 1.9 g, with stable CKD.
.
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Patient Sex Ethnicity Age at
presen-
tation
(y)
ESRF at
presen-
tation
Renal
trans-
plant
Previous
unsuccessful
therapies
Serum
creatinine
on starting
anakinra
(mmol/L)
Proteinuria
on starting
anakinra
(g/24 hr)
Response
to
anakinra
Duration
of
therapy
(y)
Continuing therapy
(Yes/No,
and reason if not
continuing)
1 F N.European 61 No No Cort, MMF,
Colch
82 16.9 Partial 7.4 Yes
2 M S. Asian 36 No Yes* Colch 194 0.1 Complete 0.9 Yes
3 F N. African 36 No No Colch, Cort 56 10.5 Complete 1.8 Yes
4 M N. European 35 No Yes Cyclo, Chlor,
Etan
ESRF ESRF Complete 9 Yes
5 M N. European 48 No Yes Colch ESFR ESRF Partial 3.2 No, stopped for renal
transplant
6 M Turkish 33 No No Colch, Cort 248 No result Partial 5.6 No, stopped when ESRF
reached
7 F N. European 36 Yes Yes* Cort 163 2.0 Complete 4.4 No, deceased
8 M N. European 63 Yes Yes None ESRF ESRF Complete 7.9 Yes
9 M N. European 67 Yes No Colch ESRF ESRF Partial 0.6 No, deceased
10 M S. European 60 No No Cort 210 10.5 None 6.9 No, no response
11 M S. Asian 41 No No Cort ESRF ESRF None 6.3 No, no response
Table 6.2.1. Summary of characteristics of the cohort. Cort = corticosteroids; MMF = mycophenolate mofetil; Colch = colchicine; Chlor =
chlorambucil; Etan = etanercept. ESRF = end stage renal failure. * Indicates renal transplantation prior to starting anakinra.
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6.2.4.5 Monitoring of amyloid deposits
Eight of the nine responders had serial SAP scans over the follow-up period, with five
(patients 3, 4, 5, 7 and 8) showing regression and three (patients 1, 2 and 6) showing
stabilisation of amyloid load, i.e. no new accumulation. Figure 6.2.2 shows the serial SAP
scans of patients 4 and 8, demonstrating amyloid regression from the spleen and liver and
spleen, respectively after successful treatment with anakinra.
Figure 6.2.1. Serial SAA concentration in 11 patients with AA amyloidosis
of uncertain cause. Results are presented as median of all pre-treatment and on-
treatment SAA measurements.
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Figure 6.2.2. Serial SAP scans showing regression of amyloid after treatment.
Panels A and B are anterior images of patient 4 taken in 2007 and 2013 respectively,
showing regression of amyloid from the spleen after successful treatment. Panels C and
D are posterior images of patient 8 taken in 2007 and 2012 respectively, showing
regression of amyloid from the liver and spleen after successful therapy.
DC
BA
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6.2.5 Discussion
AA amyloidosis is a potentially reversible cause of proteinuric renal disease. Historically
treatment has been more successful than in other types of systemic amyloidosis but has
relied completely on diagnosis of the underlying condition and targeted anti-inflammatory
treatments. The advances in antimicrobials, and effective biologics in the inflammatory
arthritides, have both reduced the incidence of AA amyloidosis and when it does develop,
have improved outcomes in what were until recently the major aetiological sources of AA
amyloidosis. However, choice of treatment to suppress inflammation in the absence of
a clear underlying disease is difficult, and patients with AA amyloidosis of unknown
aetiology remain at considerable risk of succumbing to ESRF or losing their renal grafts
if they had already received transplants.
Furthermore, these patients are often at risk of under-treatment as symptoms of systemic
inflammation are often non-specific and may be minimised by both patients and their
medical carers (NAC, unpublished data). It is well recognised that symptoms particularly
those of a non-specific nature such fatigue and anhedonia, and insidious onset, are often
minimised by patients. An empirical trial of cytokine blockade can be highly effective in
these patients and give clues as to the underlying pathological pathways but outside
experienced centres its use is very limited due to financial constraints and concerns about
possible side effects of therapies to which relatively few centres have been exposed, and
for which they are not licenced. These concerns are even more potent in the context of
renal failure, the commonest manifestation of AA amyloidosis.
Nonetheless we have demonstrated here that a therapeutic trial of anakinra is worth trying
given its potentially dramatic effect, rapid onset, and excellent safety profile even in the
context of organ failure and transplantation. In addition it is more cost-effective than the
newer immunomodulators. Current data suggest it has a better long term safety profile
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than high dose corticosteroids, other anti-cytokine therapies or immunosuppressive drugs
(175, 176). In this series one patient with HIV and previously treated TB tolerated the
treatment well. The summary of product characteristics (SPC) for anakinra states that it
must not be used in patients with severe renal impairment (defined as creatinine
clearance < 30 ml/minute) (185). Nonetheless in six patients with ESRF we have shown
that anakinra is well tolerated, and that dosing three times per week post-dialysis provides
clinically effective treatment which has not been accompanied by increased serious sepsis,
and provides a cost saving. There have been concerns about the additional risks of adding
anakinra to the immunosuppression associated with solid organ transplantation but the
data shown here on five patients (median age 36, median follow up 4.4 years) suggests a
favourable risk benefit profile in these rare cases.
This small cohort shows that even in potentially high risk cases with organ damage
secondary to AA amyloidosis, immune deficiency due to previous immunosuppression
and/or nephrotic syndrome, anakinra, when used appropriately and carefully monitored,
has proved remarkably effective and well tolerated. Although longer term follow-up of
this off-label use is clearly required our data suggests that carefully monitored empirical
trails of single cytokine suppression can have transformative effects in selected cases.
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Chapter Seven:
Changing Epidemiology of AA
Amyloidosis – Clinical Observations
Over 25 Years at a Single National
Referral Centre
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7.1 Background
Systemic AA amyloidosis is a serious and life threatening complication of chronic
inflammatory disorders. Despite the significant morbidity and mortality caused by AA
amyloidosis, and the consequent cost burden to healthcare systems, there are relatively
few published data on the incidence of AA amyloidosis.
Finnish studies report mortality from AA amyloidosis complicating rheumatoid arthritis
(RA) ranging from 9 to 24% (186) (187). A Spanish 9-year observational study of RA
attributed a mortality rate of 17% to AA amyloidosis (188). In other European studies,
mortality from AA amyloidosis has been reported as much lower in comparison: 2% to
7% (189, 190). And post-mortem examinations of individuals with RA reveal detection
rates ranging from 7% to 61% (191-194). These studies demonstrate varying incidence.
A Turkish study reported a change in incidence of AA amyloid detected on renal biopsy
over time. Akse-Onal and colleagues (195) reported incidence of 12.1% in renal biopsies
in Turkey between 1978 to 1990 and only 2% between 2000 to 2009 with no difference
in age and gender distribution, age at onset, disease severity etc. between the two
populations.
In the UK, AA amyloidosis is the third commonest type of systemic amyloidosis
diagnosed, and represents approximately 10% of new cases seen annually at the UK NAC.
CHAPTER SEVEN
142 | P a g e
7.2 Aims
We sought to examine the changing epidemiology of AA amyloidosis over a period of a
quarter of a century at a single national referral centre.
7.3 Patients and methods
7.3.1 Patients
All patients were under the care of a single national referral centre in the UK. We
performed a database search for all patients first seen between January 1990 and
December 2014. 625 patients were identified with confirmed AA amyloidosis. Patients
were divided into 3 cohorts for analysis:
 Cohort 1: 153 patients who were first seen between 1990 and 1997
 Cohort 2: 236 patients who were first seen between 1998 and 2006
 Cohort 3: 236 patients who were first seen between 2007 and 2014.
Patients gave written informed consent for retrospective analysis and publication of their
clinical data (REC reference number 06/Q0501/42).
7.3.2 Diagnosis
Diagnosis of AA amyloidosis was made either histologically, or scintigraphically where
biopsy was not possible or tissue samples were not available for review. Exclusion of
other amyloid types was by genetic analysis (hereditary forms) or serum and urine protein
electrophoresis (AL amyloidosis). Patients were reviewed six to 12 monthly after
diagnosis.
7.3.3 Other methods
Further methods are described in Chapter Two: Methods.
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7.4 Results
7.4.1 Whole-cohort characteristics
625 patients are described. 341 (55%) were male. The median age at first presentation at
our Centre was 54 years (IQR 39 - 65). The underlying diseases were as follows:
rheumatoid arthritis (RA) 28%, chronic sepsis 18%, seronegative arthritis 10%, systemic
autoinflammatory diseases (SAIDs) 9%, juvenile idiopathic arthritis (JIA) 8%,
inflammatory bowel disease (IBD) 5% and other causes 6%. In 15% of patients the
underlying inflammatory disease was uncharacterized at diagnosis of AA amyloidosis. 300
patients reached end stage renal failure (ESRF), with 159 (53%) patients in ESRF at
presentation. Median time to ESRF was 26 months. The numbers of new cases referred
annually over the study period are shown in Figure 7.1. Referral rates of new AA patients
have been stable during the past decade at an average of 30 per year, in contrast with a
three-fold increase among other types of amyloidosis (NAC, unpublished data).
Figure 7.1. Annual new referral numbers over the 25 year study period.
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7.4.2 Comparison of cohorts
7.4.2.1 Age at referral, ethnicity and underlying disease
Mean age at presentation has significantly increased from 46 in the earliest cohort (cohort
1) to 56 in the latest cohort (cohort 3) (p < 0.0001) (Figure 7.2). Ethnic group
representation remains largely unchanged, although referral of Asian patients has
increased from 4% in cohort 1 to 17% in cohort 3 (p = 0.0006). The overwhelming
majority of patients were Caucasian (Figure 7.3). A comparison of the underlying diseases
between cohorts 1 and 3 reveals a reduction in patients with juvenile idiopathic arthritis
(JIA) from 25% to 2% (p < 0.0001). Increased numbers of patients have presented with
chronic sepsis due to intravenous recreational drug use (IVDU) – 1% in cohort 1 versus
13% in cohort 3 (p < 0.0001). There has also been a rise in AA amyloidosis of unknown
aetiology from 5% to 24% (p <0.0001).The full comparison of underlying diseases
between cohorts is shown graphically in Figure 7.4.
7.4.2.2 Development of end stage renal failure
In comparison with cohort 1, significantly more patients were in established ESRF at
presentation in cohort 3 – 15% and 29% respectively (p = 0.0028). There was no
difference in survival from ESRF between the cohorts.
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Figure 7.2. Change in mean age at presentation
Figure 7.3. Ethnic group proportions by cohort.
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Figure 7.4. Comparison of underlying disease by cohort. RA, rheumatoid arthritis; JIA juvenile idiopathic arthritis;
SAIDs, systemic autoinflammatory disease; IBD, inflammatory bowel disease; IVDU, intravenous drug use.
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7.4.2.3 Survival
There was no difference in overall survival between the cohorts (Figure 7.5). However,
age at death was significantly different at a median of 54 years in cohort 1 and 62 years in
cohort 3 (p = 0.0012) (Figure 7.6).
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Figure 7.5. Survival by cohort.
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Figure 7.6. Age at death.
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7.5 Discussion
In contrast to a threefold increase in referrals to the NAC of AL and other types of
amyloidosis during the past decade, referral rates for AA amyloidosis have remained
stable. This observation that AA amyloidosis is becoming less common may be a
reflection of great advances in the use of biological agents in the effective treatment of
the inflammatory arthritides. This has both reduced the incidence of AA amyloidosis and
when it does develop, has improved outcomes in what were until recently the commonest
pathologies underlying AA amyloidosis. Whilst JIA and RA are no longer the main
aetiological sources of AA amyloidosis, greater proportions of recent AA patients have
uncharacterised underlying inflammatory disorders or chronic sepsis secondary to IVDU,
compared to historical cohorts. Both patient groups pose challenges for clinical
management, and it may be that these numbers represent an increase in referrals for
management advice due to expertise and experience with off-licence biological treatments
at the National Amyloidosis Centre, rather than a true increase in incidence of these
diseases. Similarly, the significantly increased proportion of patients in ESRF in the latest
cohort compared with the earliest is likely to be due to a referral bias in recent years.
Although ethnic group proportions have largely remained the same, with a
preponderance of Caucasian patients, significantly more Asian patients are represented in
the recent cohort compared to the oldest. This change coincides with an increase in AA
amyloidosis of unknown aetiology and suggests that novel as yet unrecognized pathology
is contributing to chronic inflammation in this group. Clearly there may be other potential
contributors such as an effect of increased migration over the study period, or perhaps
greater use of the health service by a younger generation.
The mean age at presentation with AA amyloidosis in the recent cohort is significantly
older than the earliest cohort. This again may be a reflection of the availability of effective
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biological treatments for inflammatory conditions. Whilst overall survival does not appear
to have changed despite new effective therapies, age at death has increased significantly
over the last 25 years, suggesting improved global management and supportive care
including renal replacement, as well as more effective management of the underlying
pathology.
Overall, these data suggest both falling incidence (corrected for improved diagnostic
rates) and better outcome in AA amyloidosis over a period of two-and-a-half decades,
reflecting advances in therapeutics and in overall management of complex chronic disease
in an aging population. A major problem to have evolved over this time is AA amyloidosis
of uncertain aetiology which has proved challenging to manage empirically. We hope that
newer techniques such as next generation sequencing and gene expression analysis may
aid diagnosis and effective treatment of these ‘uncharacterised’ inflammatory disorders
thereby improving overall survival.
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Chapter Eight:
The Classical Acute Phase Protein - The
Non-Pathogenic Role of Serum C-
Reactive Protein
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8.1 Background
A great deal of interest in measurement of CRP in relation to cardiovascular disease
occurred following the original observations in patients with known cardiovascular
disease (94, 95) and subsequent findings in the general population, that baseline values of
CRP are statistically significantly associated with risk of future coronary events.
Controversy arose in the field with CRP as a risk marker being promulgated by some
groups on the basis of some epidemiological studies; further controversy was contributed
by the conflation of epidemiological association with causality, leading to claims that
increased baseline CRP concentration is not only a risk marker for cardiovascular disease
but also a risk factor contributing to the pathogenesis of atherosclerosis and
atherothrombosis.
In 2005 a study was published describing the infusion of purified bacterial recombinant
CRP into human volunteers, in all of whom there followed a marked acute phase plasma
protein response (196). The authors concluded that the latter represented a
pro-inflammatory property of CRP itself, and this has promulgated the notion that CRP
contributes to the pathogenesis of cardiovascular disease.
These data suggest two rather serious potential complications for patients with chronic
inflammatory conditions. First, that an elevated serum CRP concentration associated with
chronic inflammatory conditions puts these patients at risk of developing atherosclerosis
and atherothrombosis. Second, that CRP is itself pro-inflammatory and if this is the case
then patients with inflammatory conditions would be in a persistent and dangerous state
of inflammation despite any therapy.
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8.2 Aims
In order to investigate these assertions we administered authentic highly purified current
Good Manufacturing Guidelines (cGMP) grade human CRP to seven healthy male
volunteers, in sufficient quantity to modestly raise the circulating CRP concentration in
recipients, and monitored the effects.
8.3 Subjects and Methods
8.3.1 Subjects
Seven healthy male volunteers were recruited by email advertisement within the
University College London student body. The following inclusion criteria applied:
Healthy males aged 18-25 years; Non-smoking; Normal body mass index (18.5-24.9); No
clinical evidence of active infection or allergy; No significant physical injuries or surgery
within preceding 3 months. Volunteers were pre-screened over the telephone and then
invited to a formal discussion, and screening, after written informed consent was given.
Volunteers were compensated £15 per hour for their time and effort, plus a completion
bonus of £50 if they attended all study visits to completion.
8.3.2 Study investigations and procedures
Seven study visits were conducted over a three week period (Table 8.1). Screening
involved a full medical history review, vital signs (oral temperature and resting blood
pressure and heart rate), physical examination, electrocardiogram (ECG), urinalysis and
blood tests including glucose, renal function, liver function, haematology, cardiac
biomarkers, acute phase proteins SAA and CRP, erythrocyte sedimentation rate (ESR)
and cytokine profiles. The baseline visit took place within one week of the screening visit,
subject to a positive outcome of the screening assessments, including a healthy basal
serum CRP concentration of <3 mg/L.
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Informed Consent x
Medical history x
Concomitant meds x x x x x
Adverse events x x x x x x x x x x x x x
Physical
examination
x x
Vital signs x x x x x x x x x x x x x x
ECG x x x x x
Urinalysis x
Blood samples x x x x x x x x x x
CRP administration x
Table 8.1. Schedule of procedures and assessments.
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The CRP dose was administered at the baseline visit, after the pre-dose assessments (vital
signs and blood sampling) had been completed.
8.3.3 Regulatory and Ethical Aspects
The study was approved by the Central London REC 1 Research Ethics Committee
(REC reference number 10/H0718/86)). The UK Medicines and Healthcare Products
Regulatory Agency (MHRA) confirmed that this mechanistic study protocol fell outside
the scope of the Medicines for Human Use (Clinical Trials) Regulations, 2004, the
prevailing UK law covering such studies. The study was Sponsored by University
College London, and approved by the host institution, the Royal Free Hospital. All
participants gave fully informed written consent.
8.3.4 Other methods
Further methods are described in Chapter Two: Methods.
8.4 Results
Following the bolus infusion of CRP, there was a clear dose dependent increase in
circulating CRP concentration, peaking in the 30-minute sample in all subjects and
reaching 36 and 44 mg/L respectively in the two individuals who received the top dose
of 2 mg/kg. After 30 minutes the circulating CRP concentrations fell steadily in all
subjects, at a rate consistent with the known approximately 19-hour plasma half-life of
human CRP in humans (Figure 8.1)(121). There was no evidence that infusion of
human CRP triggered any new production of CRP. Similarly, none of the seven subjects
showed any increase beyond the reference range in their circulating concentrations of
SAA, or any significant change in neutrophil or platelet counts (Figure 8.2).
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The plasma concentrations of the pro-inflammatory cytokines, IL-1β, TNFα, and IL-6, 
also confirmed that the infusion of CRP had no significant effects (Table 8.2). Only in
subject 1, who received the lowest dose of CRP was there any significant apparent rise in
just a single cytokine, TNFα, and at just a single time point. However the raw optical 
density data from the four replicates of the ELISA assay on this sample were widely
variant and included one effectively zero value consistent with the zero values in the three
other samples from this individual, and suggests that the other readings reflect a technical
aberration. Crucially the circulating SAA values were within the reference range in all
samples from all subjects. There was thus no evidence that CRP infusion affected
production of any of the cytokines assayed immunochemically or any sign of increased
functional pro-inflammatory cytokine activity in vivo. Values for the anti-inflammatory
cytokine, IL-10, were variable but there was no evidence of any consistent or
dose-dependent effect of CRP infusion.
There were no clinically significant changes in any other physical, biochemical or
haematological parameters monitored in the study (Table 8.3), and the complete set of
results for each individual subject may be found in the Supplementary Information
section.
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Figure 8.1. Serum concentration of CRP before and after infusion. Values are shown
for each individual subject at screening (S), at baseline (B) immediately before infusion of
human CRP, and at the times shown after infusion. Subject 1, CRP dose 0.25 mg/kg;
Subject 2, 0.5 mg/kg; Subject 3, 1.0 mg/kg; Subject 4; 1.25 mg/kg;
Subject 5; 1.25 mg/kg; Subject 6, 2.0 mg/kg; Subject 7, 2.0 mg/kg.
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Figure 8.2. Circulating SAA, neutrophils and platelets before and after CRP
infusion. Values are shown for each individual subject at screening (S), at baseline (B)
immediately before infusion of human CRP, and at the times shown after infusion.
Subject 1, CRP dose 0.25 mg/kg; Subject 2, 0.5 mg/kg; Subject 3, 1.0 mg/kg;
Subject 4; 1.25 mg/kg; Subject 5; 1.25 mg/kg; Subject 6, 2.0 mg/kg;
Subject 7, 2.0 mg/kg.
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Subject
(CRP dose)
Time after
CRP infusion
Plasma cytokine concentration
mean pg/mL
IL-1β IL-6 IL-10 TNFα 
1 Baseline <16 <16 <16 <16
(0.25 mg/kg) 4 h <16 <16 18 145
8 h <16 <16 <16 <16
24 h <16 <16 17 <16
2 Baseline <16 <16 41 28
(0.50 mg/kg) 4 h <16 <16 <16 17
8 h <16 <16 <16 19
24 h <16 <16 <16 <16
3 Baseline <16 <16 <16 <16
(1.00 mg/kg) 4 h <16 <16 19 <16
8 h <16 <16 44 <16
24 h <16 <16 <16 <16
4 Baseline <16 <16 <16 <16
(1.25 mg/kg) 4 h <16 <16 <16 <16
8 h <16 <16 <16 <16
24 h <16 <16 <16 18
5 Baseline <16 <16 22 21
(1.25 mg/kg) 4 h <16 16 <16 26
8 h 20 <16 <16 34
24 h <16 <16 88 28
6 Baseline <16 60 <16 23
(2.00 mg/kg) 4 h <16 67 <16 <16
8 h <16 69 <16 <16
24 h <16 59 <16 <16
7 Baseline <16 <16 <16 46
(2.00 mg/kg) 4 h <16 <16 <16 <16
8 h <16 <16 <16 <16
24 h <16 <16 18 <16
Table 8.2. Plasma cytokines monitored during and after infusion of human CRP.
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Parameter Clinically significant change
C-reactive protein Dose dependent increase followed by clearance
with expected t½
Serum amyloid A protein None
Serum albumin None
IL-1β None
IL-6 None
TNFα None
IL-10 None
Systolic blood pressure None
Diastolic blood pressure None
Heart rate None
Temperature None
Electrocardiogram None
Medications None
Total white blood cell count None
Neutrophils None
Eosinophils None
Basophils None
Lymphocytes None
Monocytes None
Platelets None
Hemoglobin None
Hematocrit None
Red cell count None
MCV None
MCH None
MCHC None
Erythrocyte sedimentation rate None
Sodium None
Potassium None
Urea None
Creatinine None
Total Bilirubin None
Alanine transaminase None
Aspartate transaminase None
Alkaline Phosphatase None
Glucose None
Cardiac Troponin T None
NT Pro-BNP None
Von Willebrand Factor antigen None
Fibrinogen D-dimer None
Prothrombin fragment 1+2 None
Plasminogen activator inhibitor 1 antigen None
Table 8.3. Other parameters monitored during and after infusion of human CRP.
Apart from the concentration of CRP which increased in a predictable dose-dependent
manner, no other parameters showed any clinically significant change.
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8.5 Discussion
Only very limited quantities of ‘normal’ human CRP are available because of the
extremely low concentration of CRP in health, and the CRP which has been used in other
work on this protein, whether isolated by researchers themselves or bought commercially,
is derived either from serum or effusion fluids of patients with malignancy or other
diseases, or is produced by recombinant technology. The human CRP produced by
recombinant E. coli bacteria is intended only for use as an in vitro immunoassay standard,
although it has been widely used for in vitro functional studies on cells (98, 197). The
Pepys group demonstrated that this source of CRP contains highly active
pro-inflammatory bacterial contaminants (198), leading one to the conclusion that the
widespread use of this recombinant CRP has been somewhat misleading.
The commercially manufactured CRP is produced at low concentrations of approximately
5 mg/L, in the culture fluid of E. coli fermenters and isolated by a single non-specific
affinity chromatography fractionation. It is therefore unlikely that it would not be
contaminated with bacterial products, including LPS; when tested by the Pepys group,
after publication of the paper, this proved to be the case. It is also unlikely that gel
filtration could possibly remove all endotoxin and other potential bacterial products from
the CRP preparation. Contamination with bacterial substances is not relevant to the
intended use of the recombinant protein as an immunoassay standard but inevitably has
major consequences when such preparations are used for in vitro functional studies with
cells or injected into human subjects.
Another potential explanation for the induction of inflammation in the experiment
involving the commercially manufactured CRP could be structural changes in the protein.
Native CRP exists as a stable pentamer, however, a dissociation mechanism of pentameric
CRP into monomeric CRP has been identified on activated platelets and damaged or
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apoptotic cells (199) and the monomers appear to be strongly pro-inflammatory.
Conditions under which the native protein structure may be destabilised causing it to
dissociate into monomeric CRP include heat exposure, an acid microenvironment or
immobilisation on tissue culture flasks, or even during preparation of material for
immunohistochemistry (200). Monomeric CRP has been identified in mice but it is not
yet established whether dissociation occurs in vivo in man.
In contrast to the persistent and increased CRP production observed by Bisoendial et al
(196, 201-204), the CRP values in the subjects in this study declined at a rate consistent
with the normal clearance of human CRP. Infusion of 1.25 mg/kg of bacterial
recombinant CRP produced initial peak CRP values of 20.5 to 28.1 mg/L, which fell
before rising again to 29 mg/L. Here, the infusion of authentic human CRP itself
triggered no new production of CRP, and the concept that autologous human CRP
triggers production of more CRP, is not supported by the results of this study.
Furthermore none of the seven recipients of a range of doses of purified human CRP
showed any increase in their circulating concentrations of SAA, the most sensitive human
acute phase protein. Once again this contrasts sharply with the Bisoendial results in which
infusion of bacterial recombinant CRP induced massive acute phase responses of SAA,
reaching more than 2,000 mg/L in some subjects (196), values typically seen in acute
sepsis or major trauma.
Our present subjects also showed no meaningful increase in cytokine production and
there was no evidence for abnormally raised pro-inflammatory cytokine activity at any
stage, with both SAA concentrations and the levels of all other acute phase reactants
within the reference range throughout. Indeed there was no significant change in any of
the clinical, physical, biochemical, coagulation, or hematological parameters which were
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assessed, despite administration of sufficient human CRP to achieve typical circulating
acute phase response values.
These findings thus demonstrate that purified, pharmaceutical grade human CRP itself
does not have any detectable pro-inflammatory effects in normal healthy adult subjects.
This critical experiment will extend to humans the well-established absence in animals of
any proinflammatory or other adverse effects of purified human CRP in vivo, and thereby
address a crucially important scientific question.
This result is consistent with the compelling evidence from very large scale observational
(205, 206) and genetic epidemiology studies (207) showing no evidence to support a
causative role of CRP in human atherosclerosis. Similarly, robust experimental animal
studies also show that CRP does not contribute to atherogenesis (208-210).
It is of the greatest clinical importance to distinguish clearly between the fact that CRP
has no inherent pro-inflammatory effects itself and its potential pro-inflammatory or
opsonising role of human CRP in individuals with pre-existing tissue damage. Within its
role as an acute phase reactant, useful in the diagnosis of inflammatory conditions and
the monitoring of effectiveness of treatments, CRP has thus far not been proven to be
either pathogenic or pro-inflammatory.
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Chapter Nine:
General Conclusions
CHAPTER NINE
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The many benefits of specialist nurse-led clinical services are well documented in the
published literature. Specialist nurse-led clinical services can be found in many different
contexts and disease areas such as heart failure, multiple sclerosis, chronic pain,
rheumatology, cardiac rehabilitation and diabetes, to name a few. In the context of this
body of work, the nurse-led clinic has made possible the provision of very specialist,
perhaps even niche, clinical care to patients with complex inflammatory conditions
requiring treatment with biologic therapies, and careful and close monitoring. It has also
made possible nurse-led clinical and academic research. Combining research with clinical
work, especially in such rare diseases where patient numbers are small, is the gold
standard. However, in order to make this possible, optimal conditions must exist – the
combination of adequate funding, infrastructure, human resources and resourceful
humans. The result when these conditions are met is benefit to the patients, the
multidisciplinary team of healthcare professionals and to the NHS as a whole.
Chronic inflammatory disorders such as RA and JIA, in the absence of effective
treatments, are known to progress inexorably to joint damage and destruction, leaving
patients debilitated and in need of social intervention such as mobility aids and disability
benefits, and medical intervention for associated co-morbidities. Autoinflammatory
diseases, although less frequent than the commoner chronic inflammatory disorders
discussed, also have a significant adverse effects on patients’ lives. As these diseases
manifest in early life normal growth and development are disturbed, as is schooling and
social development. Inflammatory diseases can therefore impact negatively not only on
patients and their families, but on the wider health service and social care system too.
Systemic AA amyloidosis is a rare but most feared complication of chronic inflammatory
disorders. The amyloid fibrils in AA amyloidosis are derived from serum amyloid A
protein, SAA, an exquisitely sensitive hepatic acute phase protein synthesized under the
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transcriptional regulation of pro-inflammatory cytokines such as IL-1, IL-6 and TNFα. 
Clinical presentation of AA amyloidosis is almost always due to the consequences of renal
dysfunction, with proteinuria and progressive renal decline, and progression to end stage
renal failure is common. Management of AA amyloidosis is centred on reducing supply
of the precursor protein by effectively treating the underlying inflammatory condition,
whilst supporting the amyloidotic organs. Where AA amyloidosis has not yet manifest as
a complication, management of the underlying inflammatory disorder remains the focus
of therapy in order to prevent the development of amyloidosis, and thereby prevent renal
failure which is not only costly, but is associated with poor quality of life in many patients.
The risk of developing of AA amyloidosis is difficult to characterise based on the cohorts
of patients who are the subject of this thesis, and there are several reasons for this. Firstly,
increasing age is a known risk factor for the development of AA amyloidosis with
childhood presentation a very rare occurrence, thus, the inclusion of paediatric patient’s
results in underestimation of both prevalence and incidence. Furthermore, as the SAIDs
are generally newly described entities, many adults were never diagnosed in earlier decades
and are now lost to follow-up and so current cohorts are heavily biased towards children.
Lastly, much of the available data are historical, dating back to when many of the effective
treatments in current use were unavailable.
Early diagnosis and initiation of treatment of inflammatory conditions is important in
order to prevent the development of organ damage including AA amyloidosis. Early
diagnosis can be problematic with the SAIDs in cases where there is no family history, as
these diseases are rare and a high index of clinical suspicion is required for successful
diagnosis. Furthermore, clinical features of the SAIDs overlap with other more common
diseases. Broad and atypical phenotypes add further diagnostic challenges. Also,
recognition of asymptomatic patients with subclinical inflammation before they develop
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renal AA amyloidosis is difficult as it is reliant upon serendipitous detection of deranged
inflammatory markers and recognition of the importance of further investigation in these
cases. Increasing knowledge and awareness of these diseases is crucial.
Another patient group presenting a diagnostic and therapeutic dilemma are those with
AA amyloidosis of uncertain or unknown cause. Basic genetic diagnostic services may be
unavailable, or unhelpful; next generation sequencing may be expensive or unavailable;
and biopsy or advanced imaging techniques may also prove non-diagnostic. At our Centre
disease activity is monitored by a combination of patient symptom diaries and serial serum
inflammatory markers. In those with suggestive symptoms with accompanying acute
phase activation a trial of therapy can be very revealing. Responses to colchicine,
corticosteroids or biologics such as anti-IL1 or anti-IL6 drugs can help to establish a
definitive diagnosis. In addition a successful therapeutic trial can allow effective
management of both symptoms and prevention of devastating complications in cases
where the disease aetiology remains unknown even after extensive investigation.
In monogenic diseases such as CAPS, huge strides have been made in terms of therapies,
and the disease has been effectively switched off in most cases. However, in turn,
pharmacological treatments, specifically unsuccessful pharmacological therapies have
revealed broader and more unusual disease phenotypes. Close and intensive follow up of
these patients is extremely important in revealing new insights into extending phenotypes
and trends and new therapeutic possibilities. Furthermore, close, intensive and long term
follow up are crucial in evaluating the overall safety and efficacy of long term treatment
with biological agents, and to determine their long term effects on quality and length of
life in these patient groups. Where the treatments have been effective, they have been
life-transforming.
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The observation that AA amyloidosis is becoming less common may be a reflection of
great advances in the use of biological agents in the effective treatment of the
inflammatory arthritides. Overall, these data suggest both falling incidence (corrected for
improved diagnostic rates) and better outcome in AA amyloidosis over a period of two-
and-a-half decades, reflecting advances in therapeutics and in overall management of
complex chronic disease in an aging population. This has both reduced the incidence of
AA amyloidosis and when it does develop, has improved outcomes in what were until
recently the commonest pathologies underlying AA amyloidosis. The mean age at
presentation with AA amyloidosis is now significantly older than in historical cohorts.
This again may be a reflection of the availability of effective biological treatments for
inflammatory conditions. Whilst overall survival does not appear to have changed despite
new effective therapies, age at death has increased significantly over the last 25 years,
suggesting improved global management and supportive care including renal
replacement, as well as more effective management of the underlying pathology. It is
hoped that newer techniques such as next generation sequencing and gene expression
analysis may aid diagnosis and effective treatment of these ‘uncharacterised’ inflammatory
disorders thereby improving overall survival.
Monitoring of the acute phase proteins SAA and CRP is crucial to assess whether the
underlying disease is adequately suppressed; in their roles as markers of the acute phase,
neither are pathogenic and both are extremely clinically useful. However, both SAA and
CRP also have pathogenic effects. The pathogenic effect of SAA is, as previously
mentioned, that it is the precursor for AA amyloidosis. The circulating concentration of
SAA is a powerful predictor of both patient survival and renal outcome. In patients in
whom SAA production is adequately suppressed amyloid deposits can be seen to regress
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and renal function can be stabilised or even improve. This can be seen in Chapters 2, 5
and 6.2.
The pathogenic effect of CRP lies in its role as an opsonin; in cardiovascular disease, CRP
is attracted to the lesion or injury site, and attracts further pro-inflammatory cells and
molecules which have the undesirable effects of increasing the size and extent of the
lesion. In patients with known cardiovascular disease elevated levels of CRP are
statistically significantly associated with risk of future coronary events. Unfortunately
inappropriate conflation of epidemiological association with causality, has led to claims
that increased baseline CRP concentration is not only a risk marker for cardiovascular
disease but also a risk factor contributing to the pathogenesis of atherosclerosis and
atherothrombosis. This has been compounded by the use of (presumably) contaminated
recombinant CRP in in vitro and in vivo studies, which produced acute phase reactions,
thereby implying that CRP of itself produces inflammation. This is clearly of concern to
all clinicians, and so we sought to explore the validity of this assertion by administering
highly purified human CRP to seven heathy volunteers. This experiment showed that
there were no pro-inflammatory effects from this pure CRP, thereby answering a very
important clinical question - CRP is used worldwide as the main measure of inflammation,
injury and infection, and response to therapy. It was therefore crucial to distinguish its
role as a simple acute phase reactant, from its role as a ‘pro-inflammatory’ agent in specific
circumstances, i.e. its role as an opsonin.
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Limitations and future directions
It remains unclear why some patients develop AA amyloidosis and others do not.
Although prolonged elevation of SAA concentration is known to be a prerequisite, some
patients with only low level inflammation for a relative short time may develop it whilst
others with very high SAA concentrations over a much longer period of time do not.
Associations have been found by other groups between particular SAA1 alleles and the
development of AA amyloidosis, and future work should include a genotypic comparison
between patients with inflammatory conditions who do and do not develop amyloidosis.
Other factors involved may be environmental or epigenetic. In Chapter seven we see that
the proportion of Asian patients diagnosed with amyloidosis has increased over the 25
year period has doubled from 4% between 1990 and 1997 to 8% between 1998 and 2006,
and quadrupled between 2007 and 2014 – this is an interesting phenomenon and warrants
further exploration.
Chapter seven also reveals a reduction in the incidence of JIA and SAIDs as diseases
underlying AA amyloidosis, whist there has been a huge rise in AA amyloidosis of
uncertain aetiology. Future work with the patient group in whom the underlying cause of
the AA amyloidosis is unknown could involve next generation sequencing (NGS), and
perhaps further imaging (CT, PET etc.) although patients may find this unnecessarily
invasive or inconvenient.
Pathogenic mechanisms in autoinflammation are complex and incompletely understood.
The genotypic and phenotypic spectra are ever expanding, even in monogenic disease
such as CAPS. Patient with CAPS who respond inadequately to treatment or who have
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atypical presentation could be investigated further with NGS. Clinically, in these patients,
dual cytokine therapy, e.g. an anti-IL-1 agent combined with anti-TNF or anti-IL-6 agent,
could be trialled although the increased risk of developing serious infections must be
carefully weighed against the potential benefit.
The SAIDs involve cradle to grave care, therefore any safety data presented herein may
only be viewed as preliminary. Longer follow up is required to reveal the true safety and
efficacy of the treatments studied within this thesis.
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Since starting on Canakinumab my life has certainly changed for the
better.
I have not had any of the painful swollen joints that have stopped
doing me doing my job,, as prior to the treatment my wrists, fingers
and elbows were sometimes immobile.
In addition, I haven't had the bad eyes, or uncontrollable fever that
was a regular occurrence prior to the treatment.
Sometimes if a fever came on at night I couldn't even raise my head or
turn over to take pain killers to ease it.
The best of everything is that I can now travel without any worries of
having uncontrollable fever and shivering, which is a god send, as now
it doesn't take good week to get over it.
Aeroplane travel was always the worst because of the cold inside the
cabin, and I used to suffer severely especially on long haul flights.
Since the start of the treatment, not a winter has gone by when I
haven't thanked heaven for medical science.
Thank you.
JK
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The Impact of Canakinumab
Until I was referred to the National Amyloidosis Centre in May 2006, I had lived most of my
life (I am 58) with chronic daily urticaria, intermittent inflamed eyes, almost daily aching joints
and muscles, at times unbelievable fatigue, episodes of feeling extremely cold and in the ten
years up to 2006 daily chronic oedema in my legs and particularly my ankles. I accepted
this as normal for me and that I had just been unlucky in the genes I had inherited from my
father who too suffered similar symptoms. I, like all the doctors and consultants I had sought
advice from over the years looked at the symptoms in isolation and it was not until an
appointment at the Urticaria Clinic at St Thomas’s hospital in London did anyone ever
suggest to me that the symptoms might be linked and that I could be suffering from Muckle
Wells Syndrome. I was thus referred to the NAC for further investigation. My perseverance
had been worth it - this was break through for me and my years of silently suffering.
To understand the impact Canakinumab has had on my life, I need to describe what it is like
living without it.
Urticaria. Every part of my body except my trunk would be covered in large, raised red
wheels which would start to appear in the second half of the day and get progressively
worse until my body was covered by the evening. If I was lucky, the wheels would go down
over night, only to start again the next day. Some days were worst than others and my legs
and arms which were covered most would sometimes feel burning to touch and yet I could
be shivering inside. Absolutely nothing alleviated the rash and it would determine what
clothes I would wear. I was so embarrassed by the sight of my arms and legs; I would wear
trousers or long sleeve tops to hide the rash. I never wore strappy dresses/tops in the
summer and I virtually gave up playing tennis in the summer months as I wouldn’t be ‘seen
dead’ in shorts and it was too hot to play in track suit bottoms!
Inflamed Eyes. Once or twice a month, I would suffer with inflamed eyes. They would start
to come up during the day and by the time I would go to bed on the first day, the pain when I
lay down would be excruciating. Painkillers had minimal effect. The only way I could
attempt to get any sleep was to press a tissue (to dry up the constant watering) against my
eye with the palm of my hand. The pressure from my palm helped to alleviate the pain and I
would lie there willing the night away. By morning I would have a very swollen eye which I
could barely open and any light would increase the pain. The inflammation would subside
over 24 – 48 hours, but leave me with cloudy vision for a further day.
Aching joints and muscles. I used to long for a day when I didn’t have aching joints (hands,
wrists, knees, ankles, hips). When really bad, I would be reduced to tears from the pain and
just crawl upstairs and into bed at the end the day as at least in the morning, I might be
slightly stiff when I got up, but invariably the pain would be gone. However, occasionally my
hands and wrists would be very swollen and red and the inflammation would last up to 2
days or more so causing me difficulty holding and turning things.
Fatigue. There would be occasions at the end of the day when I was too tired to eat, let
alone climb the stairs to bed. I have always played tennis, but found I was playing less often
as I was coming home from work exhausted from sitting at a desk all day. What I could
never understand was how I could feel drained of energy from just walking up the stairs
when it was 8 o’clock in the morning and I had just had a night’s sleep!
Episodes of feeling extremely cold. So cold, really cold inside, that not even layers of
clothing and being wrapped in a duvet would alleviate. It would creep up on me during the
day and by the time the evening came, I would be piling on the layers, the thermostat for the
central heating would be cranked up and I would be miserable whilst everyone else in the
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family roasted. Not even the thought of bed would comfort me for a warm bath had no effect
and I would lie there, wrapped in numerous items of clothing, my body aching from the
shaking of shivering, desperate to get to sleep, but sleep would allude me for hours.
Oedema. In the last ten years or so, I started to suffer with oedema with my legs always
feeling swollen and I suffered really badly with fluid retention around my ankles. In fact, I
could never really see my ankle bones, even first thing in the morning. I never dare take my
shoes off during the day for fear of never getting them back on again and there were times
when I missed out playing tennis because I couldn’t get my trainers on, let alone flex my
ankles. Trousers were the dress code.
I can be a very sceptical person and to be told that I would find out what it felt like to be
symptom free if I tried Canakinumab, I didn’t really believe, but within 24 hours of being
given the first injection, I have never had any of the above symptoms again. To say that it
has changed my life is an understatement – the impact has been immense. I am so happy
to be symptom free, it is just fantastic!
This is how my life has changed:
 I no longer suffer with any aching joints or muscle pain – I am pain free
 I no longer suffer with oedema and have ankles!
 My urticaria has never re-occurred
 I have not had an inflamed eye since being on the drug
 I no longer suffer from extreme bouts of feeling cold
 I am more active as I do not suffer with fatigue
 I play tennis once a week, all year round
 I dog walk (briskly) almost every day
 I am not restricted in the clothes I wear
 I have gone down a shoe size
 I lost several pounds in weight (no fluid retention)
 I socialise more as I am free from pain, fatigue and the embarrassment of urticaria
 My family think it is wonderful and they are happy for me and so we all benefit
 I feel like a new person which has increased my confidence and positive attitude
I almost feel Canakinumab is too good to be true and my bubble will burst. To live a life
symptom free is just second to none.
CB
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I would like to start with a bit of background. I grew up in Lesotho..and also a small town
called Ladybrand in south Africa. Not exactly a wealth of medical expertise. I remember
from a very young age always being sick. Measles mumps colds flu..you name it I've
probably had it. All the way to chickenpox at 18. I remember having pinkeye (conjunctivitis)
at least twice a month where the sunlight would hurt my eye and cause headaches. I
remember being fragile and always having sore muscles or bumps from school. I remember
doing a lot of sport but getting injured a lot and pulling my Achilles tendons (sometimes
even just waking up the next day and they would be as fat as a plum) I remember always
being cold in winter because I would never put on any weight and being blue. My hands
would turn into fat Shrek hands and would hurt to move. I remember getting a red rash all
over my body..even in summer so I would wear long sleeves in the African sun to hide
it...always looked weird to friends and class mates. I remember being in and out of
doctors/hospitals..injection after injection trying to work out what I had..and a common
answer would be arthritis.
Time passed and I learnt to manage what I had..obviously getting older and stronger I
would be smarter in my clothes etc and not get as cold as often. I would still get rashes but
learnt how to hide it well. I got used to the pain on my bones and got on with my life..it was
part of my life and I wasn't going to let it bother me.
University was the norm..no real sports as id get injured but by then I was handling my "
arthritis" well.
Then came the day in the UK I remember very well..I had decided I was tired of pink eye
and sore hands. I went to the NHS and after a few months of being sent to eye specialists
and arthritis specialists I finally went to a dermatologist who said I had Muckle-Wells
syndrome. Fair enough..sounded interesting but little did I know my referral to the royal
free would change my life completely.
After taking that first dose of canakinumab...I was no longer tired...no longer tired from the
mental and physical fighting I didn't realise I was constantly doing to deal with the disease.
As some of you know that weekend I went out all night dancing..didn't sleep..it was
amazing.
Since 2009 I have not experienced any pink eye or sore joints or pulled Achilles or caps
induced headaches... Happily I am a leopard that lost his spots too.
The main bonus of the drug..apart from not getting cold, sore, sick, tired..etc is that I have
gained confidence...I am no longer shy...no longer body/image conscious.
I have gained over 12kgs since 2009. I like my body now... I have completed maybe 7 or 8
official 10km runs..I have stupidly completed tough mudder -a 21km obstacle course
designed by the SAS. All these things I would never have dreamed of doing pre 2009.
I cant describe to you how my life has changed for the better since taking this drug..I am
me... But a better me..a way better me. I cannot imagine life without it and actually the
more the days pass the more I forget what life was like back then.
I cant express my gratitude enough for being able to take this drug and having a pain free
and active lifestyle now.
Many thanks.
AS
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Complete results for Subjects 1 to 7 in
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